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Inorganic arsenic (iAs) is a ubiquitous drinking water and food contaminant. Chronic 
exposure to iAs has been linked to diabetes mellitus in many populations. Experimental studies 
support these associations and suggest mechanisms, but the precise pathogenesis of iAs-
associated diabetes is unclear. Efficient metabolism of iAs through methylation, catalyzed by 
arsenic (+3) methyltransferase (AS3MT), influences the risk of iAs-associated disease. 
Additionally, higher intake of methyl donor nutrients such as folate and methylcobalamin (B12) 
has been linked to increased efficiency of iAs metabolism and lowered disease risk. However, 
while metabolism of iAs facilitates its excretion from the body, iAs metabolites are more toxic 
than iAs itself. The role of iAs metabolism in iAs toxicity is understudied, especially in 
cardiometabolic disease. Understanding how iAs metabolism affects iAs-associated diabetes will 
help design appropriate intervention strategies and improve risk assessment.  
This project investigated how iAs metabolism influences iAs-associated diabetes. First, 
we compared metabolite profiles of C57BL6 (WT) with As3mt-KO (KO) mice, which cannot 
methylate iAs, with and without exposure to iAs. We found that while iAs exposure was linked 
to very few metabolites, knock-out of As3mt was associated with metabolites in a sex-specific 
manner. Second, we investigated the effect of iAs exposure at environmentally-relevant doses on 
glucose metabolism in mice and the role of methyl donor nutrient supplementation. Prenatal 
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exposure to iAs elicited hyperglycemia and insulin resistance, particularly in males. Chronic iAs 
exposure in adult mice increased insulin resistance only with a low-folate, high-fat diet. Males 
were more insulin resistant than females; KO mice more than WT mice. In both studies, 
supplementation with B12 and/or folate protected against iAs-associated impairments in glucose 
metabolism, despite having a minimal effect on iAs metabolism. Third, we investigated how iAs 
and its methylated metabolites inhibit insulin secretion in pancreatic β-cells. These arsenicals 
may be impairing calcium influx by affecting ion channels. Interestingly, methylated metabolites 
appear to target different mechanisms than iAs. Taken together, this research adds novel 
knowledge about the effects of environmentally-relevant iAs exposures on glucose metabolism 
in mice, the underlying mechanisms, and the role of iAs metabolism and methyl donor nutrients 
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1. CHAPTER 1- Introduction 
 
Inorganic arsenic (iAs) is a metalloid that is found ubiquitously in the Earth’s crust and 
natural and anthropogenic processes release iAs into the air or water. Exposure to iAs in humans 
occurs primarily through ingestion of water and food. Chronic exposure to iAs has been 
associated with numerous cancers, such as lung, urothelial, and liver, skin lesions, cardiovascular 
disease, and neurological dysfunction (Abdul 2015). In the last two decades, iAs exposure has 
been linked to type 2 diabetes mellitus in many populations around the world (Maull et al. 2012; 
Kuo 2017). Experimental studies in vitro and in vivo support these associations. Several 
mechanisms of how iAs affects glucose metabolism have been suggested but how exactly iAs-
associated diabetes develops in humans remains to be elucidated. 
Diabetes mellitus is a complex, systemic metabolic disease that is characterized by 
improper insulin secretion and/or insulin action, leading to chronic hyperglycemia. It is the 8th 
leading cause of death in the world and, if uncontrolled, can lead to renal failure, peripheral 
neuropathy, and retinopathy (WHO 2016). The majority of people with diabetes have type 2 
diabetes (T2D) which generally results from an ineffective use of insulin in the body. Individuals 
with T2D are at increased risk of cardiovascular disease and some cancers (CDC 2017; 
Giovannucci 2010). Around 9% of the global population is diagnosed with diabetes, which is 
double the prevalence 20 years ago, and is expected to continue increasing. As such, diabetes is 





for the Prevention of Noncommunicable Disease 2013-2020 (WHO 2013). The high mortality 
rate and growing morbidity of diabetes and its comorbidities highlights the necessity for 
understanding the influence of iAs, a widespread environmental diabetogen. 
Studies suggest that the ability to efficiently metabolize iAs influences the risk of iAs-
associated disease, including T2D (Antonelli 2012; Kuo 2017; Hall and Gamble 2012). In most 
organisms and in humans, metabolism of iAs occurs through a series of methylation steps, 
forming monomethyl-arsenic (MAs) and dimethyl-arsenic (DMAs). DMAs is easily cleared by 
the body, thus metabolism is important for the excretion of iAs from the body. However, 
experimental studies show that the intermediates in iAs metabolism can be more toxic than iAs. 
The role of iAs metabolism in iAs toxicity is understudied, especially in the context of 
cardiometabolic disease. 
This project was designed to determine how iAs metabolism influences iAs-associated 
diabetes. Understanding how different efficiencies of iAs metabolism can either improve or 
worsen iAs-associated diabetes will help design appropriate intervention strategies to reduce risk 
of diabetes in iAs-exposed populations. This research will also improve risk assessment and the 
identification of susceptible populations. Principles identified here can be expanded to 
understand the role of iAs metabolism in other iAs-associated diseases.  
 
1.1 Human Exposure to iAs 
1.1.1 As in nature 
 Arsenic (As) is found ubiquitously in the natural environment. Chemically classified as 
metalloid, As is 20th in abundance in the Earth’s crust, 14th in seawater, and 12th in the human 





Suzuki 2002). As is often found combined with oxygen, chlorine, or sulfur in ores of silver, gold, 
cobalt, and antimony. As has been found in over 150 minerals (EPA doc; Mandel and Suzuki 
2002). Arsenopyrite, containing 46% As, is the most common As-containing mineral (Kirk 
Encyclopedia). The primary oxidation states of As are +3 and +5. As in the environment is 
typically found in its inorganic form but numerous organic forms of As, where As has formed 
bonds with carbon and hydrogen, also exist. Organic As compounds include arsenobetaine, 
arsenocholine, arsenosugars, arsenolipids, MAs, and DMAs. Many of these compounds are 
found primarily in marine animals (Borak and Hosgood 2007). Inorganic and organic As 
compounds are white to colorless powders, odorless and tasteless while pure elemental As is a 
metallic grey.  
1.1.2 Uses of As 
In Agriculture 
As-containing pesticides were widely used in the late 1800s to mid 1900s. Copper 
acetoarsenite (i.e. Paris Green) was used to control the Colorado potato beetle from 1987-1990 
(Peryea 1998). Lead arsenate became widely used from the late 1800s until 1960 when it was 
phased out due to concerns of toxicity. Chromated copper arsenate (CCA) is a wood preservative 
that is still used in the US as an insecticide and antimicrobial agent. Registered in 1940, CCA 
was discontinued from residential use in 2003 but is still permitted for nonresidential purposes 
(i.e. in marine facilities, utility poles, and sand highway structures) (EPA website). Organic 
arsenical pesticides came into use in the 1950s and were favored due to decreased toxicity 
compared to the inorganic arsenic pesticides. Dimethylarsinic acid (DMAsV) was discontinued 





restrictions (EPA MSMA). Reregistration of MSMA for continued use began in 2013 and is 
scheduled to be completed in 2019.   
Organic arsenic compounds were used extensively in the cattle, swine, and poultry 
industry. Roxarsone, nitarsone, arsanilic acid, and carbarsone were put in animal feed as an 
anticoccidial and growth stimulator as early as 1944 when roxarsone was approved for use by the 
FDA (Silbergeld and Nachman 2008). Due to reports of iAs in meat of treated animals, 
manufacturers began suspending sales of roxarsone and similar products in the 2010s. By 2015, 
the last organic As compound in use, nitarsone, was withdrawn from the market and ceased to be 
used in the growing season of 2016 (FDA).  
In semiconductors 
Elemental As is an alloying additive for metals, batteries, and lead ammunition (EPA 
1998). High-purity elemental As is needed for the production of semiconductors and electronics, 
such as LEDs, infrared detectors, and lasers (EPA 1998). Specifically, gallium arsenide is used in 
high-speed semiconductor component, high-power microwave, detectors, and fiber optics due to 
its high electron mobility and light-emitting, photovoltaic, and electromagnetic properties (IARC 
2006). 
In medicine  
Medicinal uses of As date back to before 2000 BCE. Famous early physicians such as 
Hippocrates, Aristotle, and Paracelsus have been reported to treat various illnesses with As 
(Waxman and Anderson 2001; Jolliffe 1993). While pure metallic As was rarely used, arsenides 
and arsenic salts were prescribed to prevent maladies, reduce fevers, stimulate bile production, 
remove hair, treat cervical dysplasia, and as antiseptics, antispasmodics, sedatives, and tonics 





ulcers, hypertension, heartburn, chronic rheumatism, and cancers of the skin and breast (Antman 
2001). As-containing treatments were administered as inhaled vapors, ingested solutions and 
solids, intravenously, and dermally as pastes.  
Records from the 18th to 20th century record prevalent use of a potassium bicarbonate 
arsenic trioxide solution (1% w/v) developed by Thomas Fowler. In 1878, Fowler's solution was 
reported to reduce white blood cell counts and became a standard remedy to treat leukemias 
(Waxman and Anderson 2001) until the introduction of radiation and other anti-cancer agents. In 
the late 20th century, arsenic trioxide (ATO), or Trisenox ®, reemerged as a potential therapy for 
acute promyelocytic leukemia (APL). Even with combination therapy and all-trans retionic acid 
(ATRA) treatment regimens, approximately 20-30% of patients relapse and die (Antman 2001). 
Studies in China starting in 1990 observed that ATO monotherapy had remission rates of 80-
90% and was effective in relapsed APL patients (Waxman and Anderson 2001). Long-term 
treatment with ATO caused complete (molecular) remission in some patients, which is not 
observed with ATRA. ATO was approved by the FDA in 2000 to treat APL patients that are 
unresponsive to ATRA. Ongoing studies are investigating the use of ATO-ATRA combination 
therapies. An organic arsenical, Darinaparsin (S-dimethylarsino-glutathione), is also undergoing 
clinical trials as a chemotherapeutic agent.   
1.1.3 Routes of exposure to As 
Ingestion of contaminated water or food is the primary route of exposure to As. Organic 
forms of As, typically found in seafoods, are understood to be less toxic than iAs. There is some 
concern that some organic arsenicals convert into more toxic intermediates through the process 
of degradation to DMAs (Molin et al. 2015). Studies in the past decade suggest that some 





organic arsenicals has been hard to estimate due to the lack of experimental and human data on 
acute and chronic exposures and effects. The discussion hereafter will focus on exposure to iAs.  
In the general US population, estimated average intake of iAs from drinking water and 
food, specifically rice, was 4.2 μg/day and 1.4 μg/day, respectively (Mantha et al. 2017). 
Individuals of other countries with higher rice intake may consume up to 2.8 ug/day (Mantha et 
al. 2017). Excluding smokers and individuals with occupational exposures to As via inhalation, 
exposure via air is not a significant contributor to total As exposure. The European Commission 
estimates that air accounts for less than 1% of the total exposure to As, even when models use 
high estimates of As concentrations in air (EU Commission 2000). The following sections 
discuss in more detail each source of exposure to As.  
1.1.3.1 Water 
Arsenic can be found in both surface and groundwater due to natural weathering and 
dissolution processes which occur based on pH, redox conditions, temperature, and solution 
composition (Smedley and Kinniburgh 2002). Arsenic in water is in the inorganic form, in either 
trivalent or pentavalent oxidation states (Cullen and Reimer 1989). Geothermal waters can 
contain high levels of iAs (Webster and Nordstrom 2003) and can be introduced into drinking 
water sources through natural hot springs in rivers or geothermal energy production (Bundschuh 
and Maity 2015). Runoff from mines, industrial plants, animal production facilities, and soil 






Figure 1.1. iAs contamination of major aquifers around the world. Based off the 2002 British 
Geological Survey (Smedley 2002). 
 
The current WHO and US EPA maximum contaminant limit (MCL) for iAs in drinking 
water is 10 µg/L (part per billion, ppb). Areas with iAs in water that exceeds this limit have been 
reported in numerous countries around the world, including Taiwan, Bangladesh, India, Vietnam, 
Thailand, Argentina, northern Chile, US, Australia, Canada, Cambodia, and Mexico 
(summarized in Smedley and Kinniburgh 2002; Figure 1.1). Concentrations of iAs in the more 
highly-exposed populations can exceed 2000 ppb (ATSDR 2007). In the US, the average 
concentration of iAs in groundwater is 1 ppb with higher concentrations of iAs in the western 
states (Focazio et al. 2000; Figure 1.2). Levels as high as 1000 ppb have been found in western 
states of the US (Smedley and Kinniburgh 2002). It is estimated the 8% of major public potable 
water supply systems in the US use water that exceeds the EPA MCL (Focazio et al. 2000). 
Private wells, which are not regulated by the EPA, supply water for around 14% of the US 





to be in parts of the US with high As in well water (Ayotte et al. 2017). North Carolina has the 
fourth largest population of individuals using private well water >10 ppb (Ayotte et al. 2017).  
 
Figure 1.2. Concentration of iAs in 18,850 potable water samples from public water supply 
systems and other water sources in the US. Data obtained from the United States Geological 
Survey National Water Information System. (Focacio et al. 2000). 
 
1.1.3.2 Food 
Food is another major contributor to As exposure. In areas of the US where iAs in water 
is low, dietary intake of iAs is estimated to contribute 50-85% of total iAs exposure (Kurzius-
Spencer et al. 2014, Xue et al. 2010). Organic forms of As are found in marine organisms like 
seaweed, crustaceans, and fish in the form of arsenobetaine, arsenosugars, and arsenolipids 





seaweed, and fruit juices (Wilson et al. 2015). iAs in food results from the use of iAs-
contaminated water for irrigation, use of iAs-based pesticides, or presence of iAs in soil, which 
plants readily take up (Li et al. 2016). Poultry and eggs can also contain iAs, due to the use of 
As-based compounds in the animal production industry. The FDA has a general limit of 0.5-2 
ppm iAs in foods. In 2013, a limit of 10 ppb iAs was proposed for apple juice due to its 
consumption among children (FDA 2013). 
Levels of iAs in rice are of great concern because of the high consumption of rice in 
many countries with high iAs-contamination. Additionally, many newborn formula and infant 
foods are rice-based and, thus, can be significant sources of iAs exposure in infants who are 
more susceptible to environmental insults. In fact, the dietary exposure of infants and young 
children per kilogram of body weight is 2-3 times higher than in adults. (European Food Safety 
Authority 2009). Total As in rice can be up to 100-400 ng/g and exists primarily in the form of 
iAs and DMAs (Williams et al. 2005). In the FDA’s most recent survey of As in rice and rice 
products, they found that on average white rice had more iAs than brown rice (92 vs. 154 ppb). 
Infant dry rice cereals contained on average 103 ppb iAs (104 ppb in white-rice cereal, 119 ppb 
in brown-rice cereal) (FDA 2016). Currently, there are no regulations on As in rice or rice-based 
products. In 2015, the European Commission adopted a 100 ppb iAs limit for “rice destined for 
the production of infant and children’s foods”. In 2016, the FDA proposed a 100 ppb iAs limit in 
infant rice cereals.  
1.1.3.3 Inhalation 
Release of As from geological formations into the atmosphere, water, or soil occurs 
through natural and anthropogenic processes. Volcanic eruption and forest fires are natural 





processes such as mining and smelting or burning of As-rich coal emit As into the air, where it 
attaches to particulate matter (typically <2 µM) (Mandel and Suzuki 2002). Burning of CCA-
treated wood or application of As-based pesticides are other methods of volatilizing As. While 
mean total arsenic concentrations in air range from 0.02–4 ng/m3 in remote and rural areas, and 
from 3–200 ng/m3 in urban areas, higher concentrations (> 1000 ng/m3) have been measured in 
the vicinity of industrial plants (WHO 2001).  Due to the use of As-based pesticides on tobacco 
plants, cigarettes can contain 0-1.4 µg As/cigarette (Smith et al. 1997; Lazarevic et al. 2012; 
Afridi et al. 2015) and is a source of exposure to As and other metals for smokers.  
1.2 iAs Metabolism 
 Combinations of natural and anthropogenic processes cause widespread release of iAs 
into the environment. In response, organisms have developed mechanisms to clear iAs from the 
body. Biotransformation of iAs through enzymatic methylation facilitates the clearance of iAs 
from the body as monomethyl-, dimethyl-, and sometimes trimethyl-arsenic species. The 
following sections discuss the process of iAs methylation, modifiers of iAs metabolism, and the 
importance of methylation in toxicity and iAs-associated disease.  
1.2.1 iAs methylation 
 Metabolism of iAs in humans and other mammalian species occurs through a series of 
methylation steps catalyzed primarily by arsenic (+3 oxidation state) methyltransferase 
(AS3MT). Homologs of AS3MT have been found in many organisms, ranging from bacteria to 
humans. Other methyltransferases have been reported to methylate iAs, such as N-6 adenine-
specific DNA methyltransferase 1 (Ren et al. 2011). However, AS3MT is the primary iAs-
methylating enzyme. Transfection of UROtsa urothelial cells which lack AS3MT, confers iAs 





hepatocytes via RNA interference reduces iAs methylation (Drobná et al. 2006). Furthermore, 
As3mt-knockout mice produce virtually no methylated As species as measured in the urine and in 
tissues (Drobná et al. 2009; Currier et al. 2016).  
AS3MT is highly expressed in the liver and has been found in testis, adrenal glands, and 
in all regions of the brain (Healy et al. 1988; Human Protein Atlas; Sánchez-Peña et al. 2014). 
Initial observations in liver lysates determined that iAs methylation used S-adenosylmethionine 
(SAM) as the methyl group donor (Buchet and Lawreys 1985) and that physiological reductants 
like glutathione (GSH), thioredoxin, lipoic acid, and other non-physiological reductants like 
dithiolthreitol increased methylation (Buchet and Lauwerys 1987; Buchet and Lauwerys 1988; 
Stýblo et al. 1996, Waters et al. 2004). The As3mt enzyme was first purified from the cytosolic 
fraction of livers from adult male Fisher 344 rats (Lin et al. 2000), facilitating study of the actual 
enzyme in vitro.  
The methylation of iAs by AS3MT is outlined in two conceptual models. The first model 
was developed by Frederick Challenger and colleagues (Challenger 1945; Challenger 1951) and 
revised by Cullen in 1984 (Cullen et al. 1984). In this model, AS3MT catalyzes a series of 
alternating reductions and oxidative methylations (Figure 1.3A). Products include 
methylarsonate (MAsV), dimethylarsinic acid (DMAsV), and, more minorly, trimethylarsine 
oxide (TMAsV). Trivalent As species, methylarsonous acid (MAsIII), dimethylarsinous acid 






Figure 1.3. Oxidative (A) and reductive (B) models of iAs methylation (Drobná et al. 2009).  
 
The second model was proposed by Hayakawa and colleagues in 2005, and further 
developed by Rosen et al. in 2014 (Figure 1.3B). Here, GSH-bound arsenic, As(GSH)3 and 
As(GSH)2, are the preferred substrates of AS3MT and As remains in the trivalent form 
throughout the entire methylation process. Dissociation with GSH yields unstable MAsIII and 
DMAsIII which rapidly oxidize to MAsV and DMAsV. AsIII was found to be bound to proteins 
during methylation, suggesting that the reaction could also occur with As bound to intracellular 
thiols (Naranmandura et al. 2006). A study of a recombinant human AS3MT enzyme supports 
the second model of methylation (Dheeman et al. 2014). As(GSH)3 bound preferentially to 
AS3MT over iAsIII and MAsIII was the major product formed in the first minutes of catalysis, 
which remained enzyme-bound until remethylation. Through site mutagenesis of four conserved 
cysteine residues in AS3MT, they deduced that Cys156 and Cys206 form the binding site for 
iAsIII and MAsIII and are required for all steps in methylation. Cys32 and Cys61 are not essential 
for methylation but form a disulfide bond in the process, a bond that is reduced by thioredoxin to 





In humans, iAs and its metabolites are excreted primarily in the urine, although some 
excretion through feces is possible. Thus, urinary As is a common biomarker of iAs exposure. 
Efficient iAs metabolism is generally understood as a decreased proportion of urinary iAs and an 
increased proportion of urinary DMAs. Primary and secondary methylation indices, ratio of 
MAs/iAs and DMAs/MAs respectively, are used to describe the efficiency of the individual 
methylation steps. There are benefits and limitations to using urine samples to assess iAs 
metabolism. Urine is an easy and cost-effective sample to collect. However, urine As only 
reflects recent iAs exposures, can be influenced by hydration status, and may not represent actual 
tissue levels of iAs exposure. As in hair, nails, and blood have also been used to measure iAs 
exposure. 
1.2.2 Genetic modifiers of iAs methylation 
 Single nucleotide polymorphisms (SNPs) in AS3MT have been identified in both exonic 
and intronic regions and have been associated with differences in iAs methylation. SNPs in 
exonic regions may influence the activity of AS3MT by modifying the protein structure and/or 
function.  For example, the rs11191439 polymorphism is an exonic SNP that results in a single 
allele mutation at position 14458 leading to a Met287Thr substitution. This SNP was linked to 
higher urinary MAs in more than two human studies (Agusa et al. 2011; Antonelli et al. 2012). 
Indeed, the Met287Thr substitution in AS3MT of heterozygotic donor of primary human 
hepatocytes significantly increased production of MAs (Drobná et al. 2004) and COS-1 cells 
transfected with the 287Thr allozyme had higher in vitro protein levels than the wild type protein 
in untransfected cells (Wood et al. 2006). Assessment of recombinant human AS3MT expressing 
eight different exonic SNPs showed low methylation activity in all allozymes (Li et al. 2017), 





may influence iAs metabolism by regulating gene and/or protein expression. Two intronic 
polymorphisms (e.g. rs3740390 and rs11191453) were associated with significant changes in 
urinary MAs in at least two different human studies (Antonelli et al. 2012; Agusa et al. 2011). 
Other intronic SNPs (e.g. rs3740400 in the 5’ region and rs1046778 in the 3’ untranslated 
region) were significantly associated with AS3MT protein expression (Engström et al. 2011). 
 Genetic variation in other enzymes related to iAs metabolism have also been evaluated. 
GSH-S-transferase omegas (GSTO) and purine nucleotide phosphorylase (PNP) are 
hypothesized to catalyze the reduction of iAsV (Radabaugh et al., 2002; Zakharyan et al., 2001). 
However, the current literature does not indicate that polymorphisms in GSTO, other gluthation-
S-transferase enzymes, or PNP significantly influence iAs metabolism (Antonelli et al. 2012; 
unpublished data from Stýblo lab). The methyl donor for iAs methylation, SAM, is synthesized 
through the one-carbon metabolism pathway. Polymorphisms in genes coding enzymes involved 
in this pathway, such as methylenetetrahydrofolate reductase and cystathionine-beta-synthase, 
have been linked to iAs metabolism in population studies (Porter et al. 2010; Engström et al. 
2007; Engström et al. 2009; Beebe-Dimmer et al. 2012; Kile and Ronnenberg 2008). It was 
proposed that SNPs in other SAM-utilizing methyltransferases could influence iAs metabolism. 
However, data supporting this association is limited and inconsistent (Yang et al. 2016; 
Engström et al. 2011).  
Proportions of arsenic species in urine is also determined in part by mechanisms that 
transport As out of cells. Membrane transporters such as phosphate transporters, 
aquaglyceroporins, ATP-binding cassette transporter multidrug resistance proteins (MRPs), 
organic anion transporters (OATPs), and some glucose transporters have been shown to export 





altered capacity to export DMAs (Banerjee et al. 2014) and SNPs in SLCO1B1, a member of 
OATPs, have been associated with iAs metabolism in a small cohort study (Gribble et al. 2013).  
 
1.2.3 Dietary modifiers of iAs methylation 
 S-adenosylmethionine (SAM), the methyl group donor for iAs methylation, is 
synthesized through the one-carbon metabolism (OCM) pathway, a set of biochemical reactions 
that mediate the transfer of methyl groups (Selhub 2002) (Figure 1.4). Methionine is an essential 
amino acid that is the precursor to SAM. Transfer of the methyl group in SAM results in 
homocysteine (Hcys), which can be remethylated to form methionine. 5-methyl tetrahydrofolate 
(THF), formed from the chemical conversion of folic acid or obtained through dietary folate, or 
betaine can provide the methyl group for Hcys methylation. In addition to producing SAM for 
methylation of iAs, DNA, and proteins, OCM also contributes to the production of thymidine 
and purines for DNA/RNA synthesis (Ducker and Rabinowitz 2017).  
Some B vitamins, choline, and essential amino acids obtained from the diet are integral in 
OCM (Figure 1.4). B vitamins are water-soluble and found in meats, dairy products, eggs, green 
leafy vegetables, whole grains, legumes, fruits, and nutritional supplements. Folic acid (B9), the 
primary form of folate in enriched foods and supplements, is a precursor to tetrahydrofolate 
(THF). Methylcobalamin (B12) is an essential cofactor for methionine synthase. Riboflavin (B2) 
is needed for the formation of 5-methyl THF. Activated pyridoxine (B6), pyrodoxal phosphate 
(PLP), is used in the conversion of THF to 5,10-methylene THF as well as in the transsulfuration 
pathway to form cysteine from homocysteine. Additionally, cysteine is needed for synthesis of 
GSH, which is an important reductant in iAs methylation (Thomas et al. 2007). Betaine and its 





homocysteine methyltransferase. Adequate protein intake is also important as methionine is 
needed for SAM synthesis and other amino acids are utilized in OCM reactions.   
 
Figure 1.4 One-carbon metabolism (OCM), iAs metabolism, and nutritional contributions. From 
Spratlen et al. 2017. (1) Folic acid is reduced to dihydrofolate (DHF) and tetrahydrofolate 
(THF) by dihydrofolate reductase. (2) Serine hydroxymethyl-transferase transfers one carbon 
unit from serine to THF, forming 5,10-methylene-THF and glycine. (3) 5,10-methyl THF 
reductase can reduce 5,10-methylene-THF to 5-methyl-THF. Dietary folates absorbed from the 
GI tract can also enter the one-carbon metabolic pathway as 5 methyl THF. (4) Methionine 
synthetase utilizes vitamin B12 as a cofactor to transfer the methyl group of 5-methyl-THF to 
homocysteine (Hcys), generating methionine and THF. Additionally, betaine can donate a methyl 
group for the remethylation of homocysteine to methionine in a reaction catalyzed by betaine 
homocysteine methyltransferase (BHMT). (5) Methionine adenosyltransferase activates 
methionine to form S-adenosylmethionine (SAM). (6) SAM is a methyl donor for a variety of 
acceptors, including guanidinoacetate (GAA—precursor to creatine), DNA, and As, in reactions 
catalyzed by methyltransferases. (7) Hydrolysis of the byproduct of these methylation reactions, 
S-adenosylhomocysteine (SAH), generates Hcys. (8) Hcys is either used to regenerate 
methionine or undergoes transsulfuration to be converted to cysteine. 
 
Many of these nutrients have been studied in the context of iAs metabolism. Overall, the 





direction of the relationship tends to vary by population, possibly due to age, iAs exposure, or 
sufficiency/insufficiency of other nutrients. Folate has been the most studied vitamin and was 
linked to iAs metabolism both experimentally and in human populations (Kile and Ronnenberg 
2008; Hall and Gamble 2012; Kurzius-Spencer et al. 2017). Notably, supplementation of a 
highly-iAs exposed Bangladesh population decreased urinary %iAs and increased urinary 
%DMAs, showing that supplementation may be a viable method to improve efficiency of iAs 
metabolism and possibly reduce iAs toxicity (Gamble et al. 2006). Intake of vitamin B2, B6, and 
B12 and choline have been significantly associated with increased efficiency of iAs metabolism 
(Spratlen et al. 2017, Heck et al. 2007, Hall et al. 2009, Argos et al. 2010; López-Carrillo 2016). 
Individuals with low protein or amino acids levels tend to have a decreased ability to methylate 
iAs due to methionine deficiency, as demonstrated in US cohorts (Steinmaus et al. 2005; 
Kurzius-Spencer et al. 2017) and in Bangladesh (Heck et al. 2007). These dietary nutrients have 
some association with iAs metabolism but further research is needed to clarify the nature of the 
relationship and if modifying intake of these nutrients can alter iAs metabolism and disease risk. 
1.2.4 iAs metabolism and toxicity/disease risk 
Although metabolism of iAs produces DMAsV which is more easily cleared by the body, 
the methylation process generates As species that are more toxic than iAs. Methylated trivalent 
forms of arsenic are more toxic than unmethylated or methylated pentavalent forms (reviewed in 
Thomas et al. 2001). Due to the toxicity of many intermediates of iAs methylation, iAs 
metabolism and its modifiers may be important factors determining risks of various iAs-
associated diseases. Higher urinary %MAs is associated with increased risk of skin lesions, lung 
cancer, hypertension, and urothelial cancer (Antonelli et al. 2014). SNPs in AS3MT that are 





disease, hyperlipidemia, skin lesions, and bladder and lung cancer (Gong and O’Bryant 2012; 
Das et al. 2016; De la Rosa et al. 2017). Polymorphisms in GSTO and PNP have also been 
correlated with disease (Antonelli et al. 2014). Nutritional modifiers of iAs metabolism, 
primarily folate and other B vitamins, and their influence on disease risk has also been 
investigated in the context of skin lesions, urothelial cancer, and cardiovascular disease (Kile and 
Ronnenberg 2008; Hall and Gamble 2012; Howe et al. 2017). Many of these studies were done 
in human populations. Fewer data on how iAs metabolism influences disease development and 
mechanisms are available in experimental models. 
 In summary, iAs metabolism via methylation facilitates clearance of iAs from the body. 
However, it is also an activation process, generating more toxic metabolites that may contribute 
to iAs toxicity. Variations in its efficiency, either through genetic polymorphisms or nutritional 
influences, may influence disease development and risk.  
 
1.3 iAs-associated diabetes 
Diabetes, a condition of chronic hyperglycemia, is a serious, growing public health 
problem. Global prevalence of diabetes in adults has increased substantially, from 4.7% in 1980 
to 8.5% in 2014, and in all major geographical regions (WHO 2016). Unfortunately, prevalence 
and incidence of diabetes is also growing in children (Dabelea et al. 2014; Mayer-Davis et al. 
2017).  While the concurrent rise of obesity is a main cause, it does not fully explain the 
concerning increase in diabetes observed in the last few decades. Evidence for endocrine-
disrupting chemicals and their role as obesogens and diabetogens has been growing (Janesick 
and Blumberg 2016; Heindel et al. 2017; Thayer et al. 2011). Thus, environmental exposures 





associated with higher incidence and prevalance of diabetes, specifically T2D, in multiple 
populations around the world.  
1.3.1 Diabetes: Diagnosis, Pathogenesis, and Classification 
 In 2012, diabetes mellitus was the 8th leading cause of death overall, the 5th leading 
cause of death in women specifically (WHO 2016). In addition, diabetes mellitus is often 
comorbid with cardiovascular disease, cancer, and renal disease, which also have high mortality 
rates. The global cost of diabetes in 2014 was estimated to be $612 billion, around 11% of the 
world’s healthcare costs (da Rocha Fernandes et al. 2016).  
Insulin is the primary glucose-lowering hormone responsible for maintaining glucose 
homeostasis. It is secreted by the pancreatic β-cells which are found in the islets of Langerhans 
in the pancreas. In healthy individuals, high levels of blood glucose trigger insulin secretion by 
the β-cells (Figure 1.5). Insulin then stimulates glucose uptake in adipose tissue and skeletal 
muscle and utilization of glucose in the liver and other tissues, thus lowering blood glucose 
levels to normoglycemia (Figure 1.6). In adipose tissue, insulin also works to inhibit lipolysis 
and stimulate synthesis of triacylglycerides (Dimitriadis et al. 2011). In skeletal muscle, insulin 
stimulates glycogen synthesis and protein synthesis. In the liver, insulin activates synthesis of 
glycogen and triglycerides and inhibits gluconeogenesis. Overall, insulin is an anabolic hormone, 






Figure 1.5. Mechanism of glucose-stimulated insulin secretion in pancreatic β-cells. Glucose 
enters the cell passively through glucose transporter 2, GLUT2 (1). Glucose is metabolized 
through glycolysis (2), generating ATP and increasing the ATP:ADP ratio (3). ATP blocks the 
flow of K+ into the cell through ATP-sensitive potassium channels (KATP) (4). The blockage of K
+ 
flow into the cell stimulates depolarization of the plasma membrane (5), leading to the opening 
of voltage-gated calcium channels (VDCC) (6). Increases in intracellular calcium (Ca2+) (7) 
stimulates Ca2+-dependent mechanisms that control fusion of insulin granules and release of 
insulin (8).  
 
Figure 1.6. Insulin-stimulated glucose uptake in adipocytes and myotubes. Binding of insulin to 
the insulin receptor stimulates phosphorylation of IRS-1/2 (1). Recruitment of PI3K by phospho-
IRS-1/2 enables the conversion of PIP2 to PIP3 (2), which recruits PDK1 and AKT to the cell 
surface (3). PDK1 stimulates the phosphorylation of AKT (4). Phospho-AKT facilitates the 
activation of Rab proteins, leading to translocation of GLUT4 receptors to the plasma membrane 
(5) and uptake of extracellular glucose (6). Abbreviations: IRS-1/2: Insulin receptor substrate 
protein 1/2; PI3K: phosphatidylinositol 3-kinase; PIP2: phosphatidylinositol 4,5-bisphosphate; 
PIP3: phosphatidylinositol 3,4,5-phosphate; PDK1: protein kinase 1; AKT: protein kinase B; 





Defects in insulin secretion and/or insulin action lead to hyperglycemia. In type 1 
diabetes (T1D), there is insufficient or a lack of insulin due to the destruction of β-cells via 
targeted autoimmunity. T1D constitutes 5-10% of diabetes cases. Causes of T1D tend to be 
genetic but some environmental exposures have been suggested (Knip and Simell 2012). The 
majority of individuals with diabetes have type 2 diabetes (T2D), which is characterized by the 
development of insulin resistance where tissues become less responsive to insulin (ADA 2015). 
Insulin resistance results in a chronic overproduction of insulin by β-cells, which can then lead to 
β-cell dysfunction and failure. Obesity is a major risk factor for T2D; other risk factors include 
age, diet, physical inactivity, ethnicity, and sex. The development of diabetes during pregnancy, 
gestational diabetes, increases risk of T2D in women later in life by at least seven-fold (Bellamy 
et al. 2009).  
Diabetes is diagnosed in humans using three measurements: fasting plasma glucose 
(FPG), 2-hour plasma glucose (2HPG), and glycosylated hemoglobin (A1C) (Table 1). Meeting 
the “diabetes” threshold in at least one test is sufficient for diagnosis of diabetes. FPG is the 
measurement of blood glucose levels after an 8-hour fast on two separate occasions. 2HPG is 
measured through an oral glucose tolerance test (OGTT) which measures the ability of the body 
to reduce blood glucose after a meal. Here, plasma glucose is measured two hours after an oral 
glucose load (75 grams for adults). Spontaneous adduction of glucose to hemoglobin in red 
blood cells occurs in the presence of glucose, forming glycosylated hemoglobin that persists 
through the lifespan of the red blood cell. Thus, A1C reflects blood glucose levels over 2-3 
months and can be an indicator of chronic hyperglycemia (ADA 2015). The American Diabetes 
Association (ADA) has also defined prediabetic ranges of these indicators (Table 1). Individuals 





estimated that 7.8% of the global population has prediabetes (IDF 2013). In 2015, 33.9% of US 
adults were prediabetic.  
Table 1.1 Criteria for the diagnosis of prediabetes and diabetes (ADA 2010). 
Test Normal Prediabetes Diabetes 
FPG <100 mg/dl ≥100 to < 126 mg/dl ≥ 126 mg/dl  
2HPG <140 mg/dl ≥140 to < 200 mg/dl ≥ 200 mg/dl  
A1C <5.7% ≥5.7%  to < 6.5% ≥ 6.5% 
 
1.3.2 iAs as an environmental diabetogen 
Chronic exposure to iAs has been associated with increased prevalence or incidence of 
T2D in many populations around the world. In the 2011 National Toxicology Program workshop 
assessing iAs as a diabetogen, it was concluded that there was sufficient evidence of this 
association at high levels of exposure (>150 ppb) but insufficient at low to moderate levels (<150 
ppb) (Maull et al. 2012). Since then, more epidemiological studies have been published on 
confirming this association in populations with low to moderate exposures. Two meta-analyses 
of these studies report pooled relative risks of developing T2D given iAs exposure of 1.7 and 
1.23 (Sung et al. 2015; Wang et al. 2014). The association of iAs exposure has largely been 
observed in the context of T2D. There may be an association of iAs with T1D but very few 
studies have investigated this relationship (Chafe et al 2018; Grau-Perez et al. 2017). Studies in 
rodents report hyperglycemia, impaired glucose tolerance and changes in fasting insulin after 
exposure to ppm levels of iAs (Maull et al. 2012). The diabetogenic phenotype associated with 
iAs differs by study, possibly due to differences in exposure level and/or ethnicity/strain.  
The period of exposure could also contribute to the variability in phenotype observed in 





study individuals that have likely been exposed to iAs their entire life. Furthermore, these 
individuals could also have been exposed to iAs in utero or even preconception. In these 
populations, the effects of iAs during particular exposure windows, i.e. adulthood or during 
prenatal periods, are inseparable. The role of early life iAs exposures on adult disease outcomes, 
also known as the developmental origins of disease paradigm (Heindel et al. 2015), has only 
begun to be addressed. 
How iAs is involved diabetes pathogenesis is still unclear, making it difficult to classify 
iAs-associated diabetes as type 1, type 2, or another type of diabetes. In a Mexican cohort, 
fasting plasma insulin and HOMA-IR, measures of insulin resistance, were negatively associated 
with iAs exposure (Del Razo et al. 2011). These findings suggest a defect in insulin secretion in 
iAs-associated diabetes. In a different Mexican cohort, analysis of urinary and plasma 
metabolites found a subset of metabolites that were specific to iAs-exposed, diabetic individuals 
(Martin et al. 2015). Many of these metabolites were not metabolites associated with T2D 
patients in other studies, suggesting that iAs-associated diabetes may have a different pathology. 
While iAs have been found to impair both insulin secretion and insulin action, further 
investigation is needed to elucidate the progression of iAs-associated diabetes, identifying how 
defects in insulin secretion and/or insulin action develop and the importance of these 
impairments in disease pathogenesis. A better understanding of these mechanisms, and their 
temporality in diabetes development, will help determine the appropriate typology classification 






1.3.3 Mechanisms of iAs-associated diabetes 
  Experimental studies have found that iAs affects both insulin action (resistance) and 
insulin secretion. Other proposed mechanisms include epigenetic modifications such as changes 
in DNA methylation or microRNAs, leading to differential gene expression and disease 
development. Altering DNA methylation is particularly relevant for prenatal iAs exposures since 
DNA methylation is important for proper growth and development of the fetus (Chmurzynska 
2010). The sections below summarize the evidence for these potential mechanisms of iAs.  
1.3.3.1 Effects on insulin action 
 Insulin resistance arises when insulin action is inhibited. Some iAs-exposed rodents 
develop insulin resistance (Huang et al. 2015; Palacios et al. 2012) but some do not (Kirkley et 
al. 2017; Paul et al. 2011; Liu et al. 2014; Douillet et al. 2017). iAs reduced insulin-stimulated 
glucose uptake (ISGU) in both adipocytes and skeletal myotubes by reducing expression of 
glucose transporter GLUT4 (Paul et al. 2007; Padmaja Divya et al. 2015). This decreased 
translocation of GLUT4 to the outer membrane has been proposed to be due to impairments in 
Akt or Sirt3 pathways. Exposure to iAsIII and MAsIII suppressed PDK-1 activity, leading to 
decreased phosphorylation of Akt and, thus, decreased GLUT4 transport to the membrane (Paul 
et al. 2007). In adipocytes and myotubes, the reduction in ISGU was attributed to increased 
oxidative stress, due to decreased Sirt3 signaling, which normally upregulates antioxidant 
defense (Padmaja Divya et al. 2015). In primary hepatocytes, exposure to iAsIII and MAsIII 
decreased glycogen content, a phenomenon also observed in vivo (Zhang et al. 2017; Huang et 
al. 2015). This decrease was concurrent with inhibition of insulin-dependent phosphorylation of 





its metabolites interfere with insulin-dependent signaling pathways in adipose tissue, skeletal 
muscle, and the liver. 
Obesity is strongly associated with insulin resistance due to elevated levels of fatty acids, 
adipokines, and cytokines which interfere with insulin-dependent signaling pathways (Jung et al. 
2014). iAs may promote insulin resistance by influencing adiposity. Though iAs inhibited 
differentiation of pre-adipocytes, it increased adipocyte size, lipogenesis, and lipolysis (Maull et 
al. 2012; Ceja-Galicia et al. 2017). There is also some data suggesting that iAs modulates 
adipokines to promote obesity. For example, iAs decreased mRNA expression of adiponectin, an 
adipokine that improves insulin sensitivity in the liver and muscle (Ceja-Galicia et al. 2017). In 
addition to direct effects on insulin signaling mechanisms, iAs may promote an obesogenic 
environment that would increase an individual’s risk of diabetes. 
1.3.3.2 Effects on pancreatic β-cells and insulin secretion 
Animals exposed to high levels of iAs have decreased fasting plasma insulin 
(Bonaventura et al. 2017; Paul et al. 2011), without decreases in β-cell mass (Kirkley et al. 
2017). Exposure to iAs caused inflammation of pancreatic tissues (Liu et al. 2014) and islet cell 
apoptosis (Lu et al. 2011), attributes observed in diabetic pancreata (Donath et al. 2008; Johnson 
and Luciani 2010). In vitro, iAs and its metabolites inhibit glucose-stimulated insulin secretion 
(GSIS) in β-cells and pancreatic islets at non-cytotoxic levels (Fu et al. 2010; Lu et al. 2011; 
Douillet et al. 2013; Dover et al. 2018). This inhibition may be due to increased reactive oxygen 
species, elevated endoplasmic reticulum stress, mitochondrial dysfunction, changes in calcium 
influx, and/or impairments in secretion mechanisms (Fu et al. 2010; Wu et al. 2018; Lu et al. 
2011; Dover et al. 2018; Díaz-Villaseñor et al. 2008; Bonini and Sargis 2018). Reactive oxygen 





Yao et al. 2015; Pan et al. 2016). iAs has direct effects on β-cell dysfunction or destruction 
which could lead to decreased insulin secretion.  
1.3.3.3 Effects via epigenetics and microRNAs 
 iAs exposure has been linked to alterations in DNA methylation and in microRNA 
profiles, epigenetic modifications that regulate gene expression. In an adult population in 
Mexico, iAs exposure was associated with differential DNA methylation of genes related to T1D 
and T2D (Bailey et al. 2013). Mother-child cohort studies found that prenatal iAs exposure, as 
measured by maternal urinary As, was linked to changes in DNA methylation in cord blood 
(Rojas et al. 2015; Broberg et al. 2014). Specifically, iAs exposure was associated with 
differential methylation of KCNQ1, an imprinted gene that encodes a potassium channel protein 
involved in GSIS (Rojas et al. 2015). iAs exposure is associated with expression of microRNAs 
that are associated with diabetes. These microRNAs control insulin signaling pathways in the 
liver (miR-29), β-cell proliferation (miR-24), and GSIS (miR-375) (Beck et al. 2017). Thus, iAs 
may contribute to the development of diabetes by modifying expression of important genes 
involved in glucose homeostasis through differential DNA methylation or microRNA 
expression.  
1.3.4 Metabolism of iAs and diabetes risk 
 Efficiency of iAs metabolism has been associated with altered risk of diabetes. However, 
unlike cancer and cardiovascular disease where higher urinary MAs was linked to increased risk, 
higher urinary DMAs and lower urinary MAs were associated with diabetes in at least five 
different population studies (Kuo et al. 2017). The association of elevated urinary MAs with 
adverse health effects fits well with the hypothesis of iAs metabolism as a detoxifying process, 





with diabetes and related conditions, such as BMI and obesity (Del Razo et al. 2011; Gomez-
Rubio et al. 2011; Gribble et al. 2013), suggest that the process of complete methylation to 
DMAs may contribute to toxicity.   
 In most mechanistic studies, methylated trivalent As species are more toxic than iAsIII. 
Exposure to 2 µM MAsIII decreased ISGU and inhibited Akt phosphorylation to a similar extent 
as 50 µM iAsIII (Paul et al. 2007). Hepatic glycogen and Akt phosphorylation was significantly 
decreased at 0.5 µM iAsIII and 0.2 µM MAsIII (Zhang et al. 2017). In pancreatic islets, MAsIII 
and DMAsIII significantly inhibited GSIS at lower concentrations than iAsIII (0.1 µM vs. 2 µM) 
(Douillet et al. 2013). These findings suggest that the methylated trivalent metabolites may be 
important contributors to iAs-associated diabetes. Interestingly, mice lacking the As3mt gene 
develop obesity and insulin resistance. These animals were not exposed to iAs in drinking water 
and had some iAs intake through diet (Douillet et al. 2017). Since As3mt-KO mice accumulate 
more iAs in tissues than WT mice (Currier et al. 2016), the toxicity of accumulated iAs may 
explain the differences in metabolism in As3mt-KO mice. Alternatively, knockout of As3mt may 
have impacted regulation of other genes that would lead to the adverse metabolic states observed 
in KO mice. In summary, iAs metabolism appears to be important in iAs-associated diabetes but 
the specifics of how and to what extent methylated trivalent arsenicals contribute to disease 
development remain unknown.  
 
1.4 Summary and Approach 
Chronic exposure to iAs has been associated with diabetes in many populations around 
the world. Though metabolism of iAs through methylation facilitates clearance, it also generates 





metabolism in diabetes development remains unclear. This project seeks to understand the role of 
iAs metabolism in the development of iAs-associated diabetes through three distinct approaches. 
First, we used metabolomics to characterize the As3mt-KO mouse, analyzing metabolites to 
identify disruptions in biochemical pathways associated with the As3mt-KO genotype (i.e. 
inability to methylate iAs) and with iAs exposure (Chapter 2). Second, we used nutritional 
interventions to modify iAs metabolism and metabolic phenotype in mice, in prenatal and adult 
exposure studies (Chapter 3 and 4). Third, we conducted in vitro experiments in isolated 
pancreatic islets to determine the mechanism of how iAs and its methylated metabolites inhibit 
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2. CHAPTER 2- Metabolomic profiles of arsenic (+3 oxidation state) methyltransferase 
knockout mice: Effect of sex and arsenic exposure 
 
 The first half of this chapter outlines a metabolomics study assessing the effect of iAs 
exposure and As3mt-KO on urinary and plasma metabolite profiles in mice. Based off findings 
from shifts in plasma and urinary metabolites, we conducted a follow-up study on liver 
phosphatidylcholines in these animals and is described in the latter half of the chapter.  
 
2.1 Plasma and Urinary Metabolite Profiles1 
2.1.2 Overview 
 Arsenic (+3 oxidation state) methyltransferase (AS3MT) is the key enzyme in the 
pathway for methylation of inorganic arsenic (iAs). Altered As3mt expression and AS3MT 
polymorphism have been linked to changes in iAs metabolism and in susceptibility to iAs 
toxicity in laboratory models and in humans. As3mt-knockout mice have been used to study the 
association between iAs metabolism and adverse effects of iAs exposure. However, little is 
known about systemic changes in metabolism of these mice and how these changes lead to their 
increased susceptibility to iAs toxicity.  Here, we compared plasma and urinary metabolomes of 
male and female wild-type (WT) and As3mt-KO (KO) C57BL6 mice and examined metabolomic 
                                                 
1 Madelyn C. Huang, Christelle Douillet, Mingming Su, Kejun Zhou, Tao Wu, Wenlian Chen, Joseph A. Galanko, 
Zuzana Drobná, R. Jesse Saunders, Elizabeth Martin, Rebecca C. Fry, Wei Jia, Miroslav Stýblo. (2017). Archives of 







shifts associated with iAs exposure in drinking water. Surprisingly, exposure to 1 ppm As 
elicited only small changes in the metabolite profiles of either WT or KO mice. In contrast, 
comparisons of KO mice with WT mice revealed significant differences in plasma and urinary 
metabolites associated with lipid (phosphatidylcholines, cytidine, acyl-carnitine), amino acid 
(hippuric acid, acetylglycine, urea), and carbohydrate (L-sorbose, galactonic acid, gluconic acid) 
metabolism. Notably, most of these differences were sex-specific. Sex-specific differences were 
also found between WT and KO mice in plasma triglyceride and lipoprotein cholesterol levels. 
Some of the differentially changed metabolites (phosphatidylcholines, carnosine, and sarcosine) 
are substrates or products of reactions catalyzed by other methyltransferases. These results 
suggest that As3mt KO alters major metabolic pathways in a sex-specific manner, independent of 
iAs treatment, and that As3mt may be involved in other cellular processes beyond iAs 
methylation.  
2.1.2 Introduction  
Chronic exposure to inorganic arsenic (iAs) via drinking water affects millions of people 
worldwide and is associated with an increased risk of cancer (NRC, 1999) as well as non-cancer 
diseases such as neurological (Tyler and Allen, 2014) and cardiometabolic disorders, including 
cardiovascular disease (Tsuji et al., 2014) and diabetes (Maull et al., 2012).  In spite of the 
abundant evidence linking iAs exposure to a variety of adverse health effects, questions remain 
about the underlying biological mechanisms. Studies using powerful omics technologies, 
including metabolomics, may help to answer these questions.   
Several recent studies have used metabolomics to characterize metabolic profiles 
associated with iAs exposure.  A metabolomic study carried out in the general Chinese 





Similarly, our recently published metabolomic analyses of urine and plasma from residents of 
Chihuahua, Mexico found 132 metabolites that were altered in iAs-exposed individuals (Martin 
et al., 2015). Metabolomic responses to iAs exposure have also been studied in laboratory 
animals, although most studies have focused on the effect of exposure to high levels of iAs 
(Garcia-Sevillano et al., 2014a,b; Wang et al., 2014), which may not be relevant to human 
environmental exposures. The only other study that examined effects of low, chronic iAs 
exposure was carried out in rats (Wang et al., 2015). However, rats are not considered a suitable 
animal model because avid binding of iAs metabolites to rat hemoglobin generates unique 
kinetics and pattern of iAs metabolism that differ from those in humans and other mammals (Lu 
et al., 2004). Overall, the effects of chronic iAs exposure on the metabolome of humans and of 
rodent species commonly used in laboratory studies of iAs toxicity, specifically mice, remain 
understudied. 
Results of both population and laboratory studies suggest that severity of adverse effects 
of iAs exposure is determined, in part, by efficiency of iAs metabolism (Antonelli et al., 2014; 
Tseng et al., 2009). In humans and many other species, metabolism of iAs occurs by subsequent 
enzymatic methylation of iAs to form monomethyl-As (MAs) and dimethyl-As (DMAs), and in 
some species also trimethyl-As (TMAs) metabolites (Thomas et al., 2007). Arsenic (+3 
oxidation state) methyltransferase (AS3MT) is the primary enzyme that catalyzes the 
methylation of iAs (Thomas et al., 2007). Experimental expression of rat As3mt in human 
urothelial (UROtsa) cells that do not express the AS3MT gene enables iAs methylation, and 
silencing of AS3MT in human hepatocellular carcinoma (HepG2) cells reduces the cell’s capacity 
for iAs methylation (Drobná et al., 2005; Drobná et al., 2006). Furthermore, knockout of As3mt 





accumulation of iAs in tissues (Drobná et al., 2009). For this reason, As3mt-catalyzed 
methylation of iAs was thought to be a detoxification process because it increases clearance of 
iAs from the body. However, we and others have shown that the methylated metabolites 
containing trivalent As (AsIII) contribute to the toxicities associated with iAs exposure (McCoy 
et al., 2015; Rehman et al., 2014; Stýblo et al., 2000; Tseng, 2009; Watanabe et al., 2012). Thus, 
while iAs methylation  
Since As3mt is the enzyme responsible for clearance of iAs from the body and for 
generation of trivalent methylated metabolites, As3mt-knockout (KO) cells or mice are useful 
models for studying the role of iAs metabolism in adverse effects of iAs exposure.  These 
models can also be used to explore other potential functions of AS3MT. AS3MT orthologs are 
found in many living organisms, ranging from simple invertebrates to modern-day humans 
(Thomas et al., 2007).  The conservation of AS3MT across species and during evolution suggests 
that, in addition to detoxifying iAs, this enzyme may act on other substrates (Thomas et al., 
2007) and could play a role in metabolic pathways essential for survival (Uthus, 1992). While 
As3mt-KO mice are viable and do not show signs of dysfunction, a metabolomic analysis may 
reveal clues about the role of AS3MT beyond iAs methylation. 
The present study examined plasma and urine metabolomes in As3mt-KO C57B6 mice 
and C57B6 wild-type (WT) mice exposed to iAs in drinking water and in unexposed control 
mice. The main goals were: (i) to characterize the metabolic response to iAs treatment, thus 
providing additional clues about the mechanisms underlying effects of iAs exposure, (ii) to 
compare the metabolic responses of WT mice that can efficiently methylate iAs with those of 
As3mt-KO mice that have severely impaired iAs methylation capacity, and (iii) to probe for 






Animals and treatment. All procedures involving mice were approved by the University of North 
Carolina (UNC) Institutional Animal Care and Use Committee. Male and female C57BL6 WT 
mice were obtained from Jackson Laboratories (Bar Harbor, ME) at 17 weeks (±3 days) of age. 
Male and female As3mt-KO mice on a C57BL6 background (Drobná 2009) were bred at the 
UNC Animal Facilities and were 17-20 weeks old at the beginning of the study. All mice were 
housed under controlled conditions (12-h light/dark cycle at 22+-1oC and 50±10% relative 
humidity) with ad libitum access to pelleted rodent chow (Prolab Isopro RMH 3000, LabDiet, St. 
Louis, MO). Mice drank either deionized water or deionized water containing 1 ppm As as 
arsenite (iAsIII) ad libitum for four weeks (N=15-21 per experimental group). Water with iAsIII 
was freshly prepared every week to minimize oxidation of iAsIII to iAsV. Food and water 
consumption and body weight were monitored in all treatment groups every week and two 
weeks, respectively.  
 
Urine and plasma collection. At the end of iAs-treatment, urine was collected from mice housed 
in metabolic cages (1 mouse per cage) for 24 hours without access to food to avoid food 
contamination in urine samples. Urine was aliquoted and stored at -80ºC until analysis. Blood 
from non-fasted mice was collected prior to sacrifice via submandibular bleeding using 
heparinized Caraway micro-capillaries (Fisher Sc, Pittsburgh, PA). Plasma was isolated by 
centrifugation at 2000g for 10 minutes (at 4oC) and stored at -80ºC until further analysis.  
 
Analysis of iAs metabolites in urine. Hydride generation-atomic absorption spectrometry coupled 
with a cryotrap (HG-CT-AAS) was used to determine the concentration of As species, including 





(Hernandez-Zavala et al., 2008).  As previously reported, limits of detection for this method are: 
0.05 ng As/mL for MAs or DMAs and 0.1 ng As/mL for iAs (Martin et al., 2015). The 
concentration of total speciated As in urine was calculated as sum of iAs, MAs, and DMAs. For 
quality control, a certified standard reference material Arsenic Species in Frozen Human Urine 
(SRM 2669; National Institute of Standards and Technology) was analyzed with the mouse urine 
samples. The recoveries of As from this SRM ranged from 87% for DMAs to 91% for iAs, 
 
Metabolomic analysis. Numbers of plasma and urine samples used for the metabolomic analysis 
ranged from 13 to 21 per experimental group (volumes collected from some mice were not 
sufficient for the analyses). Samples were prepared as previously described with some 
modifications (Ni et al., 2014; Qiu et al., 2014; Qiu et al., 2013). Briefly, the samples were 
extracted with cold organic solvents (for plasma - methanol:chloroform, 3:1; for urine - 
acetonitrile). The supernatant was split for targeted metabolic profiling of 180 amino acids and 
lipids with an Acquity ultra performance liquid chromatography coupled to a Xevo TQ-S mass 
spectrometer (LC-MS, Waters Corp., Milford, MA), and for untargeted metabolic profiling with 
an Agilent 7890A gas chromatograph coupled to a Leco Pegasus time of flight mass 
spectrometer (GC-MS, Leco Corp., St Joseph, MI). The raw data files generated from LC-MS 
and GC-MS were processed, respectively, with TargetLynx Application Manager (Waters Corp., 
Milford, MA) and ChromaTOF software (Leco Corp., St Joseph, MI), in order to extract peak 
signal (normalized by dividing metabolite peak area by total chromatogram area), mass spectral 
data, and retention times for each metabolite. The detected metabolites from both analytical 
platforms were annotated and combined using an automated mass spectral data processing 





Metabolomic data analysis. ANOVA and hierarchical clustering analysis were conducted using 
Partek Genomics SuiteTM Software (St. Louis, MO). Data were analyzed using a three-way 
multi-variate ANCOVA model including sex, genotype, and iAs treatment as covariates. To 
identify significantly changed metabolites between groups (i.e., differentially changed 
metabolites), significance was set with a False Discovery Rate (FDR) corrected q-value of 
q<0.05. Unsupervised two-way hierarchical clustering was performed on standardized data from 
LC-MS and GC-MS analysis with unknown metabolites excluded. Metabolites or animals were 
clustered using a Euclidean distance metric and average linkage. Results were displayed as a 
heatmap representing fold-difference from the overall mean of each metabolite. To maximize the 
probability of capturing relevant metabolites for pathway analysis, a less stringent cutoff value of 
p<0.05 was used to select metabolites for pathway analysis. Pathways with p<0.05 using the 
online tool, MetaboAnalyst (Xia, 2010), were determined to be significant. The KEGG Pathway 
database was used to create a pathway map specific to this investigation (Kanehisa, 2000).   
 
Plasma lipid analysis. Plasma triglycerides and cholesterol associated with high density 
lipoproteins (HDL) fraction and with a combined low density/very low density lipoprotein 
(LDL/VLDL) fraction were analyzed using commercial enzymatic assays according to 
manufacturer’s instructions (Wako Diagnostics, Mountainview, CA and Abcam, Cambridge, 
MA, respectively). Data was analyzed with a full factorial three-way ANOVA analysis 
considering sex, treatment, and genotype with post hoc Student’s t tests assessing relevant 







iAs methylation phenotype and body weight 
The speciation analysis of As by HG-CT-AAS was conducted in the 24-hour urine 
samples collected from mice in all experimental groups. The average concentrations of total 
speciated As in the urine of WT and As3mt-KO mice treated with 1 ppm As in drinking water 
were about 10-fold higher than in the urine of the corresponding controls (466 ng/ml vs. 47 
ng/ml in WT, 545 ng/ml vs. 57 ng/ml in KO mice) (Figure A.1). Knockout of As3mt had no 
statistically significant effects on total urinary As levels within the control groups.  However, in 
iAs-treated animals, KO mice had significantly higher levels of total speciated As levels in urine 
as compared to iAs-treated WT mice. No significant differences were found between male and 
female mice in any groups.  The majority of total speciated As in the urine of As3mt-KO mice 
was represented by iAs: on average 58% for controls and 91% for iAs-treated mice. In contrast, 
iAs accounted for only 8 and 10% of total speciated As in urine of WT controls and iAs-treated 
mice, respectively. DMAs was the major As metabolite, representing 40% of total urinary As in 
control KO mice and 89% in control WT mice. In iAs-treated animals, DMAs constituted 9% of 
total urinary As in KO mice and 92% in WT mice. Notably, treatment with 1 ppm As had no 
significant effects on body weights of either WT or As3mt-KO mice (Figure A.2). There were no 
differences in the weights of female KO and WT mice, regardless of treatment. However, male 
KO mice treated with iAs were heavier at sacrifice than the iAs-treated, WT males. There were 
no differences in food consumption. Male WT mice drank more water than female WT mice and 
male KO mice (Figure A.3). 
Plasma and urine metabolites identified by metabolomics analyses 
The targeted analysis using LC-MS identified 172 metabolites in plasma and 135 





plasma and urine, respectively, and 184 plasma and 320 urinary unidentified metabolites which 
were excluded from subsequent analyses. Thus, a total of 248 plasma and 233 urinary metabolites 
were identified (Table A.1) and used in the statistical analyses. Unsupervised two-way clustering 
analysis showed that animals with similar metabolite profiles clustered primarily by sex and, to a 
much lesser extent, by genotype or iAs treatment (Figure 2.1). Further comparisons characterized 
differences in the plasma and urine metabolomes between experimental groups differentiated by 
sex, genotype and treatment. 
 
Figure 2.1. Urinary and plasma metabolites identified by metabolomic analyses: Heat maps 
generated by unsupervised two-way clustering analysis show relative levels of metabolites 
(columns) in plasma (A) and urine (B) of control (0 ppm) and iAs-treated (1 ppm) male (M) and 
female (F) wild-type (WT) and As3mt-KO (KO) mice (rows). The metabolite levels are mean 
centered with high relative levels indicated in red and low relative levels indicated in blue.  
 
Changes in plasma and urine metabolomes associated with iAs treatment 
 Direct comparisons of plasma and urinary metabolite concentrations of control mice and 
iAs-treated mice revealed only minor shifts associated with iAs treatment, and only in plasma of 
female As3mt-KO mice (Table 2.1). All three significantly changed urine metabolites (two acyl-
carnitine species and a sphingomyelin species) were associated with lipid metabolism. No 





However, the effect of iAs treatment can be inferred indirectly by comparing the number of KO-
associated metabolites in iAs-treated and control mice. For example, 42 metabolites were 
changed in plasma and urine of control female KO mice when compared with control female WT 
mice; however, only 15 metabolites were found significantly changed in comparison of KO and 
WT female mice treated with 1 ppm iAs (Table 2.1; Figure A.4).  Similar differences in numbers 
and types of KO-associated metabolites can be seen in male control mice when compared to 
male iAs-treated mice (Table 2.1; Figure A.4). These observations imply that the effect of iAs-
treatment on the plasma and urine metabolite profiles may be greater than that indicated by direct 
comparison.  
 
Table 2.1. Plasma and urinary metabolites found significantly changed (q<0.05) in comparisons 
assessing effect of iAs treatment in male and female wild-type (WT) and As3mt-knockout (KO) 








Metabolite q-value Fold 
change 
KO, female 
1 ppm vs 0 ppm 
C18:1 0.01 -1.50  none     
C14 0.02 -1.36       
SM (OH) C14:1 0.01 1.79       
KO, male 
1 ppm vs 0 ppm  
none      none     
WT, female 
1 ppm vs 0 ppm   
none      none     
WT, male 
1 ppm vs 0 ppm 
none      none     
*CX:Z, acyl-carnitine; SM(OH)CX:Z, sphingomyolipid (X indicates number of carbons of the 










Changes in plasma and urine metabolomes associated with As3mt KO 
To characterize the effect of As3mt knockout on plasma and urine metabolomes, we 
identified all plasma and urinary metabolites that were shifted in control and iAs-treated male 
and female KO mice when compared to their respective wild-type counterparts (Table 2.2). From 
these comparisons, we selected the plasma and urinary metabolites that changed in both KO 
male and female mice, thus isolating metabolites associated with As3mt KO, regardless of sex. 
Control female KO mice had more than double the number of the KO-associated metabolites 
found in male KO mice (Figure 2.2). In the iAs-treated groups, female KO mice showed half as 
many KO-associated metabolites as compared to males (Figure 2.2). The KO-associated 
metabolites common to control male and female KO mice were two phosphatidylcholine (PC) 
species (PC aa C36:0, PC aa C40:4) and cytidine, all increased in KO mice.  Three KO-
associated metabolites, all PC species, were common to iAs-treated male and female KO mice 
(PC aa C26:0, PC aa C36:5, PC ae C34:1).  
 
Figure 2.2. Number of urinary and plasma metabolites significantly changed (q<0.05) in 
As3mt-knockout (KO) male and female mice in comparison with wild-type (WT) counterparts. 
Venn diagrams show overlapping and sex-specific plasma and urinary metabolites of control 
(left) and iAs-treated (right) mice. The bolded numbers represent the total number of changed 
metabolites in each section of the diagram; the arrows indicate metabolites that increased or 





KO-associated changes in urine metabolome 
  In comparisons of control animals, female KO mice had more differentially changed 
urinary metabolites than KO males when compared to respective WT mice. A total of 27 
metabolites were changed in KO female controls but only seven metabolites had a fold change 
greater than 2: 2-hydroxybutyric acid, L-sorbose, gluconic acid, galactonic acid, cytidine, urea, 
and sarcosine (Table 2.2, Figure 2.3A-C). Thirteen metabolites were changed in control KO 
males, including five with fold changes greater than 2: cytidine, acetylglycine, hippuric acid, 
carnosine, and one acyl-carnitine species (C14:2-OH) (Table 2.2, Figure 2.3A, D-F). The highest 
fold changes were found for acetylglycine and hippuric acid, but acetylglycine decreased by 8-
fold while hippuric acid increased by 16-fold. Similar, though not significant, changes in 
hippuric acid and acetylglycine were found in comparisons of female KO mice vs. WT mice. 
Cytidine was increased in urine of both male and female KO mice as compared to respective WT 
mice (Table 2.2, Figure 2.3A). In comparisons of iAs-treated mice, male KO mice had more 
significantly changed metabolites than KO females (15 vs. 11) when compared to the respective 
WT mice. Of the 11 changed metabolites in female KO mice, six metabolites had fold changes 
greater than 2: citrulline, aminoadipic acid, 2-hydroxybutyric acid, glutamate, and two PCs (PC 
aa C26:0 and PC ae C30:2) (Table 2.2). The urinary concentration of 2-hydroxybutyric acid 
remained significantly decreased in female KO mice after treatment with iAs (Table 2.2). In 
male KO mice, seven metabolites had fold changes greater than 2: 4-hydroxybenzoic acid, 
carnosine, gluconolactone, cytidine, hippuric acid, and two acylcarnitine species ( C14:2-OH and 
C14:2) (Table 2.2). Cytidine and hippuric acid were still significantly increased in iAs-treated 
male KO mice as compared to iAs-treated male WT mice but acetylglycine levels were no longer 





lower in iAs-treated as compared to control mice, but these differences were not statistically 
significant (Figure 2.3A,B). The urinary levels of these two metabolites followed similar trends 
in female mice but changes due to knockout of As3mt were not statistically significant.  
Table 2.2. Plasma and urinary metabolites found significantly changed (q<0.05) in comparisons 
of As3mt–KO (KO) and wild-type (WT) male and female mice. Fold change indicates difference 












Control, female  
KO vs WT (42)* 
Urea 0.03 -5.97 PC aa C38:3 <0.01 1.34 
2-Hydroxybutyric acid <0.01 -2.48 PC aa C38:0 <0.01 1.29 
Suberic acid 0.02 -1.81 PC aa C36:3 0.04 1.17 
Adipic acid 0.01 -1.57 PC aa C42:1 0.04 1.19 
Pelargonic acid 0.03 -1.45 PC ae C40:2 0.02 1.20 
Glycolic acid 0.03 -1.39 PC aa C36:1 0.02 1.20 
3-Methyl-2-oxovaleric acid 0.04 -1.22 PC ae C42:2 0.04 1.21 
Creatinine 0.04 -1.04 PC ae C36:5 0.01 1.22 
PC ae C36:5 0.04 1.21 PC aa C42:2 0.02 1.23 
PC aa C36:0 0.01 1.25 PC aa C36:2 0.04 1.23 
PC ae C36:3 <0.01 1.26 PC aa C40:1 0.02 1.24 
PC ae C36:4 <0.01 1.28 PC aa C40:4 0.03 1.26 
C18:1-OH 0.04 1.38 PC aa C40:6 0.02 1.27 
C18 0.02 1.45 PC aa C38:4 0.03 1.28 
D-Threitol 0.03 1.50 Valine 0.04 1.28 
Ribonolactone 0.04 1.52       
Myoinositol 0.02 1.60       
C18:1 <0.01 1.62       
L-Arabitol 0.01 1.63       
1,5-Anhydrosorbitol 0.03 1.77       
Adenosine 0.03 1.78       
Dopamine 0.04 1.80       
Cytidine 0.04 2.21       
Sarcosine 0.04 2.21       
Galactonic acid <0.01 3.36       
Gluconic acid <0.01 3.36       
L-Sorbose 0.05 4.00       
Control, male 
KO vs WT (17)* 
Acetylglycine <0.01 -16.82 Carnosine 0.01 -1.49 





C14:2-OH 0.02 -2.31 PC aa C32:1 <0.01 1.47 
Aspartate <0.01 -1.96 Oxoglutaric acid 0.04 1.59 
C7-DC 0.02 -1.85       
Uracil 0.04 -1.64       
PC aa C36:0 <0.01 1.29       
PC aa C40:4 <0.01 1.58       
2-Hydroxy-3-
methylbutyric acid 
<0.01 1.69       
C6 (C4:1-DC) 0.01 1.69       
PC aa C40:5 <0.01 1.82       
Cytidine <0.01 2.74       
Hippuric acid <0.01 8.51       
iAs-treated, female 
KO vs WT (15)* 
Citrulline 0.01 -3.58 PC aa C26:0 <0.01 -1.19 
PC aa C26:0 0.02 -2.50 PC aa C38:3 0.01 1.29 
Aminoadipic acid 0.01 -2.41 PC aa C36:5 0.01 1.27 
2-Hydroxybutyric acid <0.01 -2.32 PC aa C36:1 <0.01 1.26 
PC ae C30:2 <0.01 -2.30       
Glutamate 0.02 -2.15       
Ketoleucine <0.01 -1.64       
PC ae C34:1 <0.01 -1.39       
PC aa C38:6 <0.01 -1.33       
PC ae C40:6 <0.01 -1.28       
PC ae C36:4 <0.01 1.24       
iAs-treated, male 
KO vs WT (36)* 
C14:2-OH <0.01 -2.91 C18:1 <0.01 -1.99 
4-Hydroxybenzoic acid 0.03 -2.81 C18:2 <0.01 -1.97 
Carnosine <0.01 -2.25 C7-DC 0.01 -1.86 
Gluconolactone 0.01 -2.01 C18 <0.01 -1.86 
C14:2 0.02 -1.98 Carnosine <0.01 -1.82 
Uridine 0.02 -1.90 C16 <0.01 -1.75 
D-Glucuronic acid 0.04 -1.31 Spermidine <0.01 -1.70 
2-Hydroxy-3-
methylbutyric acid 
<0.01 1.45 C16:2-OH <0.01 -1.61 
Adenine 0.03 1.52 C18:1-OH 0.03 -1.59 
Succinic acid 0.05 1.79 Kynurenine 0.02 -1.51 
O-Phosphoethanolamine 0.01 1.86 C14:2 0.01 -1.50 
Glycerol 3-phosphate 0.01 1.94 C16:1-OH 0.03 -1.45 
PC aa C40:5 <0.01 2.18 t4-OH-Pro <0.01 -1.42 
Cytidine <0.01 2.49 Phenylalanine 0.03 -1.37 
Hippuric acid 0.01 9.42 Tryptophan 0.04 -1.33 
      PC ae C34:1 0.02 -1.24 
      PC aa C26:0 <0.01 -1.14 
      PC aa C36:5 0.02 1.26 





      PC aa C40:3 0.01 1.51 
      PC aa C32:1 <0.01 1.59 
*Numbers in parentheses indicate total number of changed metabolites in that comparison. CX; acyl-
carnitine where X indicates number of carbons of the fatty acid tail. SM; sphingomyolipid. 
Phosphatidylcholine notation: PC; phosphatidylcholine, aa; two fatty acid ester linkages, ae; one ester and 
one ether linkage, CY:Z is a description of the fatty acid composition of two PC tails where Y indicates 
total number of carbons in both fatty acid tails and Z indicates total number of double bonds. 
 
 
Figure 2.3. Relative concentrations of selected metabolites determined by GC-MS (A,B,D,E) or 
LC-MS (C, F) in urine of wild-type (WT) and As3mt-knockout (KO), male (M) and female (F) 
mice, control (0 ppm) or iAs-treated (1 ppm). Mean and SE are shown with N=13-21 per group. 





KO-associated changes in plasma metabolome 
Fewer metabolites were found to be significantly changed due to knockout of As3mt in 
plasma than in urine. Notably, most of the KO-associated metabolites in plasma were PC 
species. The greatest number of changed PCs was found in the comparison of control KO and 
WT females; all these PCs were increased in plasma of KO females, although the fold-change 
did not exceed 1.34 (Table 2.2). When male control KO mice were compared with control WT 
males, two PCs were changed (one increased and one decreased), along with carnosine 
(decreased) and oxoglutaric acid (increased).  In comparisons of iAs-treated KO and WT mice, 
PCs were changed (generally increased) in plasma of both female and male KO mice (Table 2.2). 
All 4 changed metabolites in plasma of females were PCs (3 increased, 1 decreased). The iAs-
treated male KO mice had more significantly changed PCs in the plasma than iAs-treated 
females (6 vs. 4), as well as more significantly changed metabolites overall (21 vs. 4), when 
compared to the respective WT mice. The KO-associated metabolite changes in iAs-treated male 
mice included decreased levels of carnosine, spermidine, kynurenine, and various acyl-carnitine 
species, though fold-changes did not exceed 2. Plasma acyl-carnitines were changed only in 
comparison of iAs-treated male KO and WT mice.  
 
Metabolic pathways affected by iAs treatment and As3mt knockout  
Because very few metabolites were found to be changed by iAs treatment using the 
q<0.05 filter (Table 2.1), a less stringent cutoff value of p<0.05 was used to identify significantly 
changed plasma and urinary metabolites for the analysis of pathways affected by iAs-treatment, 
as well as by As3mt KO (Table A.2 and A.3). Using Metaboanalyst, many pathways were 





contained only one to three changed metabolites (hits) and often the same few metabolites were 
responsible for hits in multiple pathways (Table A.4). Furthermore, the Metaboanalyst program 
considered all PC species as one metabolite, thus underestimating effects on PC metabolism.  
Even with a less stringent cutoff, a relatively small number of metabolites were identified 
as significantly changed due to iAs treatment (Table A.2). The pathways enriched as a result of 
iAs-treatment were genotype- and sex-specific. Pathways of amino acid metabolism were 
enriched only in iAs-treated male and female WT mice when compared to the respective 
controls; however, the enriched pathways in WT females were associated with D-glutamate, 
histidine, and valine/leucine/isoleucine metabolism, while pathways of L-glutamate, 
alanine/aspartate/glutamate, arginine/proline, and beta-alanine metabolism were enriched in male 
WT mice (Table A.4). In KO mice, the pathways enriched by iAs treatment were associated 
mainly with metabolism of lipids (in males) and carbohydrates (in females).  
Pathways of amino acid metabolism were also enriched in comparisons of As3mt-KO and 
WT mice, but again the numbers and types of these pathways were both sex- and treatment-
specific (Table A.4). Enrichment of pathways associated with lipid (including PC) metabolism 
was found in control and iAs-treated KO males, but not in KO female mice. Although most 
changes in individual PC metabolites were detected in the comparison of control female KO 
mice to control WT females (Table 2.2), no significantly enriched pathways of PC metabolism, 
or lipid metabolism in general, were found by the pathway analysis, likely because the program 
treated the numerous PC species as one metabolite. In iAs-treated mice, As3mt KO was also 
linked to the enrichment of pathways of carbohydrate metabolism, but the enriched carbohydrate 





As3mt KO in either male or female mice included the pathways of glutathione, propanoate, and 
panthothenate and coenzyme A metabolism (Table A.4).  
To generate a holistic picture of the pathways affected by As3mt KO without the 
restrictions inherent to the pathway analysis program, a pathway map of metabolites 
differentially changed (q<0.05) due to As3mt KO was constructed using KEGG’s mus musculus-
specific pathway map database (Figure 2.4). The resulting map includes the enriched pathways 
described in Table 2, but highlights the sex-specific differences, the direction of change, and 
depicts the metabolites that are reported to form connections between the affected pathways.  
 
Effects of iAs-treatment and As3mt KO on plasma lipid concentrations 
 To further probe changes in plasma lipids, particularly the PC metabolites that were 
observed across all comparisons, we measured concentrations of plasma triglycerides and of 
lipoprotein cholesterol as indirect measures of plasma lipoprotein concentrations. Average 
triglyceride concentrations were generally higher in KO mice as compared to WT mice, but this 
difference was statistically significant only in iAs-treated males (Figure 2.5A). The plasma of 
KO male mice contained significantly more triglycerides than plasma of KO females, regardless 
of iAs treatment, and control WT male mice had higher levels of triglycerides than control WT 
females. Treatment with iAs had no significant effects of triglyceride levels in either WT or KO 
mice. Very few statistically significant differences were found in the VLDL/LDL-cholesterol 
levels (Figure 2.5B). WT females had lower VLDL/LDL cholesterol than KO females but this 
difference was only significant in iAs-treated animals. In contrast, WT males had higher 
VLDL/LDL-cholesterol levels than KO males, but only statistically significant in control males. 





interaction to be statistically significant (p=0.005), thus confirming that the effect of genotype on 
VLDL/LDL cholesterol is different in males than in females. Treatment with iAs had no effect  
on VLDL/LDL- or HDL-cholesterol in any group. HDL-cholesterol levels were higher in plasma 
of male as compared to female mice, in both WT and KO animals (Figure 2.5C). 
 
Figure 2.4. Concentrations of lipids in plasma of wild-type (WT) and As3mt-knockout (KO), 
male (M) and female (F), control (0 ppm) and iAs-treated (1 ppm) mice: A, triglycerides   (N=9-
19); B, LDL/VLDL-cholesterol (N= 8-15); C, HDL-cholesterol (N= 8-15). Data shown as mean 






Figure 2.5. Diagram of metabolic pathways involving metabolites significantly altered (q<0.05) in plasma or urine of control and/or 
iAs-treated male and female As3mt-knockout mice when compared to corresponding wild-type males and females. Arrows indicate a 









Effects of iAs treatment 
We identified very few metabolites in KO and WT mice that were significantly changed 
due to iAs treatment using a direct ANOVA comparison. This result is consistent with data 
reported by Wang and associates (2015) who conducted a metabolomic study in male Sprague-
Dawley rats exposed to 0.5, 2, or 10 ppm iAs in drinking water for 3 months. They found no or 
very few changes in the plasma metabolome at 0.5 and 2 ppm, but observed major changes in 
lipid, amino acid, and nucleotide metabolism at 10 ppm As. Thus, treatment with 1 ppm As for 
only 4 weeks may not be sufficient to result in metabolic disturbances in rats or mice. It is also 
possible that mice in our study adapted to iAs, due to background exposure to iAs in the diet.  
Adaptation to iAs has been reported in mice exposed to iAs via inhalation (Aranyi et al., 1984). 
Though we did not analyze As in the mouse diet, the results of As analysis in urine of control 
mice (Figure A.1) indicate a low-level background As exposure. Thus, background exposure to 
iAs from diet used in this study could result in adaptation leading to only minor metabolic 
changes after additional exposure to 1 ppm As.  
The lack of major metabolic shifts in mice exposed to 1 ppm As also raises questions 
about differences between rodents and humans in metabolism of and susceptibility to iAs. Mice 
are thought to metabolize iAs more efficiently than humans (Vahter, 1994), and thus may be 
more resistant to iAs exposure. Our recent study in Chihuahua, Mexico showed that exposures to 
only ppb levels of As in drinking water (up to ~200 ppb) result in extensive metabolite shifts in 
human plasma and urine (Martin et al., 2015).  This result may indicate higher susceptibility of 
humans to iAs toxicity and may justify application of higher doses of iAs in laboratory studies 





Effects due to As3mt KO: The role of sex 
Unsupervised hierarchical clustering analysis showed that mice with similar metabolite 
profiles were clustered primarily by sex, and less by genotype or treatment (Figure 2.1). 
Significantly changed metabolites were different in males and females, further indicating that sex 
modifies the effect of the KO genotype on the metabolite profiles. Pathway analysis suggests that 
changes associated with knockout of As3mt were related to lipid, amino acid, and carbohydrate 
metabolism. Lipid metabolism was changed in both KO males and females but alterations in 
other pathways appeared to be largely sex specific.  
 
Effects on lipid metabolism 
Decreased levels of plasma PCs, increased triglycerides, increased acyl-carnitines and 
lyso-PCs have been previously reported in mice administered 3 mg As/kg/day by gavage 
(Garcia-Sevillano et al., 2014a). Increased levels of acyl-carnitines and lyso-PCs were also found 
in plasma of rats exposed to 10 ppm As in drinking water (Wang et al., 2015).  Changes in the 
same types of lipid metabolites were also found in the present study, but these changes were 
primarily associated with As3mt KO and to a much lesser extent with iAs treatment.  
Knockout of As3mt was associated with extensive changes in PC species and a related 
metabolite, cytidine, across all comparisons, with the most prominent changes in the comparison 
of female KO vs. female WT mice (Table 2.2). Biosynthesis of PCs occurs via two pathways: the 
cytidine-diphosphate (CDP) pathway and the pathway catalyzed by phosphatidyethanolamine N-
methyltransferase (PEMT). In the CDP-pathway, CDP-choline is combined with diacylglycerol 
to form PC. The PEMT pathway involves three subsequent methylations of 
phosphatidylethanolamine using S-adenosylmethionine (SAM) as a methyl group donor. The 





Akesson, 1975). Notably, knockout of PEMT in mice has been shown to alter plasma 
lipoproteins levels in a sex-specific manner (Noga and Vance, 2003) and PEMT activity appears 
to be regulated by estrogen (Resseguie et al., 2007). Both CDP- and PEMT-pathways are 
necessary for normal production of plasma lipoproteins (Yao and Vance, 1988; Noga et al., 
2002; Jacobs et al., 2004), specifically VLDL.  
Results of the plasma triglyceride and lipoprotein cholesterol analyses performed in this 
study did not mirror the changes we observed in PC metabolites, although the higher levels of 
VLDL/LDL cholesterol in iAs-treated female KO vs. WT mice were consistent with the overall 
higher levels of plasma PCs (Table 2.2, Figure 2.5). Triglycerides in plasma of iAs-treated male 
KO mice were significantly higher than in plasma of WT counterparts; this difference may be 
associated with higher body weight of the KO mice (Figure A.2). Nevertheless, we found 
differences due to sex in all lipid measures. Future studies should examine mechanisms by which 
knockout of As3mt affects pathways of PC synthesis and degradation, and lipid metabolism in 
general, in a sex-specific manner.  
Acyl-carnitines were also among lipid metabolites changed in response to As3mt KO, 
particularly in male mice. Acyl-carnitines facilitate transfer of fatty acids into the mitochondria 
for fatty acid oxidation (Peng et al., 2013; Reuter and Evans, 2012). The changes in acyl-
carnitines observed in KO mice in this study could reflect changes in rate of fatty acid oxidation, 
and consequently, in energy production. 
 
Effects on amino acid and nitrogen metabolism 
A number of metabolites related to amino acid metabolism were changed in As3mt-KO 





had the greatest fold changes in the urine of male KO mice as compared to WT mice. However, 
while the hippuric acid level increased, the level of acetylglycine decreased in As3mt-KO mice 
(Figure 2.3D,E). The same trends, while not statistically significant, were found in female mice. 
Hippuric acid and acetylglycine are products of the conjugation of glycine with benzoyl-CoA 
and acetyl-CoA, respectively, which is catalyzed by glycine N-acyltransferase (Dempsey et al., 
2014; Schachter and Taggart, 1954). Degradation of dietary polyphenols by gut microorganisms 
is thought to be a major source of benzoic acid and other glycine conjugation substrates (Knights 
and Miners, 2012; Lees et al., 2013). Elimination of the gut bacteria using antibiotics or germ-
free mice was shown to eliminate hippuric acid excretion (Lees et al., 2013; Nicholls et al., 
2003; Yap et al., 2008). As such, hippuric acid is considered a urinary microbial-mammalian 
cometabolite. Excretion of acetylglycine in urine was increased in mice after ingestion of 
alcohol, presumably due to increased formation of acetic acid (Manna et al., 2011). Colonic 
bacteria can ferment dietary fiber to form acetate, possibly explaining the association of 
acetylglycine with dietary fiber intake in humans (Cummings et al. 1983; Lustgarten et al., 
2014). Thus, the changes in urinary levels of hippuric acid and acetylglycine found in this study 
could be associated with influences on the microbiome, possibly due to As3mt KO or due to 
different diets used at the UNC animal facility where the KO mice were bred and at the Jackson 
lab where the WT mice were purchased.   
An almost 6-fold decrease in urea levels was found in urine of female KO, but not in 
urine of male KO mice, in comparisons with corresponding WT mice (Figure 2.3B). The 
production of urea in the urea cycle is the major mechanism for disposal of nitrogen during 
catabolism of amino acids. The decrease in urea production seen here in female KO mice may 





Effects on energy/carbohydrate metabolism 
 Growing evidence suggests that iAs is an environmental diabetogen that impairs glucose 
homeostasis (Maull et al., 2012). Previous metabolomics studies have shown changes in 
carbohydrate metabolites in humans (Martin et al., 2015) and laboratory animals (Garcia-
Sevillano et al., 2014 a,b; Wang et al., 2015) exposed to iAs. However, our metabolomics 
analysis found only minor effects of iAs treatment on pathways of carbohydrate metabolism, and 
only in KO female mice (Table A.4). Most of the changes in carbohydrate metabolites and 
metabolic pathways were associated with As3mt KO, and these changes were sex-specific (Table 
2.2; Table A.4).  
Effects on metabolites associated with methylation reactions 
 The inability of As3mt-KO mice to efficiently methylate iAs may have resulted in altered 
availability of SAM for other methylation reactions, thus influencing plasma or urinary levels of 
substrates and/or products of these reactions. The KO-associated increases in plasma PC levels 
may reflect higher activity of the PEMT pathway due to increased SAM availability. Currently, 
iAs is the only known substrate of As3mt but our metabolomic analyses in As3mt-KO mice 
could indicate other, so far unidentified, substrates. Here, we found that knockout of As3mt in 
mice affected levels of metabolites in two other methylation pathways: the metabolism of 
carnosine and sarcosine.  
The concentration of carnosine was significantly decreased in the plasma and urine of 
both control and iAs-treated KO male animals as compared to corresponding WT males (Figure 
2.3F). Carnosine is a dipeptide of beta-alanine and L-histidine and is found at high 
concentrations in skeletal muscle and the brain (Boldyrev et al., 2013). Methylation of carnosine 





(Boldyrev et al., 2013; McManus, 1962; Winnick and Winnick, 1959). A decrease in plasma 
carnosine in KO males could reflect an increased formation of anserine due to increased SAM 
availability. The sex differences in carnosine levels in plasma of WT mice found in this study 
(Figure 2.3F) are consistent with previous studies showing that males have more carnosine in 
skeletal muscle than females (Baguet et al., 2012; Penafiel et al., 2004).  Sarcosine levels were 
significantly higher in urine of control KO females as compared to control WT females, and also 
in urine of control KO females as compared to KO males (Figure 2.3C). Sarcosine is formed by 
methylation of glycine, catalyzed by glycine N-methyltransferase (GNMT), and is also a 
byproduct of hydrolysis of dimethylglycine in the betaine homocysteine methyltransferase 
pathway (Luka et al., 2009). The formation of sarcosine by GNMT is thought to play a role in 
regulation of cellular methylation capacity (Cook et al., 1989; Horne et al., 1989; Luka et al., 
2009; Mudd et al., 1980). Thus, an increase in sarcosine could indicate an increased availability 
of SAM in control KO mice that are not able to efficiently methylate iAs in the diet. The sex-
dependence and the effects of iAs treatment on these changes, however, require further 
investigation. 
2.1.6 Conclusions 
 This study was the first to examine metabolomic profiles associated with knockout of 
As3mt in mice treated with iAs and in control mice. Surprisingly, we found that treatment with 1 
ppm As for 4 weeks elicited little or no change in the metabolite profile of both WT and As3mt-
KO mice, males and females. This finding is consistent with results of previous metabolomics 
studies in rodents exposed to low levels of iAs, suggesting that higher exposure levels may be 
required to reproduce in mice the metabolomic changes observed in people exposed to iAs in the 





plasma and urine metabolomes and these changes were often sex specific, implying that sex 
hormones may play an important role in regulation of the As3mt-catalyzed reactions or in 
systemic responses to the knockout of As3mt. Many of the altered metabolites were associated 
with lipid (specifically PC) and lipoprotein metabolism, carbohydrate metabolism, and amino 
acid metabolism. Some of the altered metabolites were substrates or products of SAM-dependent 
methylation reactions, suggesting that knockout of As3mt altered SAM utilization in these 
reactions or that As3mt may methylate other, As-unrelated substrates. It is unclear, why WT male 
mice drank more water than mice in any other group and whether this difference could explain 
some of the sex- or KO-dependent differences in the urine or plasma metabolomes. However, 
these data suggest that studies comparing WT and As3mt-KO mice should monitor water 
consumption and account for possible differences in data evaluation. Future studies using 
targeted, tissue-specific metabolomics or metabolite/enzyme-specific analyses are needed to 








2.2 Hepatic phosphatidylcholines2,3 
2.2.1 Introduction 
 Inorganic arsenic (iAs) exposure through drinking water affects millions of people 
worldwide and is implicated in multiple cancers as well as non-cancer diseases. In humans, iAs 
is enzymatically methylated to mono- and dimethylated metabolites that are excreted mainly in 
urine (Thomas et al. 2007). Methylation of iAs is catalyzed by arsenic (+3 oxidation state) 
methyltransferase (AS3MT). Polymorphisms in AS3MT have been found to be associated with 
altered iAs metabolism and differing risks of cancer and metabolic disease (Antonelli et al. 
2014). The As3mt-knockout mouse is a useful model for assessing the role of iAs metabolism in 
disease associated with iAs exposure. However, apart from the inability to methylate arsenic, the 
metabolism of the As3mt-KO mice has been poorly characterized.  
 Recently, we published a study comparing the urinary and plasma metabolomes of 
C57BL/6 mice (WT) and As3mt-knockout (KO) mice (Huang et al. 2016), with and without 
exposure to iAs. While we found few metabolites to be changed due to iAs treatment in either 
mouse strain, we found more significantly changed metabolites in comparisons of WT and KO 
animals, particularly among phosphatidylcholines (PCs) and other metabolites related to lipid 
metabolism.  
 PCs are primary components of cellular membranes, are precursors to signaling 
molecules, and make up 60-80% of the phospholipid component of plasma lipoproteins (Cole et 
al. 2012). All nucleated cells synthesize PCs, but the liver is a major site for PC synthesis and 
                                                 
2 Madelyn C. Huang, Christelle Douillet, Miroslav Styblo. (2016) Archives of Toxicology. 90:3125-3128. 
Reproduced with permission. 
 






plasma lipoprotein assembly (Cole et al. 2012). Notably, methylation of iAs occurs primarily in 
the liver (Watanabe and Hirano 2013), making it a target organ for iAs toxicity. The liver of 
As3mt-KO mice is particularly susceptible because it accumulates iAs (Currier et al. 2016; 
Hughes et al. 2010). To further probe the effects of As3mt knockout on PC metabolism, we 
measured concentrations of molecular PC species in livers from mice in our recent metabolomics 
study and compared hepatic PCs profiles with those previously found in plasma.  
 
2.2.2 Materials and Methods 
Animals and treatment. In the metabolomic study, adult male and female C57BL/6J WT and 
As3mt-KO mice were exposed to 0 and 1 ppm As as arsenite in drinking water for 4 weeks 
(N=15-21/group) (Huang et al. 2016). Right medial lobes of the livers were collected at sacrifice, 
snap-frozen in liquid nitrogen, and stored at -80oC until analyzed. 
 
PC analysis. Liver tissue homogenate (150 µg protein) was extracted as previously described 
(Bligh and Dyer 1959) except substituting dichloromethane for chloroform. An internal standard 
1,2-dimyristoyl-sn-glycero-3-phosphocholine (1.0 µg, Avanti Polar Lipids, Alabaster, AL) was 
added to the organic layer and an aliquot (10%) was injected into a tandem quadrupole mass 
spectrometer for continuous electrospray ionization (positive ions). Precursor ions of m/z 184 
were measured for analysis of PC molecular species (Han et al. 2012) and quantitated using 
LipidView (Simons et al. 2012). Signals for molecular species of PC were ratioed to the signal 






Data Analysis. The relative concentrations of PC species were analyzed as described in our 
metabolomic study, using Partek for hierarchical clustering analysis and for ANCOVA analysis 
with sex, genotype, and iAs treatment as covariates (Huang et al. 2016).  A p-value cutoff at 
p<0.05 and a false-discovery rate q-value cutoff of q<0.1 were used to determine PC species 
significantly changed due to genotype, sex or iAs treatment.  
2.2.3 Results and Discussion 
Twenty nine PC species were identified in livers from all treatment groups. These species 
clustered primarily due to sex, followed by genotype, and not due to iAs treatment (Figure A.5).  
There were only 1-3 significantly changed hepatic PCs in comparisons of 0 ppm (untreated) and 
1 ppm groups (Table A.5). These results are consistent with the major effect of sex and only 
minor effects of iAs exposure on plasma and urine metabolomes found in our metabolomics 
study (Huang et al. 2016).  
As3mt KO changed greater numbers of hepatic PCs than did iAs exposure, but the extent 
of these changes differed between male and female mice.  In untreated mice, more hepatic PCs 
were changed due to KO in male as compared to female mice (12 vs. 4), and this trend was also 
seen in iAs-treated mice (9 vs. 8) (Figure 2.6A). Conversely, in the plasma, more PCs were 
changed due to As3mt KO in female as compared to male mice in both unexposed (48 vs. 14) 
and exposed groups (16 vs. 12) (Figure 2.6B). In addition, As3mt KO affected different PCs in 
males and females; few PCs were found changed in both sexes. Only 1 hepatic PC, PC (38:3), 
was increased due to KO in both male and female untreated mice; in iAs-treated mice, two PCs 
were changed—PC (38:3) increased and PC (32:0) decreased—in both males and females 
(Figure 2.6A, Figure 2.7). In plasma, only 8 PCs were changed in both untreated males and 





concentrations in KO mice did not exceed 1.6; however, great numbers of PCs in both liver and 
plasma were affected (Figure 2.6; Table A.6). Taken together, these results suggest that As3mt 
KO has a major effect on PC metabolism and that this effect is sex-dependent. 
 
 
Figure 2.6. Number of hepatic (A) and plasma (B) PC species significantly changed (P<0.05) in 
comparisons of As3mt-knockout (KO) and wild-type (WT) control and iAs-treated mice. Bolded 
numbers indicate total number of PCs changed in each comparison, for the compartment; 
arrows indicate increase or decrease of PCs in KO mice.  
 
The KO- or sex-associated changes in hepatic and plasma PC profiles may reflect 
alterations in hepatic PC synthesis (Vance 2008), export (Robins et al. 1991), or in PC 





molecules (Cole et al. 2012). Any combination of these processes could underlie the observed 
changes in PC profiles. Notably, in all of the KO vs WT comparisons, some PC species were 
significantly changed in both plasma and liver (Table 2.3). In particular, PC (38:3) was found 
changed (increased) due to KO in both plasma and liver of both untreated and iAs-treated male 
and female mice (Figure 2.7). Future studies should examine the fatty acid tail composition and 
metabolism of PC (38:3) in iAs-exposed mice.  With further characterization, this PC species 
may serve as a biomarker of iAs exposure or of iAs methylation capacity.  
 
Table 2.3. Phosphatidylcholine (PC) species significantly changed in comparisons of As3mt-
knockout (KO) and wild-type (WT) mice in both plasma and liver. 
Comparison PC speciesa Fold changeb in 
plasma 
Fold change in liver 
Untreated females 

















































aPhosphatidylcholine notation: PC(X:Y) indicates a phosphatidylcholine X total carbons and Y 
double bonds. PC(O-X:Y) indicates a phosphatidylcholine with one acyl and one ester linkage to 
the fatty acid tails with X total carbons and Y double bonds. 







Figure 2.7. Relative abundance of the phosphatidylcholine (PC) species (C38:3 in liver (A) and 
plasma (B) of wild-type (WT) and As3mt-knockout (KO), untreated (0 ppm) and iAs-treated (1 
ppm), male (M) and female (F) mice; *p<0.05 and q<0.01. 
 
2.2.4 Conclusion 
In conclusion, we found differences in hepatic PCs of WT and As3mt-KO mice that 
paralleled our previous findings in urinary and plasma metabolomes. While only minor 
differences in hepatic PCs were linked with iAs-treatment, major changes PCs were associated 
with As3mt KO, in a sex-specific manner. Notably, some As3mt-KO-associated PCs were found 
in both plasma and liver, suggesting that the effects of As3mt KO on PCs are systemic. These 
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3. CHAPTER 3- Prenatal arsenic exposure and dietary folate and methylcobalamin 




Inorganic arsenic (iAs) is an established environmental diabetogen. The link between iAs 
exposure and diabetes is supported by evidence from adult human cohorts and adult laboratory 
animals. The contribution of prenatal iAs exposure to the development of diabetes and 
underlying mechanisms are understudied. The role of factors that modulate iAs metabolism and 
toxicity in adults and their potential to influence diabetogenic effects of prenatal iAs exposure 
are also unclear. The goal of this study was to determine if prenatal exposure to iAs impairs 
glucose metabolism in mice and if maternal supplementation with folate and methylcobalamin 
(B12) can modify this outcome. C57BL/6J dams were exposed to iAs in drinking water (0, 100, 
and 1000 µg As/L) and fed a folate/B12 adequate or supplemented diet from before mating to 
birth of offspring. After birth, dams and offspring drank deionized water and were fed the 
folate/B12 adequate diet. The metabolic phenotype of offspring was assessed over the course of 
14 weeks. Male offspring from iAs-exposed dams fed the folate/B12-adequate diet developed 
fasting hyperglycemia and insulin resistance. Maternal folate/B12 supplementation rescued this 
phenotype but had only marginal effects on iAs metabolism in dams. The diabetogenic effects of 
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prenatal iAs exposure in male offspring were not associated with changes in global DNA 
methylation in the liver. Only minimal effects of prenatal iAs exposure or maternal 
supplementation were observed in female offspring. These results suggest that prenatal iAs 
exposure impairs glucose metabolism in a sex-specific manner and that maternal folate/B12 
supplementation may improve the metabolic phenotype in offspring. Further studies are needed 
to identify the mechanisms underlying these effects. 
 
3.2 Introduction 
Globally, 9% of the human population has diabetes mellitus, a condition of chronic 
hyperglycemia (WHO 2016), which is associated with high morbidity and for which there is no 
cure.  Type 2 diabetes mellitus (T2D) represents 90-95% of diabetes cases and is characterized 
by insulin resistance followed by beta cell dysfunction and impaired insulin secretion.  The 
prevalence of T2D has almost doubled since 1980 (WHO 2016) and is expected to continue 
increasing (Rowley et al. 2017). While the increase in obesity is the main driver for the rise of 
T2D, particularly in children (Mayer-Davis et al. 2017), obesity alone does not explain the trends 
in T2D seen around the world.  Exposures to environmental chemicals such as inorganic arsenic 
(iAs), bisphenol A, or various persistent organic pollutants may contribute (Thayer et al. 2011; 
Maull et al. 2012).  Furthermore, a growing amount of data on environmentally-induced T2D 
supports the developmental origins of health and disease paradigm, in which adverse health and 
disease outcomes later in life are results of prenatal exposures to environmental chemicals 






iAs is a common drinking water and food contaminant. The World Health Organization 
and U.S. EPA limit for iAs concentration in drinking water is 10 parts per billion (ppb), or 10 µg 
As/L (WHO 2017; US EPA 2001). In many areas around the world, iAs levels in drinking water 
exceed this limit. Chronic exposure to iAs has been shown to be associated with increased 
incidence or prevalence of T2D in many geographical regions (Maull et al. 2012; Sung et al. 
2015). In some of these regions, residents have been exposed to iAs only recently. For example, 
in Bangladesh, chronic exposure to iAs in drinking water began with the introduction of new 
wells drilled in the 1970s (Smith et al. 2000). However, in other regions, water contaminated 
with iAs has been used for drinking and cooking for generations (e.g., in Taiwan or Mexico); 
many residents in these regions have been exposed to iAs from preconception to adulthood. 
Thus, it is unclear how iAs exposure during different developmental windows (e.g., prenatal vs 
postnatal) contributes to the prevalence or incidence of T2D in these regions.  
 Data on the effects of prenatal iAs exposure on T2D development later in life is limited. 
In humans, cord blood As levels, a marker of in utero exposure, have been associated with 
changes in DNA methylation of genes that are implicated in T2D and with altered expression of 
microRNAs that are involved in T2D-related dysfunctions (Martin et al. 2017a). In laboratory 
studies, rats and mice exposed to iAs prenatally or during both pre- and postnatal windows 
developed diabetic phenotypes (Dávila-Esqueda et al. 2011; Bonaventura et al. 2017; Ditzel et al. 
2016; Sanchez-Soria et al. 2014; Rodriguez et al. 2016). However, different phenotypes were 
associated with different levels of iAs exposure and with different exposure windows. Taken 
together, human and animal data indicate that prenatal exposure alone, or combined with 





Mechanisms underlying the diabetogenic effects of iAs during the prenatal exposure 
window have never been systematically studied. The human data suggest that iAs exposure could 
disrupt DNA methylation during fetal development in utero, and that a competition between iAs 
and DNA methylation pathways for a methyl group donor could be an underlying mechanism 
(Martin et al. 2017a). In humans and many animal species, iAs is metabolized in a series of 
methylation steps to form monomethylarsenic (MAs), dimethylarsenic (DMAs), and in some 
species also trimethylarsenic. Metabolism of iAs facilitates its excretion from the body. The 
methylation of iAs is catalyzed by arsenic (+3 oxidation state) methyltransferase which uses S-
adenosylmethionine (SAM) as a methyl group donor (Thomas et al. 2007). SAM is also the 
methyl donor for DNA methylation by DNA methyltransferases (Anderson et al. 2012). It has 
been hypothesized that an increased demand for SAM during iAs exposures could disrupt DNA 
methylation of genes that regulate insulin production and/or glucose metabolism, thus, affecting 
the susceptibility of adult offspring to T2D. 
Several micronutrients, including the B-vitamins folate (B9) and methylcobalamin (B12), 
are required for the synthesis of SAM (Selhub 1999). In adult cohort studies, high folate intake 
has been associated with greater efficiency of iAs metabolism, typically understood as a lower 
proportion of urinary iAs and MAs and higher proportion of urinary DMAs, and with lower risk 
of iAs-associated urothelial cancers and skin lesions (Argos et al. 2010; Gamble et al. 2005; 
Gamble et al. 2006; Hall et al. 2007; Hall et al. 2012; Huang et al. 2008). Similar effects have 
been reported for B12, but data are limited and inconsistent (Hall et al. 2012; Heck et al. 2007). 
Animal studies generally support the positive association between folate intake and efficiency of 
iAs metabolism (Wlodarczyk et al. 2012; Spiegelstein et al. 2003; Tsang et al. 2012; Spiegelstein 





supplementation has been found to alleviate iAs-induced apoptosis, oxidative stress, and 
hepatotoxicity (Acharyya et al. 2015; Mukherjee et al. 2006; Chattopadhyay et al. 2012), 
suggesting possible protective effects of these vitamins in iAs-associated diseases.  
Increasing efficiency of iAs methylation, thus increasing clearance of iAs from the body,  
by increasing folate and/or B12 intake may also improve health outcomes associated with in 
utero iAs exposures, although few studies have addressed this hypothesis. In a Bangladesh 
cohort, higher maternal folate and B12 levels were associated with lower concentrations of cord 
blood As (Hall et al. 2007). On the other hand, the increased efficiency of iAs metabolism 
throughout pregnancy was not associated with folate or B12 status in a different cohort of 
Bangladeshi women (Gardner et al. 2011; Li et al. 2008).  Mice with impaired folate transport 
had higher rates of exencephaly than wild-type mice when exposed in utero to iAs. However, the 
deficiency in folate transport in these mice was not associated with altered iAs methylation 
efficiency (Wlodarczyk et al. 2001). In our studies, high dietary folate intake decreased iAs 
levels and increased ratios of DMAs/MAs in livers of pregnant CD-1 mice exposed to iAs 
(Tsang et al. 2012). Exposure to 85 ppm iAs combined with folate supplementation had more 
profound effects on global DNA methylation in fetal livers than exposure to iAs or folate 
supplementation alone (Tsang et al. 2012), suggesting that epigenetic effects of prenatal iAs 
exposure in fetus can be modulated by maternal folate intake.  
No studies to date have investigated the role of maternal dietary folate or B12 
supplementation in modifying the risk of T2D in offspring exposed prenatally to iAs. The goal of 
the present study was to determine (i) if prenatal exposure to environmentally relevant levels of 
iAs results in an impaired metabolic phenotype (e.g. hyperglycemia, insulin resistance, glucose 





affects the metabolism of iAs in dams and the metabolic phenotype of the offspring. Our results 
suggest that prenatal iAs exposure impairs glucose homeostasis in offspring in a sex-dependent 
manner. Notably, maternal folate and B12 supplementation had a minimal effect on iAs 




Mice and Diets. All procedures involving mice were approved by the University of North 
Carolina Institutional Animal Care and Use Committee. Eight-week old male and female 
C57BL/6J mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). Two types of 
purified AIN-93G diet (Dyets, Bethlehem, PA) were used: (1) diet that contained 2 mg/kg folate, 
the level needed to support pregnancy and fetal health (Reeves et al. 1993), and 10 µg/kg B12 
the level that represents adequate intake for adult mice (American Institute of Nutrition 1977), 
and (2) diet containing 6 mg/kg folate and 50 µg/kg B12 (Dyets, Bethlehem, PA). These diets are 
hereafter referred to as folate/B12 adequate and folate/B12 supplemented, respectively. A large 
amount of each diet from the same lot was purchased for this study to avoid biases associated 
with lot-to-lot differences in diet composition. After delivery to UNC, both male and female 
mice were fed the folate/B12 adequate diet and drank deionized water (DIW) for one week prior 
to exposure. Mice were housed under controlled conditions with 12-h light/dark cycle at 22 ± 
1°C and 50 ± 10% relative humidity. Food and water consumption was measured weekly.  
 
Exposures and mating. After one week on the folate/B12 adequate diet and DIW, dams and sires 





and different levels of folate and B12 in the diet:  (1) 0 ppb As and folate/B12 adequate diet, (2) 
100 ppb As and folate/B12 adequate diet, (3) 1000 ppb As and folate/B12 adequate diet, (4) 0 
ppb As, and folate/B12 supplemented diet, (5) 100 ppb As and folate/B12 supplemented diet, 
and (6) 1000 ppb As and folate/B12 supplemented diet. There were 6 dams in each treatment 
group except for the 0 ppb/folate/B12 supplemented group which had 9 dams. Drinking water 
(DIW) with iAs (sodium arsenite, ≥99% pure; Sigma-Aldrich, St. Louis, MO, USA) was 
prepared weekly to minimize oxidation of iAsIII to iAsV. After one week of treatment with iAs 
and feeding with either folate/B12 adequate or supplemented diet, dams and sires from the same 
treatment group were allowed to mate for one week (3 dams:1 sire). During mating, one dam in 
the 100 ppb/folate/B12 adequate group had to be euthanized because of significant loss of 
weight, leaving only 5 dams in this group. After mating, dams were housed 3 per cage and 
remained on the exposures and diets throughout gestation until parturition. After giving birth, the 
dams in all treatment groups were placed on the folate/B12 adequate diet and drank only pure 
DIW. All offspring were weaned at three weeks of age and maintained on the folate/B12 
adequate diet and DIW for the remainder of the study. Experimental design is summarized in 
Figure 1 in Appendix B (Figure B.1).    
 
Analysis of iAs and its metabolites in mouse diet. Arsenic species were measured in the adequate 
and folate/B12 supplemented diets using hydride-generation atomic absorption spectrometry 
coupled with a cryotrap (HG-CT-AAS) as previously described (Hernández-Zavala et al. 2008; 
Currier et al. 2011). The diets were pulverized and microwave digested in ultra-pure phosphoric 






Analyses carried out in dams: 
Analysis of iAs and its metabolites in urine. HG-CT-AAS was used to determine the 
concentrations of arsenic (As) species in spot urine samples collected from dams after the first 
week of exposure, just prior to mating.  The HG-CT-AAS analysis determined concentrations of 
total iAs (iAsIII + iAsV), total MAs (MAsIII + MAsV) and total DMAs (DMAsIII + DMAsV); no 
TMAs was detected. In this study, total As in urine is defined as the sum of all As species 
detected.    
Plasma folate analysis. Plasma was isolated from blood collected from dams via tail bleed after 
one week of iAs exposure. Samples were diluted in Dulbecco’s phosphate-buffered saline 
(Mediatech, Manassas, VA, USA) and analyzed using ELISA kits following manufacturer’s 
protocol (Monobind Inc, Lake Forest, CA). 
 
Procedures involving offspring: 
Phenotyping. Body weight of weaned offspring was monitored weekly. Body composition (lean 
and fat mass) was determined at 14 weeks of age by magnetic resonance imaging using 
EchoMRI Three-in-One Composition Analyzer and Labmaster version 3.2.2 software (Echo 
Medical Systems, Houston, TX, USA). Blood for measurement of fasting blood glucose (FBG) 
and fasting plasma insulin (FPI) was obtained via tail bleeds after a 6-hour fast. FBG was 
measured by a OneTouch Ultra 2 glucometer (LifeScan, Milpitas, CA, USA) at 7, 8, 13, 14, and 
18 weeks of age. FPI was measured at week 8 and 14. Plasma insulin levels were determined by 
ELISA (Millipore, Billerica, MA) following the manufacturer’s protocol. FBG (mg/dL) and FPI 
(µU/mL) were used to calculate the homeostasis model assessment-insulin resistance (HOMA-









Glucose tolerance tests were administered at 7 and 13 weeks of age. Fasted mice were injected 
intraperitoneally (i.p.) with 2 g/kg body weight of D-glucose (Sigma-Aldrich) dissolved in 
Dulbecco’s phosphate-buffered saline (Mediatech, Manassas, VA, USA). Blood glucose levels 
were measured at 15, 30, 60 and 120 min post-injection. To quantify glucose tolerance, the area 
under the curve (AUC) was calculated for a plot of blood glucose (mg/dL) versus time (minutes) 
using Prism 5 (GraphPad, La Jolla, CA, USA). 
Global DNA methylation in liver of offspring. Livers collected during sacrifice were flash-frozen 
in liquid nitrogen, and stored at -80C. DNA was extracted using Allprep DNA/RNA extraction 
kit (Qiagen, Venlo, Nederlands). Global DNA methylation was assessed using the MethylFlash 
Methylated DNA Quantification kit (Epigentek, Farmingdale, NY). Percent 5-mC was calculated 
using the equation provided by the manufacturer: 
%5 − 𝑚𝐶 =  
(𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑏𝑠 − 𝑁𝐶 𝐴𝑏𝑠) ÷ 𝑛𝑔 𝑠𝑎𝑚𝑝𝑙𝑒 𝐷𝑁𝐴
(𝑃𝐶 𝐴𝑏𝑠 − 𝑁𝐶 𝐴𝑏𝑠) × 2 ÷ 𝑛𝑔 𝑃𝐶 𝐷𝑁𝐴
× 100 
where Abs= absorbance at 450 nm, NC= negative control (0% 5-mC), and PC= positive control 
(50% 5-mC). 
 
Statistical Analysis. Differences due to iAs exposure were assessed using ANOVA and Tukey’s 
post-hoc tests. Differences due to sex or diet were assessed using two-tailed Student’s T-tests 
between groups of interest (e.g., to determine significant effect of sex: male offspring from dams 
fed the folate/B12 adequate diet and exposed to 0 ppb iAs were compared to female offspring 
from dams fed the folate/B12 adequate diet and exposed to 0 ppb iAs animals). Three-way 





diet, dam iAs exposure) in most metabolic measures. This analysis also identified significant 
two-way and three-way interactions between the three variables. All statistical analyses were 




Dams were exposed to iAs in drinking water and fed the specified diets 1 week before 
and 1 week during the mating. This time period is sufficient to establish equilibrium of As 
(Hughes et al, 2003) and folate (Schmitz et al. 1994) in blood and tissues of mice. With limited 
data on B12, we assumed that this time was also sufficient to reach B12 equilibrium. There were 
no differences in body weight at the start of exposure or at the beginning of mating (Figure B.2). 
Folate levels in plasma of the folate/B12 supplemented dams were significantly higher than in 
dams fed the folate/B12 adequate diet (Figure 3.1). Notably, exposure to 100 ppb iAs, but not 
1000 ppb iAs, significantly increased plasma folate in dams in both adequate and supplemented 
groups. Plasma B12 concentration could not be measured due to insufficient volume of blood 






Figure 3.1. Plasma folate concentrations of dams fed folate/B12 adequate and supplemented 
diets and exposed to iAs. Plasma was isolated from blood collected via tail bleed from dams 
after exposure to iAs for one week, shortly before mating. Mean +SEM for N=3 are shown. * 
p<0.05 significantly different from controls (0 ppb iAs) within the same diet group; # p<0.05 
significantly different from dams fed the adequate diet.  
 
To determine effects of folate/B12 intake on iAs metabolism, we measured 
concentrations of iAs and its metabolites in spot urine samples collected from dams (Figure 3.2). 
Total As concentrations were proportionally higher in urine of dams exposed to 100 ppb and 
1000 ppb iAs as compared to untreated controls. DMAs was the major urinary metabolite 
representing 85-94% and 79-93% of total As in urine of iAs-treated dams fed adequate diet and 
supplemented diet, respectively. There were no significant differences in %DMAs, %MAs, or 
%iAs in urine due to the exposure or supplementation (Figure B.3). Folate/B12 supplementation 
increased total As levels (i.e., sum of As species) in urine in both 100 and 1000 ppb exposure 
groups, but these effects were not statistically significant (Figure 3.2D). Marginally significant 
effects of folate/B12 supplementation were found in the urine of dams exposed to 100 ppb iAs 





dams (p=0.11 and 0.079, respectively). The content of As in the folate/B12 adequate and 
supplemented diets ranged from 40 to 43 ppb; only iAs was detected.  
 
Figure 3.2. Arsenic metabolites in urine of dams fed a folate/B12-adequate or supplemented diet 
and exposed to 0, 100, or 1000 ppb iAs. (A) iAs, (B) MAs, (C) DMAs, and (D) sum of As. Spot 
urine samples were collected from dams exposed to iAs for 1 week, shortly before mating. Mean 
+ SEM for N=5-9 is shown. *p<0.05 significantly different from respective control (0 ppb) 
within the same diet group; ǂ p<0.05 significantly different from 100 ppb iAs exposure. 
 
Number of offspring. Since dams were housed 3 per cage, the number of pups per litter could not 
be determined and assessed statistically. Instead, the total numbers of offspring in each treatment 





Phenotypes of the offspring 
Food and water consumption.  There were no significant differences in food or water 
consumption due to prenatal iAs exposure or maternal supplementation throughout the course of 
the study (data not shown). Male offspring tended to eat and drink more than female offspring. 
Body weight. Only minimal differences were observed in body weight between offspring of the 
same sex after weaning, regardless of treatment (Figure B.4). Males were heavier than females 
throughout the entire study. Few statistically significant differences were found between 
treatment groups and only at few time points. There were no significant differences in body 
weight at the end of the study, except that female offspring from supplemented dams exposed to 
100 ppb iAs were heavier than controls at sacrifice. 
Body composition. Body composition was assessed at 14 weeks of age. At this time point, male 
offspring had higher body weight and higher lean mass than female offspring, but had similar 
%fat (Figure 3.3). Prenatal exposure to iAs had little or no effect on body composition of the 
offspring from either the folate/B12 adequate or supplemented dams. However, male offspring 
from dams fed the adequate diet and prenatally exposed to 1000 ppb iAs had higher %fat than 
the corresponding controls (p=0.09) and males exposed prenatally to 100 ppb iAs (p=0.018) 
(Figure 3.3B). Notably, maternal supplementation significantly lowered %fat in male offspring 
exposed to 1000 ppb iAs to levels even lower than those found in controls (Figure 3.3B). 
Maternal supplementation also increased body weight and lean mass in female controls, but had 
no statistically significant effect on %fat (Figure 3.3).  
Fasting blood glucose (FBG). Blood glucose after a 6-hour fast was measured at week 7, 8, 13, 
14, and 18 of age (Figure 3.4). In general, male offspring had higher FBG than female offspring, 
regardless of supplementation or exposure. Prenatal exposure to iAs had significant effects on 






Figure 3.3. Body weight and composition of male and female offspring prenatally exposed to 
inorganic arsenic: (A) Body weight, (B) fat mass (expressed as % of body weight), and (C) lean 
mass were determined in 14-week old offspring from dams exposed to 0, 100, or 1000 ppb iAs in 
drinking water and fed either a folate/B12-adequate. Mean + SEM for N=7-16 is shown. ǂ 
p<0.05 significantly different from 100 ppb iAs exposure; # p<0.05 significantly different from 







Figure 3.4. Fasting blood glucose of offspring prenatally exposed to iAs. Fasting blood glucose 
was measured in (A) male and (B) female offspring from dams exposed to 0, 100, or 1000 ppb 
iAs in drinking water and fed either a folate/B12-adequate (closed circles) or supplemented 
(open squares) diet. Blood was collected from offspring at age 7, 8, 13, 14 and 18 weeks. Mean 
+ SEM of N=5-16 is shown. * p<0.05 significantly different from controls (0 ppb iAs) within the 
same diet goup; ǂ p<0.05 significantly different from 100 ppb iAs exposure; # p<0.05 
significantly different from offspring from dams fed the adequate-diet.  
 
Specifically, males exposed prenatally to iAs had higher FBG than control males at multiple time 
points (Figure 3.4A). The trajectory of FBG levels during the 18 weeks of the study differed 
between males in different exposure groups. In males exposed prenatally to 100 ppb, FBG 
peaked between weeks 13 and 14 and then decreased to the control level at week 18; in males 
exposed to 1000 ppb iAs, FBG increased at week 14 and remained significantly higher than the 
control levels until the end of the study. In comparison, iAs exposure did not increase FBG in 





significant. In contrast, prenatal iAs exposure or folate/B12 supplementation had little or no 
effects on FBG of female offspring (Figure 3.4B). 
FBG was higher in 7-week old females from adequate-diet dams exposed to 100 ppb iAs 
compared to respective controls, but no effects of iAs exposure were observed in other groups or 
time points. Maternal supplementation significantly decreased FBG in 7-week old females 
prenatally exposed to 100 ppb iAs, but no statistically significant effects of the supplementation 
were found in this or the 1000 ppb iAs exposure group at other time points. Additionally, control 
females from supplemented dams had higher FBG than control females from adequate diet dams, 
but only at week 7; the effects of maternal supplementation at later time points were not 
statistically significant. 
Glucose tolerance. Intraperitoneal glucose tolerance tests were conducted at week 7 and 13 
(Figure 3.5). Female offspring were generally more glucose tolerant than males, regardless of 
 
Figure 3.5. Glucose tolerance of offspring prenatally exposed to iAs. Intraperitoneal glucose 
tolerance tests were administered to offspring of dams exposed to 0, 100, or 1000 ppb iAs in 
drinking water and fed either a folate/B12-adequate or supplemented diet. Area under the curve 
for (A) 7-week old and (B) 13-week old offspring is shown. Mean + SEM of N=7-16 is shown. 
*p<0.05 significantly different from controls (0 ppb iAs) within the same diet group; # p<0.05 






prenatal iAs exposure or maternal supplementation. Surprisingly, 7-week old female offspring 
from supplemented dams in the control group were more glucose intolerant that females from 
control adequate dams (Figure 3.5A).  At this time point, glucose tolerance was significantly 
lower in female offspring from adequate-diet dams exposed to 100 ppb iAs as compared to the 
respective controls (Figure 3.5A). There were no significant effects of prenatal iAs on glucose 
tolerance in 7-week old male offspring. At week 13, there were no differences in glucose 
tolerance in females or males due to prenatal iAs exposure or maternal supplementation (Figure 
3.5B). In male offspring, supplementation improved glucose tolerance in animals prenatally 
exposed to 100 ppb iAs.  
 
Fasting plasma insulin (FPI) and HOMA-IR. FBG and FPI values were used to calculate 
HOMA-IR, a measure of insulin resistance, at weeks 8 and 14. FPI and HOMA-IR in all 
offspring were higher at week 14 compared to week 8 (Figure 3.6). At week 8, there were no 
significant differences in FPI and HOMA-IR due to prenatal iAs exposure in either female or 
male offspring (Figure 3.6A-B). Maternal supplementation lowered HOMA-IR in control male 
offspring and in female offspring exposed prenatally to 1000 ppb iAs, but these effects were only 
marginally significant. At week 14, there were no significant differences in FPI and HOMA-IR 
in female offspring related to iAs exposure or maternal diet. In contrast, in males from dams fed 
the adequate diet, prenatal iAs exposure increased HOMA-IR compared to the respective 
controls (Figure 3.6D). This effect was statistically significant for 100 ppb exposure but not for 
1000 ppb exposure (p=0.21). However, no effects of iAs exposure on FPI were found. Notably, 
maternal supplementation decreased HOMA-IR in both 100 and 1000 ppb groups and decreased 






Figure 3.6. Fasting plasma insulin and HOMA-IR measures of offspring prenatally exposed to 
iAs: Fasting plasma insulin (A, C) and HOMA-IR (B,D) of 8-week old offspring (A,B) (N=7-16) 
and 14-week old offspring (C, D) (N=5-15) from dams exposed to 0, 100, or 1000 ppb iAs in 
drinking water and fed either a folate/B12-adequate or supplemented diet. Mean + SEM is 
shown. *p<0.05 significantly different from controls (0 ppb iAs) within the same diet group; # 
p<0.05 significantly different from offspring from dams fed the adequate-diet.  
 
Significant effects and interactions. Three-way factorial ANOVAs were conducted to assess 
overall significance of sex, maternal supplementation (dam diet), and prenatal iAs exposure as 
variables affecting the measurements of metabolic phenotype (e.g., to assess if sex is a 
significant variable in FBG measures, after averaging over all other variables). Sex of the 
offspring was a significant variable in most metabolic measures (Table 3.1). Dam diet and iAs 
exposure were significant variables only in some outcomes. The ANOVA analysis also identified 
significant interactive effects of these variables. The interaction of sex of the offspring with dam 
diet or iAs exposure were significant in some outcomes, indicating that the effect of dam diet or 






Table 3.1. p-values from three-way ANOVA tests assessing the significance of sex, dam diet, or 




Global DNA methylation. DNA methylation was assessed only in livers of male offspring from 
folate/B12 adequate and supplemented dams exposed to 0 or 1000 ppb iAs, i.e., the offspring 
with different phenotypes at the time of sacrifice. Specifically, the male offspring from the 
folate/B12 adequate dams exposed to 1000 ppb iAs had significantly higher FBG levels and 
HOMA-IR than male offspring from the adequate control dams (Figures 3.4 and 3.6).  
Supplementation of dams with folate/B12 prevented this increase, suggesting that epigenetic 
mechanisms may underlie the effects of iAs exposure and/or folate/B12 supplementation. We 
found that the fraction of methylated DNA (%5-mC) was significantly higher in livers of 





































AUC <0.01 0.04 0.60 0.05 0.50 0.02 0.14
FPI 0.02 0.35 0.98 0.24 0.89 0.09 0.16
HOMA-IR <0.01 0.33 0.81 0.14 0.92 0.14 0.10
Week 14 measures
Body Weight <.0001 0.29 0.72 0.43 0.03 0.46 0.48
Lean mass <.0001 0.39 0.11 0.32 0.02 1.00 0.88
%Fat 0.86 0.85 0.01 0.60 0.85 0.12 <0.01
AUC <.0001 0.78 0.47 0.81 0.46 0.08 0.66
FPI 0.01 0.42 0.83 0.41 0.96 0.19 0.12
HOMA-IR 0.01 0.15 0.69 0.33 0.69 0.01 0.03
Fasting Blood Glucose
Week 7 <.0001 0.31 0.17 0.01 0.13 0.75 0.06
Week 8 <.0001 0.33 0.12 0.01 0.30 0.89 0.05
Week 13 0.01 0.13 0.05 0.35 0.03 0.04 0.09
Week 14 0.08 0.02 0.24 0.52 <0.01 <0.01 0.04





offspring from both control and iAs-exposed dams fed the folate/B12 supplemented diet as 
compared to offspring from dams fed the adequate diet (Figure 3.7). However, no significant 
effects of iAs exposure on DNA methylation were found.  
 
Figure 3.7. Percent global DNA methylation in livers of male offspring exposed prenatally to 
iAs. DNA methylation was assessed in livers of male offspring of dams exposed to 0 and 1000 
ppb iAs in drinking water and fed a folate/B12-adequate or supplemented diet. Mean + SEM for 
N=3-7 is shown. # p<0.05 significantly different from offspring of adequate-diet dams.  
 
3.5 Discussion 
Effect of prenatal iAs exposure 
Numerous studies in adult human cohorts and in adult laboratory animals support the 
association between iAs exposure and T2D (Maull et al. 2012; Kuo et al. 2017). Less is known 
about the role of prenatal iAs exposure in the development of T2D, or metabolic disease in 
general, later in life. Previously published laboratory studies used rats or mice with either 
prenatal exposure or combined prenatal and postnatal exposures. In rats, the combined pre- and 
post-natal exposure to iAs (3-50 ppm) produced hyperglycemia, impaired glucose tolerance, and 
insulin resistance (increased HOMA-IR). Effects on plasma insulin levels were inconsistent 





whole-life exposure to 50 ppm iAs increased HOMA-IR, but only in female offspring 
(Bonaventura et al. 2017). In another study, female CD-1 offspring exposed to a very low level 
of iAs in drinking water (10 ppb) during gestation accumulated more fat than unexposed controls 
and exhibited impaired glucose tolerance and fasting hyperinsulinemia; male mice were not 
studied (Rodriguez et al. 2016). In a study by Ditzel et al., Swiss Webster mice were exposed to 
100 ppb iAs either prenatally, postnatally, or both pre- and postnatally, and fed a Western-style 
diet (2016). Here, only male mice with combined prenatal and postnatal exposures developed an 
adverse metabolic phenotype characterized by insulin resistance and increased plasma 
triglyceride levels. These males were also heavier than unexposed male controls. Thus, the 
published studies on prenatal iAs exposures and its effects on glucose metabolism include a 
variety of exposure periods and iAs doses, and report a variety of metabolic phenotypes, some of 
which are sex-dependent. Notably, levels of iAs in rodent diets used in these studies are usually 
not measured or reported. Analyses of several types of rodent chows in our lab and in other 
laboratories have found total As levels to range from ~10 to over 400 ppb, with iAs being a 
major As species in some of these diets (Douillet et al. 2017; Murko et al. 2018). Thus, exposure 
to iAs from chow diet could be a significant confounder in laboratory studies, particularly in 
studies examining effects of low-level iAs exposure in drinking water. 
In this study, we used the C57BL/6J mice, a strain commonly used for laboratory study 
of obesity-related T2D and metabolic disease. To limit background exposure to iAs from diet, we 
fed the mice a purified diet that contained only ~40-50 ppb iAs. We exposed these mice to 100 
or 1000 ppb As in the form of iAs, levels that are consistent with human environmental 
exposures. We found that mice exposed to iAs during preconception and gestation periods 





insulin resistance, and fat accumulation. These phenotypic characteristics have also been 
reported in some of the previous prenatal exposure studies (Ditzel et al. 2016; Dávila-Esqueda et 
al. 2011; Bonaventura et al. 2017; Sanchez-Soria et al. 2012). We did not observe significant 
differences in glucose tolerance, as had been reported by Rodriguez et al. (2016) and 
Bonaventura et al (2017). Impaired glucose tolerance indicates a failure of the pancreas to 
adequately respond to a high glucose dose, while high FBG usually reflects increased activity of 
gluconeogenesis or glycogenolysis during fasting (Petersen et al. 2017). The lack of differences 
in glucose tolerance between exposed and control offspring in this study suggests that the 
pancreas was able to produce enough insulin to handle the glucose challenge during the glucose 
tolerance tests. Increased FBG levels, which appear to drive the increase in HOMA-IR, may 
point to the mechanisms regulating hepatic gluconeogenesis and/or glycogenolysis as a target of 
iAs exposure. In general, the effects on glucose homeostasis found in our study were not as 
dramatic or persistent as those found in some of the other studies, in which animals were 
exposed to iAs both pre- and postnatally, and which used higher iAs doses or did not control for 
the exposure to iAs from animal diet. It is possible that higher iAs doses and/or continued 
postnatal iAs exposure, in addition to the prenatal exposure, are necessary to observe more 
robust or persistent effects on metabolic outcomes.  
In the present study, manifestation of the adverse metabolic phenotype depended strongly 
on sex, an important biological variable that has not been systematically examined in previous 
studies. We found that the male offspring were more susceptible than the female offspring to the 
adverse effects of prenatal iAs exposure. These results differ from findings reported in rats after 
whole-life (pre- and postnatal) exposure to much higher levels of iAs (50 ppm) where females 





Sex-dependent responses to prenatal iAs exposure, specifically smaller fetal size and altered 
DNA methylation patterns in cord blood, have also been reported in human studies (Broberg et 
al. 2014; Pilsner et al. 2012). It has been suggested that these differences may be related to 
sexual dimorphisms in epigenetic pattering in the placenta, which could lead to differential 
transport of toxicants, nutrients, and signaling factors (Martin et al. 2017b). Inclusion of male 
and female offspring in future prenatal iAs exposure studies in both animals and humans should 
help characterize the extent and mechanisms of this differential susceptibility. 
Effects of maternal folate and B12 supplementation 
Low folate and/or vitamin B12 intake have been linked to low iAs methylation capacity 
in human studies (Argos et al. 2010; Gamble et al. 2005; Gamble et al. 2006; Hall et al. 2007). It 
has been proposed that risk of iAs-associated disease could be lowered by stimulating iAs 
metabolism via increasing SAM availability through dietary supplementation with these B-
vitamins. In the present study, plasma folate levels were higher in the folate/B12-supplemented 
dams as compared to dams fed the adequate diet. However, no significant stimulation of iAs 
metabolism was observed. The concentrations of MAs and DMAs were higher in urine of the 
supplemented dams compared to dams fed the adequate diet, but because of small numbers of 
mice per treatment group, these differences were only marginally significant. No differences 
were found in urinary total As levels or in %DMAs, the indicator of iAs methylation efficiency. 
In comparison, folate supplementation in an iAs-exposed Bangladeshi population increased 
%DMAs in urine from 72% to 79% (Gamble et al. 2006). However, this population was folate-
deficient while the mice in our study had adequate folate intake. This may explain why we did 





Notably, we found that exposure to 100 ppb iAs increased plasma folate levels in dams 
fed either the adequate or supplemented diet (Figure 3.1). This finding has never been reported in 
human or laboratory studies. Chi and coworkers have recently reported that iAs exposure results 
in upregulation of microbial genes that regulate synthesis and metabolism of folate in mouse 
colon (Chi et al. 2017). Thus, the increase in plasma folate in iAs-exposed dams in the present 
study may be due to stimulation of folate synthesis in gut microbiome. 
Despite only small effects on iAs metabolites in urine, maternal folate and B12 
supplementation rescued the metabolic defects observed in male offspring exposed prenatally to 
iAs. These protective effects could be due to changes in the methylation of fetal DNA. Maternal 
folate and/or B12 supplementation has previously been reported to affect DNA methylation in 
offspring (Cooney et al., 2002; Waterland et al., 2003; Yadav et al. 2018) and to alter body 
weight, glucose tolerance, insulin resistance, and expression of genes regulating food intake in 
rat offspring (Cho et al. 2015). Effects of gestational iAs exposure on DNA methylation and 
expression of genes in the fetus have also been reported. Specifically, gestational exposure to iAs 
was associated with altered DNA methylation and expression of genes in cord blood of 
newborns, including methylation of genes associated with T2D (Rojas et al. 2015). It is possible 
that maternal folate/B12 may prevent the reprograming of fetal T2D-associated genes by iAs 
exposure, conferring the protective effects observed in the present study. In this study, we did 
find that maternal supplementation with folate/B12 increased global DNA methylation in the 
livers of male offspring; however, we did not assess DNA methylation of specific genes. Our 
future studies will focus on DNA methylation of T2D-associated genes as a potential mechanism 






In conclusion, we found modest defects in the metabolic phenotype of C57B/6J mice 
after prenatal (combined preconception and in utero) exposure to environmentally relevant levels 
of iAs in drinking water. These defects included hyperglycemia and insulin resistance and were 
found almost exclusively in male offspring, indicating that sex plays a major role in T2D risk 
associated with this type of iAs exposure. Maternal folate and B12 supplementation alleviated 
the adverse effects of prenatal iAs exposure for some metabolic endpoints but did not increase 
urinary As excretion or significantly change the profiles of As species in urine. Tissue analyses 
of As metabolites may help to better understand the role these vitamins play in iAs metabolism 
in mice. Altered DNA methylation remains a potential mechanism of the adverse metabolic 
effects of prenatal iAs exposure and of the protective effects of maternal folate/B12 
supplementation in the offspring. Further investigation into the methylation of specific T2D-
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4. CHAPTER 4- Metabolic phenotype of folate-deficient and folate-supplemented male 
and female mice exposed to inorganic arsenic 
 
4.1 Overview 
Chronic exposure to inorganic arsenic (iAs) is associated with type 2 diabetes mellitus. 
Increased efficiency of iAs metabolism, catalyzed by arsenic (+3 oxidation state) 
methyltransferase (AS3MT), is linked to lowered risk of iAs-associated diseases. High folate 
intake has been associated with increased iAs metabolism. The goal of this study was to assess 
how modifying iAs metabolism using nutritional intervention alters diabetogenic effects of iAs 
exposure, with and without high-fat diet (HFD). Male and female C57BL6 and As3mt-knockout 
mice drank 100 ppb iAs for 37 weeks. Mice ate a purified diet with low (0.2 mg/kg) or high (10 
mg/kg) folate for 24 weeks, then HFD with the same folate levels for 13 weeks. Metabolic 
phenotype, body composition, and iAs metabolism were examined. We found that high folate 
intake had little effect on iAs metabolism. At 24 weeks, iAs exposure and folate intake had 
minimal effects on metabolic parameters. As3mt-KO mice gained more fat and had higher fasting 
plasma insulin than WT. KO males were more insulin resistant than KO females despite similar 
%fat mass. HFD increased differences in insulin resistance between WT and KO, and between 
sexes. Notably, with HFD, iAs-exposed KO and WT males with low folate gained more fat and 
were more insulin resistant than respective unexposed controls. Our data suggest that folate 
intake and low-dose iAs exposure have little effect on metabolic parameters. However, iAs 





potential toxicant-nutrient interactions. Male mice, both WT and KO, were more prone to 
developing insulin resistance. 
 
4.2 Introduction 
Chronic exposure to inorganic arsenic (iAs) is a global public health problem.  Over 200 
million people worldwide are exposed to iAs in drinking water at levels higher than the 10 µg 
As/L limit established by the World Health Organization and US Environmental Protection 
Agency (Naujokas et al. 2013). Even more people consume foods with potentially unsafe iAs 
levels (Stanton et al. 2015). Chronic exposure to iAs has been linked to cancer (Abdul et al. 
2015) and non-cancer diseases such as type 2 diabetes mellitus (T2D) (Maull et al. 2012, Sung et 
al. 2015, Wang et al. 2014). T2D is a condition of chronic hyperglycemia and affects 9% of the 
world population. The prevalence of T2D has increased rapidly over the past decade (CDC 2017, 
WHO 2016). Though obesity is a major risk factor for T2D, it does not fully explain the increase 
in T2D prevalence. Growing evidence suggests that environmental diabetogens like iAs may 
play a role (Maull et al. 2012).  
Efficiency of iAs metabolism has been associated with differing risks of iAs-associated 
diseases, including T2D (Antonelli et al. 2012). In humans and some animal species, iAs is 
metabolized in a series of methylation steps catalyzed by arsenic (+3 oxidation state) 
methyltransferase (AS3MT), forming monomethyl-arsenic (MAs) and dimethyl-arsenic (DMAs), 
which are excreted primarily in the urine. High proportions of DMA (%DMAs) and low 
proportions of iAs (%iAs) and MAs (%MAs) in the urine are generally considered indicators of 
an efficient iAs metabolism. While urinary high %MAs and low %DMAs have been positively 





2017), T2D risk has been linked to high urinary %DMAs and/or low %MAs (Kuo 2017 et al.; 
Mendez et al. 2016; Grau-Perez et al. 2017), indicating that full methylation of iAs to DMAs, 
possibly to its toxic trivalent form (DMAsIII) may enhance the diabetogenic effects of iAs 
exposure (Del Razo et al. 2011).  
S-adenosylmethionine (SAM) is the methyl group donor for the AS3MT-catalyzed 
reactions (Thomas et al. 2007). Synthesis of SAM occurs through the one-carbon metabolism 
pathway and requires folate, an essential micronutrient and vitamin (Selhub 1999). In human 
studies carried out in arsenicosis-endemic areas of Bangladesh, high folate status has been 
associated with higher %DMAs and lower %iAs in urine (Gamble et al. 2005). Folate 
supplementation increased efficiency of iAs metabolism as manifested by increased %DMAs in 
urine and blood (Gamble et al. 2006; Peters et al. 2015). High folate intake was also inversely 
related to precancerous skin lesions in this population (Pilsner 2009). Thus, studies in high iAs 
exposure areas such as Bangladesh suggest that, by modifying iAs metabolism, folate intake 
could alter risk of some diseases associated with iAs exposure. Furthermore, a study in Taiwan 
found that higher plasma folate and urinary %DMAs were associated with decreased risk of 
urothelial cancers (Huang et al. 2008). Other results from human cohorts in other geographical 
regions, however, have been inconsistent (Spratlen et al. 2017, Steinmaus et al. 2005, Kurzius-
Spencer et al. 2017), possibly due to differences in iAs exposures (generally lower than in 
Bangladesh), ethnicity, or nutritional status of the study populations. Notably, the associations 
between folate intake, iAs metabolism and iAs-associated T2D have never been examined in 
human populations. In addition, there have been no experimental studies of the role of dietary 





The goal of our present study was to determine if varying folate intake modifies the 
metabolic phenotype of wild-type (WT) male and female C57BL/6J mice exposed to iAs (100 
ppb in drinking water), with and without a high-fat diet as an additional metabolic stressor. To 
determine if folate affects T2D development by mechanisms independent of iAs methylation, we 
also used As3mt-knockout (KO) mice that cannot methylate iAs. Our results show that iAs 
exposure alone had only minimal effects on metabolic phenotypes of WT and KO mice while fed 
a low-fat diet with low or high folate content. However, iAs exposure increased insulin 
resistance in both male and female WT and KO mice on the high-fat diet with low folate content; 
high folate intake may have a protective effect against effects of iAs. We also found that KO 
mice, particularly males, accumulated more fat than WT mice and developed insulin resistance 
regardless of iAs exposure or folate intake. Folate-supplemented WT female mice had lower 
%iAs in the urine and livers as compared to WT females with low folate intake. However, folate 
intake had little to no effect on measures of iAs metabolism in WT male or KO male and female 
mice. Thus, low iAs exposure did not produce a diabetic phenotype in C57BL/6J mice unless 
combined with high-fat diet and low folate intake. Folate supplementation may protect against 
the diabetogenic effects of the combined exposure to iAs and high-fat diet, but this effect does 
not seem to involve a modification of iAs metabolism. 
 
4.3 Methods 
Mice. All procedures involving mice were approved by the University of North Carolina 
Institutional Animal Care and Use Committee.  Male and female C57BL/6J WT mice were 
obtained from Jackson Laboratories (Bar Harbor, ME, USA) at 3 weeks of age. Male and female 





Facilities. Both WT and As3mt-KO mice were housed under controlled conditions with 12-h 
light/dark cycle at 22 ± 1 °C and 50 ± 10% relative humidity.  
 
Study design and treatment. Three-week old male and female C57BL6 and As3mt-KO mice 
consumed a purified low-fat AIN-93G diet (LFD) (17% calories from fat, Envigo Teklad, 
Madison, WI) with adequate folate content (2 mg/kg) and drank deionized water (DIW) for two 
weeks prior to the initial metabolic phenotyping. After two weeks on the purified, folate-
adequate diet, a baseline intraperitoneal glucose tolerance test (IPGTT) was administered and 
fasting blood glucose (FBG) levels were measured in all mice. Male and female WT and KO 
mice were then separated into 4 groups with similar average baseline fasting blood glucose levels 
(N=16-20 per group). Groups were randomly assigned to treatments: 1) 0 ppb iAs, low-folate 
diet, 2) 100 ppb iAs, low-folate diet, 3) 0 ppb iAs, high-folate diet, or 4) 100 ppb iAs, high-folate 
diet. Drinking water containing iAs (AsNaO2, ≥99% pure; Sigma-Aldrich, St. Louis, MO, USA) 
was prepared weekly to minimize oxidation of iAsIII to iAsV. Animals were fed the AIN-93G diet 
with either low- (0.2 mg/kg) or high (10 mg/kg) folate content. After 24 weeks, mice in all 
treatment groups were switched from LFD to a purified AIN-93G diet with high fat content 
(HFD) (45% calories from fat; Envigo Teklad, Madison, WI) with the same low or high folate 
levels. Mice were maintained on this diet for additional 13 weeks. Water consumption was 







Metabolic phenotyping. All mice were phenotyped at week 5 and 24 while on LFD, and after 8 
weeks on HFD. Tissues were collected at sacrifice after 37 weeks of iAs exposure (13 weeks on 
HFD). The study design is summarized in Figure B.1. The phenotyping included:  
(1) Body composition assessment using EchoMRI three-in-one Composition Analyzer 
and Labmaster version 3.2.2 software (Echo Medical Systems, Houston, TX, USA).  
(2) Measurements of fasting blood glucose (FBG) and fasting plasma insulin (FPI) in 
blood collected via tail cut from mice fasted for 6 hours. FBG levels were measured using the 
OneTouch Ultra 2 glucometer (LifeScan, Milpitas, CA, USA) at weeks 5 and 24 on LFD and 
after 8 weeks on HFD. FPI was measured at week 24 on LFD and after 8 weeks on HFD using 
ELISA (Crystal Chem, Elk Grove Village, IL). FBG (mg/dL) and FPI (µU/mL) were used to 
calculate the homeostasis model assessment-insulin resistance (HOMA-IR) value: 




(3) IPGTT was administered to all mice at week 5 on LFD. Fasted mice were injected 
intraperitoneally with 2 g/kg b.w. of D-glucose (Sigma-Aldrich) dissolved in Dulbecco’s 
phosphate-buffered saline (Mediatech, Manassas, VA, USA) and glucose levels were measured 
in blood collected by tail bleeds 15, 30, 60 and 120 min post-injection. To quantify glucose 
tolerance, area under the curve (AUC) was determined for a plot of blood glucose (mg/dL) 
versus time (minutes) using Prism 5 (GraphPad, La Jolla, CA, USA). 
 
Plasma folate analysis. Plasma for folate analysis was isolated from blood collected via tail 
bleed at week 6 on LFD and at sacrifice (after 13 weeks on HFD). Plasma was diluted in 
Dulbecco’s phosphate-buffered saline (Mediatech, Manassas, VA, USA) prior to measurement 





Analysis of arsenic metabolites in urine, liver, and diet. A spot urine sample was collected from 
all mice after 5 weeks on LFD and at sacrifice. Liver was collected at sacrifice. Arsenic (As) 
speciation analysis was carried out using hydride-generation atomic absorption spectrometry 
coupled with a cryotrap (HG-CT-AAS), as previously described (Hernandez-Zavala et al. 2008; 
Currier et al. 2011). The HG-CT-AAS analysis determined concentrations of total iAs (iAsIII + 
iAsV), total MAs (MAsIII + MAsV) and total DMAs (DMAsIII + DMAsV); no trimethylarsenic 
was detected. Total As content in urine and liver was calculated as the sum of all As species 
detected. Arsenic species in pulverized diets were measured via HG-CT-AAS after phosphoric 
acid digestion (Currier et al. 2016). 
 
Statistical analysis. Four-way ANOVAs were done assessing the effect of arsenic, folate, sex, 
and genotype on all measured endpoints. Post-hoc Student’s T-tests between groups of interest 
were assessed (e.g. to determine a significant effect of folate: male, 0 ppb iAs, low folate WT 
mice were compared to male, 0 ppb iAs, high folate WT mice). Analyses were conducted in JMP 
(SAS Institute Inc, Cary, NC). 
 
4.4 Results 
Food and water consumption. Exposure to iAs and folate intake had little to no effects on food or 
water consumption throughout the entire study (Figure C.2 and C.3). No significant differences 
were found in food consumption between WT and KO mice, although KO mice in several LFD 
and HFD groups drank less water than their WT counterparts. Females tended to consume less 
food than males regardless of treatment. Food consumption increased among both female and 





Arsenic levels in diets. As was measured in each of the diets used in the study. Total As in the 
diet ranged from 36-49 ppb and consisted primarily of iAs (89-100%). 
Plasma folate. As expected, mice fed the high-folate diet had significantly higher plasma folate 
levels than mice on the low-folate diet, in both LFD and HFD conditions (Figure 4.1). There 
were no statistically significant differences in plasma folate levels due to iAs exposure and very 
few due to As3mt KO. Significant differences were found between KO males and KO females 
between the LFD and HFD. Here, levels of plasma folate in males exposed to 0 and 100 ppb iAs 
were higher than plasma of females in respective treatment groups. In addition, folate levels in 
plasma of male and female WT mice on a LFD was higher at week 6 than at sacrifice, i.e. 13 
weeks after switching to HFD.   
 
Figure 4.1.  Plasma folate levels. Folate was measured using commercial ELISA kits 
(Monobind) in plasma collected after 5 weeks on LFD and iAs (A: LFD) and at sacrifice (B: 
HFD). Data shown as mean ± SEM for N= 6-10. F= significant effect of folate, G=  significant 
effect of genotype, S= significant difference due to sex. 
 
Arsenic species analysis 
 
Arsenic species in the urine. Concentrations of As species in urine were measured after 6 weeks 





urine of WT and KO mice exposed to 100 ppb iAs as compared to controls. Total As 
concentrations were higher in WT than KO mice exposed to iAs. Female WT and KO mice 
exposed to iAs had higher concentrations of total As in urine than their male counterparts, but 
this difference was statistically significant only for WT mice at week 6 on LFD. Urine from WT 
mice contained primarily of DMAs (75-96% of total As), followed by iAs (8-40%). DMAs was 
not detected in urine of As3mt-KO mice; iAs was the primary As species representing 97-100% 
of total As. MAs was not detected or was present only in traces in urine of either WT or KO 
mice. Effects of folate intake on proportions of As species in urine were relatively minor and 
inconsistent across the treatments. In most treatment groups, folate intake had no statistically 
significant effects on total urinary As. High-folate intake increased total As levels in urine only 
in male KO mice fed LFD for 6 weeks and exposed to iAs (Figure 4.2A). This was also observed 
in the control WT female group at sacrifice (Figure 4.2D). High folate intake had some 
significant effects on %As species in urine. Specifically, %iAs was lower and %DMAs was 
higher in urine of both control and iAs-exposed female WT mice after 6 weeks on LFD with 
high folate content as compared to WT females with low folate intake (Figure 4.2B,C).  
High folate intake also decreased %iAs in urine of control female WT mice at sacrifice 
(Figure 4.2E), but had no effects on %DMAs (Figure 4.2F).  There were little or no statistically 
significant effects of folate on proportions of As species in urine of KO female or WT and KO 







Figure 4.2. Arsenic speciation in urine collected from male and female WT and As3mt-KO mice 
on a low or high folate diet and exposed to 0 or 100 ppb iAs in drinking water, before and after a 
high-fat diet. Total As, %iAs, and %DMAs in urine after 6 weeks of exposure and low-fat diet (A-
C) and at sacrifice (37 weeks exposure, 13 weeks of high-fat diet; panels D-F). MAs were not 
detected in any sample. Mean ± SEM for N=8-17. P<0.05 for the following comparisons: S, 
males vs females of the same diet, exposure, and genotype; F, low vs high folate intake animals 
of the same genotype, exposure, and sex; G, KO vs WT mice of the same sex, diet, and exposure; 
E, 0 vs 100 ppb iAs-exposed mice of the same sex, genotype, and folate level. 
 
Arsenic species in the liver. Concentrations of As species were measure in livers collected at 
sacrifice (Figure 4.3). Except for WT female mice, the hepatic concentrations of total As were 
higher in mice exposed to 100 ppb iAs as compared to unexposed controls. Total As 
concentrations were generally higher in livers of KO as compared to WT mice, and were higher 
in livers of female KO mice exposed to 100 ppb iAs than in livers of male KO mice in the same 
exposure group (Figure 4.3A). iAs and MAs were the major As species found in livers of control 
male and female WT mice representing 31-65% and 17-38% of total As, respectively (Figure 
4.3B,C); only traces of DMA were detected in most liver samples. Exposure to 100 ppb iAs 
increased total As levels, lowered %iAs and increased %DMAs in the livers of both male and 





contained mainly iAs (82-97% of total As) regardless of the exposure. High folate intake 
lowered total liver As in female WT mice, with marginal significance (p=0.06) in control 
females. However, high folate intake lowered %iAs, increased %MAs, and increased %DMAs 
(p=0.06) in female WT mice exposed to 100 ppb iAs (Figure 4.3). There were no differences in 
total As or proportions of As in liver of other treatment groups.  
 
Figure 4.3. Arsenic speciation in liver collected from male and female WT and As3mt-KO mice 
on a low or high folate diet and exposed to 0 or 100 ppb iAs in drinking water, before and after a 
high-fat diet. Total As (sum As species) (A), %iAs (B), %MAs (C), and %DMAs (D) were 
determined in liver samples collected at sacrifice (37 weeks exposure, 13 weeks of high-fat diet). 
Mean ± SEM for N=8-14. P<0.05 for the following comparisons: S, males vs females of the 
same diet, exposure, and genotype; F, low vs high folate intake animals of the same genotype, 
exposure, and sex; G, KO vs WT mice of the same sex, diet, and exposure; E, 0 vs 100 ppb iAs-






Metabolic phenotypes  
 
Body weight. Over the first 24 weeks of exposure while fed LFD, growth rates of male and 
female mice were similar; males tended to be heavier throughout (Figure C.4). Males gained 
more weight than females (Fig C.5A, C). There were minor differences in body weight due to 
iAs exposure or folate intake. KO females gained more weight than WT females over the course 
of 24 weeks on the LFD; there were no differences in weight gain between WT and KO males 
(Figure C.5A, C). On the HFD, weight gain increased in all groups. Male and female weight gain 
became more similar during HFD consumption, with %weight gain being higher in female 
groups (Figure C.5B, D). KO female mice gained more weight during HFD feeding than KO 
males and WT females (Figure C.5B, D). Still, there were only few differences in body weight or 
weigh gain associated with iAs exposure or folate intake. 
 
Glucose metabolism. FBG was measured prior to exposure, at weeks 5 and 24 in iAs-exposed 
and control mice on LFD, and at week 8 on HFD. Glucose tolerance was assessed prior to 
exposure and at week 5. Prior to exposure, both WT and KO males had higher FBG and lower 
glucose tolerance than respective females. No differences in FBG or glucose tolerance between 
treatment groups were found (data not shown). Exposure to iAs and folate intake had little 
effects on FBG or glucose tolerance across all time points. However, differences were found 
between KO and WT mice. After 5 weeks of iAs exposure, male and female KO mice had higher 
FBG than WT mice (Figure C.6A); no differences due to KO were found in glucose tolerance 
(Figure C.6B). The differences in FBG between WT and KO mice persisted at week 24 on LFD 
(Figure 4.4A). At week 8 after switching to HFD, FBG in mice in all treatment groups increased 





differences were independent of iAs exposure or folate intake, and were not always statistically 
significant. Feeding HFD eliminated many of the significant differences in FBG between WT 
and KO mice found at weeks 5 and 24. 
 
Figure 4.4. Fasting blood glucose (FBG) of male and female WT and As3mt-KO mice on a low 
or high folate diet and exposed to 0 or 100 ppb iAs in drinking water, before and after a high-fat 
diet. FBG was measured in mice after 24 weeks of exposure and low-fat diet (A) and after 8 
weeks on a high-fat diet (B). Mean ± SEM for N= 14-20. P<0.05 for the following comparisons: 
S, males vs females of the same diet, exposure, and genotype; F, low vs high folate intake 
animals of the same genotype, exposure, and sex; G, KO vs WT mice of the same sex, diet, and 
exposure; E, 0 vs 100 ppb iAs-exposed mice of the same sex, genotype, and folate level.    
 
Body composition. All males were significantly heavier than females at week 24 on LFD and 
after 8 weeks of HFD (Figure 4.5). Body composition was assessed using MRI. After 24 weeks 
of iAs exposure while on LFD, both male and female KO mice had higher %fat mass and lower 
%lean mass compared to WT mice (Figure 4.5C,E). There were little or no significant 
differences in %fat or % lean mass between males and females in either WT or KO groups. No 
effects of iAs exposure and only random effects of folate on body composition were found. After 
8 weeks on HFD, all mice gained weight and had higher %fat mass and lower %lean mass than 
at week 24 on LFD (Figure 4.5B,D,C). KO mice still had higher %fat mass and lower %lean 





were greater than the differences found on LFD. However, %fat mass and %lean mass were not 
significantly different between male and female mice in either KO and WT groups.  
 
Figure 4.5. Body composition of male and female WT and As3mt-KO mice on a low or high 
folate diet and exposed to 0 or 100 ppb iAs in drinking water, before and after a high-fat diet. 
Body weight, %fat, and % lean mass were analyzed after 24 weeks on a low-fat diet (A, C, E) 
and after 8 weeks on a high-fat diet (B, D, F). Mean ± SEM for N= 13-20. P<0.05 for the 
following comparisons: S, males vs females of the same diet, exposure, and genotype; F, low vs 
high folate intake animals of the same genotype, exposure, and sex; G, KO vs WT mice of the 
same sex, diet, and exposure; E, 0 vs 100 ppb iAs-exposed mice of the same sex, genotype, and 






Insulin resistance. Both WT and KO male mice had significantly higher FPI and HOMA-IR 
compared to respective female mice at week 24 on LFD and after 8 weeks on HFD (Figure 4.6). 
After 24 weeks on LFD, KO mice had significantly higher FPI and HOMA-IR than WT mice in 
all treatment groups, more pronounced in males than in females (Figure 4.6A). There were no 
significant differences in FPI or HOMA-IR due to iAs exposure and only a minimal effect of 
folate intake was found in control female WT mice (Figure 4.6C). FPI and HOMA-IR increased 
in all animals after 8 weeks on HFD, with greater increases found in male KO mice (Figure 
4.6B,D).  
 
Figure 4.6. Fasting plasma insulin and HOMA-IR values of male and female WT and As3mt-KO 
mice on a low or high folate diet and exposed to 0 or 100 ppb iAs in drinking water, before and 
after a high-fat diet. Fasting plasma insulin and HOMA-IR were analyzed after 24 weeks of iAs 
exposure on a low-fat diet (A,C) and after 8 weeks on a high-fat diet (B, D).  Mean ± SEM for 
N= 13-20. P<0.05 for the following comparisons: S, males vs females of the same diet, exposure, 
and genotype; F, low vs high folate intake animals of the same genotype, exposure, and sex; G, 
KO vs WT mice of the same sex, diet, and exposure; E, 0 vs 100 ppb iAs-exposed mice of the 





Unlike during LFD, iAs exposure had significant effects during HFD. Here, exposure to iAs 
increased HOMA-IR values in WT females, WT males, and KO males consuming the low-folate 
diet (Figure 4.6D). In contrast, no significant effects of iAs exposure were found among groups 
of mice fed the high-folate diet. High folate intake decreased FPI and HOMA-IR in WT males 
exposed to 100 ppb iAs, but these effects were only marginally significant (FPI: p=0.07, HOMA-
IR: 0.07). In KO males, high folate intake did not change either FPI or HOMA-IR.  
 
4.5 Discussion 
Effect of iAs exposure 
In humans, chronic exposures to moderate to high levels of iAs in drinking water (≥150 
ppb) have been associated with T2D (Maull et al. 2012, Kuo et al. 2013). Even lower iAs 
exposures have been linked to an increased prevalence or incidence of T2D in recent studies 
(Kuo et al. 2017). In laboratory studies of iAs-associated diabetes, mice and rats developed 
impaired glucose tolerance and increased FBG after chronic exposure to high (ppm) levels of iAs 
in drinking water (Maull et al. 2012, Paul et al. 2007, Paul et al. 2011, Davila-Esqueda et al. 
2012). However, at lower doses that are more consistent with human exposures, the results are 
inconsistent. For example, Huang et al. have reported that female ICR mice exposed to 50 ppb 
iAs develop hyperglycemia, impaired glucose tolerance, and decreased fasting plasma insulin 
(2015). In contrast, our laboratory found only minor impairment of fasting glycemia and glucose 
tolerance in male and female C57BL/6 mice after exposure to 100 ppb iAs (Douillet et al. 2017). 
The differences between these findings could be due to strain differences but also due to iAs 
exposure through diet, which most laboratories do not address. Grain-based chow diets can 





Thus, the background dietary iAs exposure could be a confounding factor especially for studies 
examining effects of low (ppb) levels of iAs in drinking water. In the present study, we used a 
purified diet that contained 36-49 ppb iAs.  
We did not observe any major effects of iAs exposure on glucose metabolism in mice 
after 24 weeks on LFD. However, after an additional 8 weeks on a HFD, there was a significant 
increase in FPI and HOMA-IR in exposed male KO mice and both male and female WT mice. 
This finding suggests that the combined low-level iAs exposure and HFD may elicit a 
diabetogenic phenotype characterize by insulin resistance. In comparison, we have previously 
reported that mice fed a HFD and exposed to much higher levels of iAs in drinking water (25 and 
50 ppm) were more glucose intolerant, but had lower FPI and HOMA-IR, and had less %fat 
mass than control unexposed mice (Paul et al. 2011). In that study, little to no effects of iAs 
exposure were found in mice fed a LFD. Thus, both the Paul et al. study and the present study 
strongly suggest that iAs exposure elicit more pronounced diabetogenic effects when combined 
with consumption of a HFD. However, the diabetogenic phenotypes associated with low vs high 
iAs exposure (%fat mass, fasting glycemia, FPI, glucose tolerance and insulin resistance) differ 
significantly, suggesting that different pathologies may underlie iAs-associated diabetes at low 
and high levels of exposure. 
Effect of As3mt-KO 
We have recently reported that As3mt-KO mice that drank DIW but were exposed to iAs 
(~100 ppb) from a rodent chow diet became obese and insulin resistant. (Douillet et al. 2017). In 
the present study, a similar phenotype was found in control As3mt-KO mice fed a purified diet 
with lower iAs content (36-49 ppb). These mice (particularly males) accumulated more fat and 





adverse phenotype in both female and male KO mice. Results of these two studies suggest that 
the predisposition of As3mt-KO mice to obesity and development of insulin resistance could be 
due to the background exposure to iAs from the diets. Indeed, KO mice that could not effectively 
methylate iAs retained more As in the liver (and probably in other tissues) and excreted less As 
in urine than WT mice (Figures 4.2 and 4.3). Dietary iAs that accumulated in the tissues could 
impair mechanisms that regulate glucose metabolism, specifically insulin signaling pathways, 
resulting in insulin resistance. iAs exposure has also been shown to alter epigenetic programing 
of genes regulating glucose metabolism (Martin et al. 2017; Martin et al. 2016). Thus, the As3mt-
KO mice that are bred on a regular rodent chow may be pre-programmed to become insulin 
resistant later in life.  
The question is, however, what causes fat accumulation in these mice. There were no 
significant differences in food consumption (i.e., energy intake) between WT and KO mice in 
this study (Figure C.3). It is possible that there may be differences in energy expenditure that 
could lead to obesity. Obesity alone can cause, and clearly contributes to insulin resistance in KO 
mice. However, exposure to iAs has not been linked to obesity in human studies and iAsIII has 
been shown to inhibit adipocyte differentiation and adipogenesis in in vitro models (Wang et al. 
2005; Trouba 2000). Hyperinsulinemia, which characterizes the metabolic phenotype of KO 
mice, has been shown to drive lipid synthesis even in the presence of insulin resistance 
(Shimomura et al. 2000; Brown and Goldstein 2008). Thus, this mechanism may explain fat 
accumulation by KO mice. It is also possible that accumulation of iAs in tissues of KO mice in 
utero or in postnatal life affects other mechanisms involved in metabolic homeostasis, including 





Effect of sex 
We found a significant difference in insulin resistance between male and female mice 
which did not seem to be related to fat accumulation. In KO and WT mice, males and females 
had similar %fat mass; however, males were much more insulin resistant than the females. Thus, 
fat accumulation does not explain the sex difference in insulin resistance. The sexual dimorphism 
in susceptibility to metabolic disease has been documented in humans and in mice (Kautzky-
Willer et al. 2016; Mauvais-Jarvis 2015; Jaworski et al. 2011; Bonaventura et al. 2017; Soares 
2017). Differences in adipose tissue storage, energy metabolism, and sex hormone programming 
and activation are known to underlie this difference (Kautzky-Willer 2016). This difference was 
more pronounced in As3mt-KO mice as compare to WT mice, as was observed in our previous 
study (Douillet et al. 2017). iAs accumulation in tissues as a result of As3mt-KO may exaggerate 
these pathways, resulting in a greater difference between sexes than those in WT mice.    
Effect of folate 
Folate is a dietary nutrient that is required for SAM synthesis (Selhub 1999). 
Supplementation with folateor high intake of folate has been associated with increasing iAs 
methylation capacity and lowered disease risk in human studies (Hall and Gamble 2012). 
However, the potentially protective effects of folate via iAs metabolism in either humans or 
laboratory animals have not been adequately studied. In mice that lack folate transporter 
proteins, iAs metabolism was found to be less efficient than in WT mice, but only when fed a 
folate-deficient diet (Spiegelstein 2005, Spiegelstein 2003). Dietary folate supplementation was 
shown to significantly decrease iAs concentration and increase DMAs/MAs ratio in the liver of 
in iAs-exposed CD-1 mice (Tsang et al. 2012). Thus, when designing the present study, we 
expected to find major differences in iAs metabolism efficiency between mice fed the low-folate 





expected that a high folate intake would reduce adverse effects of iAs exposure by stimulating 
iAs metabolism and excretion. Additionally, we predicted that altering folate levels in As3mt-KO 
mice would not alter diabetogenic effects of iAs because these mice cannot methylate iAs. 
However, the results of the study did not fully confirm these expectations. 
The consumption of a high-folate diet significantly alter proportions of As species in the 
urine of WT female mice at week 6, decreasing %iAs and increasing %DMAs (Figure 4.2B-C). 
Similar shifts in %iAs (decreased by 4%) and %DMA (increased by 7%) have been reported in 
urine of Bangladeshi residents after supplementation with folate (Gamble et al. 2006), changes 
which were interpreted as stimulation of iAs metabolism by folate. However, in the present study 
the high folate intake did not increase total amount of As excreted in urine and did not decrease 
As levels in the livers of WT female mice at the end of the study (Figure 4.3). In addition, high 
folate intake had no effect on iAs metabolism in male WT mice. In this study, we did not use 
antibiotics to inhibit folate production by the gut bacteria (Rossi et al. 2011), which may explain 
the relatively modest, two-fold difference in plasma folate levels between mice with low and 
high folate intake, despite a 50-fold difference in dietary folate levels. The minimal difference in 
iAs metabolism between mice on the low vs. high-folate diet could be also due to stimulation of 
folate production by gut microbiota. A recent study showed that iAs exposure upregulates 
microbial genes responsible for folate synthesis in mouse colon (Chi et al. 2017).  
Despite the minor or no effects on iAs metabolism, the high folate intake seemed to 
rescue the adverse phenotype in female and male WT mice exposed to iAs, by preventing 
increases in FPI and HOMA-IR observed in mice with low folate intake. However, a similar 
trend was observed in male KO mice, suggesting that this effect of folate is independent of iAs 





(excretion and tissue retention) of As in WT mice and what the implications of our findings are 
for folate interventions in human populations exposed to iAs. 
 
4.6 Conclusions 
Our data indicate that chronic exposure to 100 ppb iAs in drinking water, in addition to 
the background exposure to 36-49 ppb iAs in the diet, had little effect on the metabolic 
phenotype of WT male and female mice fed LFD, regardless of folate intake. However, when 
combined with a HFD, iAs exposure and low folate intake elicit insulin resistance in both male 
and female WT mice, highlighting potential toxicant-nutrient interactions. In contrast with 
findings in human studies, high folate intake did not significantly increase the efficiency of iAs 
metabolism, but it did protect against the diabetogenic effects of iAs exposure, specifically iAs-
induced insulin resistance. As previously observed, As3mt-KO mice are more prone to 
developing obesity and insulin resistance than WT mice, which could be due to the background 
exposure to iAs in the diet and/or the accumulation of iAs from the diet in tissues. The 
differences in the susceptibility of male and female mice to developing insulin resistance, despite 
having similar levels of obesity and iAs metabolism efficiency, point to sex as an important 
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5. CHAPTER 5- Arsenite and its trivalent methylated metabolites inhibit glucose-
stimulated calcium influx in murine pancreatic islets5 
 
5.1 Overview 
 Chronic exposure to inorganic arsenic (iAs), a common drinking water and food 
contaminant, has been associated with an increased risk of type 2 diabetes mellitus in numerous 
populations around the world. The mechanisms underlying the diabetogenic effects of iAs 
exposure have been investigated in our laboratory using both animal and in vitro models. We 
have previously shown that in pancreatic islets, arsenite (iAsIII) and its methylated trivalent 
metabolites, methylarsonite (MAsIII) and dimethylarsinite (DMAsIII), inhibit glucose-stimulated 
insulin secretion (GSIS), without effects on insulin gene expression or insulin content. The goal 
of the present study was to determine if inhibition of GSIS is due to effects of arsenicals on 
calcium (Ca2+) influx, an essential regulatory step that activates insulin granule fusion and 
release of insulin from β-cells in response to glucose. Glucose metabolism in β-cells stimulates 
production of ATP, which results in closure of KATP channels and leads to membrane 
depolarization, followed by opening of L-type voltage-gated calcium (Cav1.2) channels. Influx of 
Ca2+ stimulates insulin release. We found that in vitro exposure for 48 hours to non-cytotoxic 
concentrations of iAsIII, MAsIII, and DMAsIII inhibited Ca2+ influx in isolated murine pancreatic 
islets stimulated with glucose. MAsIII was a more potent inhibitor of Ca2+ influx than either iAsIII 
                                                 
5 The authors would like to thank Dr. Pablo Ariel and the UNC Microscopy Services Laboratory for their technical 





or DMAsIII. The arsenicals also inhibited Ca2+ influx and insulin secretion in islets treated with 
depolarizing levels of potassium chloride in the absence of glucose. Treatment with Bay K8644, 
a Cav1.2 channel agonist, did not restore insulin secretion in arsenical-exposed islets. In contrast, 
tolbutamide, a KATP channel blocker, restored insulin secretion in MAs
III and DMAsIII-exposed 
islets but not in islets exposed to iAsIII. Our findings show that iAsIII, MAsIII, and DMAsIII inhibit 
glucose-stimulated calcium influx in islets, possibly by interfering with KATP and/or Cav1.2 
channel function. The mechanisms underlying inhibition of GSIS by iAsIII may differ from those 




Around 9% of the global population is diagnosed with diabetes, a condition of chronic 
hyperglycemia (WHO 2016). The majority of these individuals have type 2 diabetes (T2D), 
which involves insulin resistance, a result of impaired insulin signaling pathways in insulin-
sensitive tissues, followed by insufficient insulin secretion by pancreatic β-cells. The prevalence 
of T2D is increasing and is expected to double in the next twenty years if current trends continue 
(Chen et al. 2012). While obesity is a major factor in the rise of T2D, environmental chemicals, 
termed “diabetogens”, have also been implicated (Maull et al. 2012).  
Numerous epidemiological studies from populations around the world have shown 
inorganic arsenic (iAs), a prevalent drinking water and food contaminant, to be a diabetogen 
(Maull et al. 2012; Kuo et al. 2017). We have reported that human exposure to iAs is negatively 
associated with fasting plasma insulin and HOMA-IR, a measure of insulin resistance (Del Razo 
et al. 2011), suggesting that iAs may interfere with insulin secretion by the pancreas. However, 





(iAsIII), can impair both insulin secretion in pancreatic β-cells and insulin action in glucose 
utilizing tissues (Douillet et al. 2013, Fu et al. 2010, Paul et al. 2007, Zhang et al. 2017). In 
addition, exposure to iAs has been shown to modify DNA methylation and/or expression of T2D 
associated genes in both human population and laboratory models. Hence, the contributions of 
these mechanism to the pathogenesis of iAs-associated diabetes in vivo remain unclear. 
Our lab has shown that in vitro exposure of isolated murine pancreatic islets to iAsIII and 
its trivalent methylated metabolites, methylarsonite (MAsIII) and dimethylarsinite (DMAsIII), 
inhibited glucose-stimulated insulin secretion (GSIS) without altering cell viability, insulin 
content, or insulin gene expression (Douillet et al. 2013). These findings indicate that arsenicals 
impair the insulin secretion process rather than insulin production. Furthermore, methylated 
metabolites of iAsIII were more potent inhibitors of GSIS than iAsIII. These findings are 
consistent with results of several studies that have linked T2D risk in iAs-exposed populations to 
high proportions of DMAs or low proportions of MAs in urine (Del Razo et al. 2010; Kuo et al 
2017). Thus, the production of methylated metabolites in the pathway of iAs metabolism is likely 
to play an important role in etiology of iAs-associated diabetes. Yet, the exact mechanisms by 
which these metabolites impair GSIS have never been systematically investigated. 
GSIS begins with the entry of glucose into the β-cell followed by oxidation of glucose in 
glycolysis and downstream ATP-producing pathways, including oxidative phosphorylation. The 
generation of ATP leads to the closure of ATP-dependent potassium (KATP) channels, 
specifically KIR6.1 or KIR6.2 channels, causing depolarization of the cell membrane. 
Depolarization initiates the opening of voltage-gated calcium channels, primarily L-type 
channels (Cav1.2) (Wiser et al. 1999, Barg et al. 2001), leading to an increase in intracellular 





plasma membrane and the release of insulin into the bloodstream. The fact that insulin secretion 
does not occur when β-cells are stimulated with glucose in Ca2+-free medium strongly suggests 
that Ca2+influx and insulin secretion are tightly linked.  In addition, inhibition of calcium 
channels with pharmacological agents was shown to agents GSIS (Wollheim and Sharp 1981).  
In 2008, Díaz-Villaseñor et al. reported that iAsIII decreased insulin secretion and 
glucose-stimulated Ca2+ influx in a Rin-m5F β-cell line (Díaz-Villaseñor et al. 2008). Our study 
builds on this finding demonstrating that (1) exposure to iAsIII or its methylated metabolites, 
inhibits glucose-stimulated Ca2+ influx in isolated murine pancreatic islets, and that (2) both 
KATP and Cav1.2 channels are likely targets of these arsenicals in β-cells. 
 
5.3 Methods 
Cells and treatment. Pancreatic islets were isolated from adult C57BL6 male mice as previously 
described (Douillet et al. 2013). Briefly, the pancreas was perfused and digested with 1 mg/ml 
collagenase P (Roche Diagnostics Crop, Indianapolis, IN) and islets were purified using a Ficoll 
PM-400 gradient (GE Healthcare, Chicago, IL). After isolation, islets were incubated overnight 
at 37 °C with 5% CO2 in RPMI 1640 medium with 10% fetal bovine serum, 10 mM HEPES, 1 
mM sodium pyruvate, 100 U/ml penicillin, and 100 μg/ml streptomycin (all from Gibco, 
Waltham, MA). Islets were exposed for 48 hours to either iAsIII (sodium arsenite, >99% pure, 
Sigma-Aldrich, St. Louis, MO), MAsIII (methylarsine oxide, >98% pure), or DMAsIII 
(iododimethylarsine, >98% pure). Media were changed every 24 hours to minimize oxidation of 






Measurement of intracellular calcium. Islets (40-50 per experiment) exposed to arsenicals and 
control (unexposed) islets were incubated with 2 µM fura-2AM (Thermo Fisher Scientific) and 
arsenicals for 30 minutes at 37º C in KRP buffer (114 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 
1.16 mM MgSO4, 10 mM HEPES, 2.5 mM CaCl2, 0.1% BSA, 25.5 mM NaHCO3, pH 7.2). 
Imaging was carried out in a Delta T live-cell imaging flow-chamber (Bioptechs) at 37C, 5% 
CO2, and a perfusion flow rate of 0.3 ml/min. Fura-2 fluorescence at 520 nm wavelength 
following excitation with 340 nm (F340) or 380 nm (F380) wavelengths (Semrock FURA2-C000 
dichroic filter set) was captured every 6 seconds using an Olympus IX81 inverted microscope 
and a Hammamatsu ORCA R2 cooled CCD camera. Camera exposure times were kept 
consistent between experiments. Imaging was controlled by Velocity (PerkinElmer, Coventry, 
England). The ratio (F340/F380), a proxy for calcium concentrations, was calculated for each 
measurement using ImageJ, assessing only changes in fluorescence in islets within the image. 
All islets were visible in the image. Ratio values were normalized to (i.e. divided by) the average 
ratio value after 5 minutes in 2.5 mM glucose. After plotting ratio vs. time, the area under the 
curve for 8 minutes, starting when 16.7 mM glucose/KCl entered the perfusion system, was 
calculated in Excel and assessed for statistical significance.  
 
Insulin secretion assay. Islets (15 islets/well) were transferred into 12-well plates containing a 
glucose-free buffer (114 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.16 mM MgSO4, 20 mM 
HEPES, 2.5 mM CaCl2, 0.2% bovine serum albumin, and 25.5 mM NaHCO3 (all from Sigma-
Aldrich, St. Louis, MO)) for 1 h at 37 °C and 5% CO2, followed by a 1-hour incubation with 2.5 
mM glucose (Sigma-Aldrich, St. Louis, MO) and a 1-hour incubation with 16.7 mM glucose 





St. Louis, MO). Medium from each incubation step was frozen and stored for insulin analysis. 
Insulin concentrations were determined using Rat/Mouse Insulin ELISA kit (MilliporeSigma, 
Burlington, MA). 
 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. After the 48-hour 
exposure, islets were incubated in phenol-free RPMI islet medium with 0.5 mg/ml MTT for 1 
hour at 37C. The formed formazan was dissolved in DMSO and absorbance read at 570 nm with 
a background correction of 630 nm (Stýblo et al. 2002). 
 
Quantitative PCR. Total RNA was collected from islets (100/treatment) after stimulation with 
16.7 mM glucose using RNeasy kits (Qiagen, Valencia, CA) and analyzed by a Nanodrop 2000c 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA). cDNA was prepared with the 
iScript cDNA synthesis kit  (Biorad, Hercules, CA). Gene expression was quantified using 
PowerUp SYBR green master mix (Thermo Fisher Scientific, Waltham, MA) and primers for the 
alpha subunit in Cav1.2 channels, Cacna1c, and 18S, purchased through Thermo Fisher 
Scientific (Waltham, MA). Primer sequences for Cacna1c were 
CAGCCCAGAAAAGAAACAGG (forward) and GGATTCTCCATCGGCTGTAA (reverse); 
primer sequences for 18S were CGCGGTTCTATTTTGTTGGT (forward) and 
AGTCGGCATCGTTTATGGTC (reverse) (Santulli et al. 2015). Target gene expression was 
normalized to the 18S gene. PCR reactions were performed in a LightCycler 480 II (Roche, 





Statistical Analysis. Data presented as mean ± SEM. Significance was determined using one-way 
ANOVAs followed by post hoc Student’s two-tailed T-tests. Analyses were conducted in JMP 
(SAS Institute, RTP, NC).  
 
5.4 Results 
Following the design of our published study (Douillet et al. 2013), we first re-examined 
effects of trivalent arsenicals on GSIS in isolated pancreatic islets. We confirmed that 48-hour 
exposures to 2 µM iAsIII, 0.5 µM MAsIII, and 0.5 µM DMAsIII significantly inhibit GSIS (Figure 
5.1A), but are not cytotoxic for the islets (Figure 5.1B).  
 
Figure 5.1. Glucose-stimulated insulin secretion in arsenic-exposed pancreatic islets. Isolated 
pancreatic islets were exposed to arsenicals for 48 hours and stimulated with 2.5 mM glucose for 
1 hour followed by 16.7 mM glucose for 1 hour. Insulin secretion (A) and cell viability measured 







Effect of trivalent arsenicals on calcium influx 
Calcium influx was examined in islets exposed to a range of iAsIII, MAsIII, and DMAsIII 
concentrations and in control, unexposed islets. Here, the Fura-2 signal was measured in islets at 
2.5 mM glucose followed by stimulation with 16.7 mM (Figure 5.2). In control islets, 
introduction of 16.7 mM glucose into the flow system was followed by a sharp increase in Ca2+ 
influx that plateaued. Ca2+ influx was inhibited in islets exposed to arsenicals as indicated by a 
smaller or delayed increase in the fluorescent signal and a smaller area under the curve (Figure 
5.2A-C). The impairment of Ca2+ influx by arsenicals did not follow a typical dose-response 
pattern, but MAsIII was clearly the most potent inhibitor, significantly suppressing Ca2+ influx at 
concentrations as low as 0.05 µM  (Figure 5.2D).  
 
Figure 5.2. Glucose-stimulated calcium influx in arsenic-exposed pancreatic islets. Isolated 
pancreatic islets were exposed to arsenicals for 48 hours and stimulated with 16.7 mM glucose 
(indicated by arrow).  Levels of intracellular calcium were measured over time and are shown in 
time course profiles of an average of all experiments (A-C). Area under the curve (D) was 
calculated from time of glucose injection to end of run and are shown as mean ± SEM for N=5-





There were no differences in basal intracellular calcium levels between control and exposed 
islets prior to stimulation with 16.7 mM glucose. For subsequent experiments, we used 
concentrations of arsenicals that caused significant decreases in intracellular calcium levels after 
stimulation with 16.7 mM glucose.  
 
Effect of trivalent arsenicals on Cav1.2 channels 
Inhibition of KATP channels by increased levels of ATP causes depolarization of the β-
cell membrane, stimulating the opening of L-type voltage-gated calcium channels (Cav1.2) 
(Wiser et al. 1999, Barg et al. 2001). To determine if the inhibition of calcium influx by 
arsenicals was due to inhibition of events after depolarization, we stimulated the islets with 
depolarizing levels of potassium chloride (35 mM KCl) in the absence of glucose. Treatment 
with KCl stimulated both Ca2+ influx and insulin secretion in control islets (Figure 5.3). KCl-
stimulated Ca2+ influx was significantly decreased in MAsIII- and DMAsIII-exposed islets; the 
decrease was marginally significant in iAsIII-exposed islets (p=0.1) (Figure 5.3A-B). All three 
arsenicals significantly decreased KCl-stimulated insulin secretion (Figure 5.3C). 
To test if arsenicals inhibit insulin secretion by affecting calcium influx through Cav1.2 
channels, we measured GSIS in control and arsenical-exposed islets treated with Bay K8644, a 
Cav1.2 channel-specific agonist that prolongs the time Cav1.2 channels are in the open state and 
potentiates insulin secretion (Panten et al. 1985). Unexposed islets stimulated with 16.7 mM 
glucose and 2 µM Bay K8644 secreted more insulin than those stimulated with 16.7 mM glucose 
alone (Figure 5.4). However, stimulation with glucose and Bay K8644 did not rescue the 
inhibition of insulin secretion in islets exposed to arsenicals. Though, arsenical-exposed islets 
stimulated with glucose and Bay K8644 secreted more insulin than the exposed islets stimulated 






Figure 5.3. KCl-stimulated calcium influx in arsenic-exposed pancreatic islets. Isolated 
pancreatic islets were exposed to arsenicals for 48 hours and stimulated with 35 mM potassium 
chloride (KCl), a potent insulin secretagogue. Levels of intracellular calcium (A) were measured 
over time and are shown in time course profiles of an average of 4 biological experiments, where 
the arrow indicates injection of KCl. Area under the curve (B) was calculated from time of KCl 
injection to end of run and shown as mean ± SEM of N=4, 30-40 islets/experiment. Insulin 
secretion (C) was measured in the absence of glucose (Basal) and after 1-hour stimulation with 







Figure 5.4. Bay K8644-stimulated insulin secretion and Cav1.2 channel expression in arsenic-
exposed pancreatic islets. Isolated pancreatic islets were exposed to arsenicals for 48 hours and 
stimulated for 1 hour each with 2.5 mM glucose, 16.7 mM glucose, and 16.7 mM glucose with 2 
µM Bay K8644. Mean ± SEM of N=3-4 biological replicates (each assay done in triplicate, 15 
islets/condition) are shown. *p<0.05 for comparison of arsenical-treated islets to unexposed 
controls. ǂp<0.05 for the comparison of 16.7 mM glucose and 16.7 mM glucose + 2 µM Bay 
K8644. 
 
 Thus, arsenicals may be affecting the transcription or activity of Cav1.2 channels or 
downstream mechanisms that depend on the function of these channels. To assess Cav1.2 
expression, we measured mRNA levels of Cav1.2α1, the pore-forming subunit of Cav1.2 channel, 
in control islets and in islets exposed to 2 µM iAsIII, 0.5 µM MAsIII or 0.5 µM DMAsIII for 48 
hours. We found no statistically significant differences in Cav1.2α1 mRNA levels between 






Figure 5.5. Expression of the alpha subunit of L-type calcium channels in arsenical-exposed 
islets. Isolated pancreatic islets were exposed to arsenicals for 48 hours and stimulated for 1 
hour each with 2.5 mM glucose and 16.7 mM glucose. Relative Quantitative Value (RQV) of the 
expression of the alpha subunit of Cav1.2 channels (Cacna1c) after GSIS is shown as mean ± 
SEM for N=4 biological replicates.   
 
Effect of trivalent arsenicals on the KATP channel 
Closure of KATP channels by ATP prevents influx of potassium ions and triggers 
membrane depolarization. To further test the effects of arsenicals on membrane depolarization, 
we measured insulin secretion from control and arsenical-exposed glucose-stimulated islets after 
treatment with tolbutamide, a KATP-channel blocker. Tolbutamide-stimulated insulin secretion 
was inhibited in islets exposed to iAsIII but restored insulin secretion in MAsIII- and DMAsIII- 
exposed islets, although these concentrations prevented glucose-stimulated Ca2+ influx (Figure 
2). Insulin secretion in MAsIII- and DMAsIII- exposed islets was restored to the level of insulin 






Figure 5.6. Tolbutamide-stimulated insulin secretion in arsenic-exposed pancreatic islets. 
Isolated pancreatic islets were exposed to arsenicals for 48 hours and stimulated for 1 hour each 
with 2.5 mM glucose, 16.7 mM glucose, and 16.7 mM glucose +200 µM tolbutamide. Mean ± 
SEM of N=3-4 biological replicates (each assay done in triplicate, 15 islets/condition) are 
shown. *p<0.05 for comparison of arsenical-treated islets to unexposed controls. ǂp<0.05 for 
the comparison of 16.7 mM glucose and 16.7 mM glucose +200 µM tolbutamide. 
 
5.5 Discussion 
Exposure to iAs has been associated with diabetes in many populations around the world 
(Maull et al. 2012, Kuo et al. 2017). Experimental studies show that iAsIII and its methylated 
trivalent metabolites inhibit insulin secretion in pancreatic islets and β-cells (Douillet et al. 2013; 
Fu et al. 2010; Díaz-Villaseñor et al. 2008; Dover et al. 2018) and some mechanisms for this 
inhibition have been proposed. For example, chronic exposure to iAsIII has been shown to 
upregulate Nrf2, an oxidative stress-sensitive transcription factor, and Nrf2-dependent 
transcription of antioxidant enzymes in INS-1 β cells and other cell types. (Lau et al. 2013). Fu et 





oxygen species involved in GSIS signaling (Fu et al. 2010). Dover et al. found that exposure to 
iAsIII and MAsIII, but not DMAsIII, impaired mitochondrial respiration in glucose-stimulated 
INS-1 cells (Dover et al. 2018), suggesting an impairment in ATP production, a critical step in 
GSIS regulation. In 2008, Díaz-Villaseñor et al. showed that exposure of rat insulinoma 
(RINm5F) cells to iAsIII inhibited glucose-stimulated Ca2+ influx and increased calpain-10 
activity and SNAP-25 proteolysis, proposed mechanisms involved in granule exocytosis (Díaz-
Villaseñor et al. 2008).  
In this study, we found that iAsIII and its methylated trivalent metabolites inhibited 
glucose-stimulated Ca2+ influx in isolated pancreatic islets at concentrations that also inhibit 
GSIS, but do not impair islet viability. We also found that MAsIII and DMAsIII, and to a lesser 
extent iAsIII, inhibited Ca2+ influx and insulin secretion in islets stimulated with a membrane 
depolarizing concentration of KCl, suggesting that arsenicals affect insulin regulating 
mechanisms downstream from the membrane depolarization. Furthermore, stimulation with the 
Cav1.2 channel agonist, Bay K8644, did not restore GSIS in islets exposed to arsenicals. 
Notably, 48-hour exposure to arsenicals did not suppress the Cav1.2 mRNA expression, pointing 
to inhibition of Ca2+ channel trafficking or activity as a mechanism underlying the inhibition of 
GSIS by trivalent arsenicals. Taken together, these data suggest that iAsIII, MAsIII and DMAsIII 
may target Cav1.2 channels, either interfering with the channel trafficking or inhibiting 
activity/conductance of the Cav1.2 channels within the plasma membrane of β-cells. It is also 
possible that these arsenicals target Ca2+ dependent mechanism(s) that stimulate insulin vesicle 
assembly and exocytosis downstream of Ca2+ channels. 
Cav1.2 channel expression at the plasma membrane and activity are regulated by various 





Auxiliary subunits of calcium channels regulate channel translocation to the membrane or 
channel activity (Dolphin 2012). In β-cells, the α2 subunit is bound to the δ subunit through a 
disulfide bond (Dolphin 2012). This α2- δ complex then binds to core α1 subunits and can 
increase plasma membrane expression of Cav1.2, leading to increased glucose-stimulated 
calcium influx (Dolphin 2012; Yang and Berggen 2006; Gao et al. 2000). Since trivalent 
arsenicals bind readily to thiols, they could be interfering with the formation of the α2- δ complex 
and inhibiting channel translocation.  
Cav1.2 channel trafficking and activity are also regulated by various kinases (reviewed in 
Yang and Berggren 2006). In islets and β-cells, inhibition of Ca2+/calmodulin-dependent kinase 
II decreased insulin secretion, paralleled by a decrease in calcium influx (Dadi et al. 2014). 
Protein kinase Akt upregulates Cav1.2 channels in excitable cells; phosphorylation by Akt 
promotes Cav1.2 stabilization and increases trafficking to the plasma membrane (Catalucci et al. 
2009; Viard et al. 2004). Akt kinases are expressed in β-cells and has been reported to be a 
positive regulator of insulin secretion (Cui et al. 2012). We have previously shown that iAsIII and 
its trivalent methylated metabolites, MAsIII and DMAsIII, inhibit the phosphorylation/activation 
of Akt and the Akt-mediated signaling in adipocytes (Paul et al. 2007) and hepatocytes (Zhang et 
al. 2017). This inhibition of Akt phosphorylation could contribute to the inhibition of Ca2+ influx 
in the islets exposed to trivalent arsenicals.   
Our experimental data suggest that arsenicals may interfere with Cav1.2 channel function 
directly, i.e. by reacting with the proteins/subunits that are responsible for regulation of Ca2+ 
flow through the channel. However, it is unlikely that the trivalent arsenical would be directly 
binding to these channels since Cav1.2 channels contain few cysteine residues and the primary 





Alternatively, arsenicals could be binding to allosteric binding sites, leading to changes in 
calcium channel activity. Measurement of calcium flux across the Cav1.2 channel via the patch 
clamp technique would be needed to determine if arsenicals directly impair flow of Ca2+ through 
the membrane-bound channels.  
Similar to KCl, tolbutamide stimulates membrane depolarization by blocking KATP 
channels at the SUR1 subunit, leading to insulin secretion. However, depolarization with 
tolbutamide is more physiological than artificially raising ion levels with KCl. Stimulation with 
tolbutamide restored GSIS in islets exposed to MAsIII and DMAsIII, suggesting that these 
arsenicals also affect KATP channels. The KATP channel has two subunits that regulate channel 
closure: ATP interacts with the Kir6.2 subunit and tolbutamide interacts with the sulfonylurea 
receptor protein 1 (SUR1) (Babenko 1999). MAsIII and DMAsIII may be interfering with ATP 
levels or ATP-KATP channel interactions at the Kir6.2 subunit, effects which would be overcome 
by tolbutamide stimulation. Real-time measurement of intracellular ATP would determine if this 
is the case. Suppression of ATP activation of KATP channels by arsenicals could also explain why 
Bay K8644-stimulation did not restore insulin secretion. During glucose stimulation, the 
membrane potential of the β-cell membrane oscillates between depolarizing and non-
depolarizing levels, thus Cav1.2 channels oscillate between open and closed states, leading to 
oscillations in intracellular Ca2+ levels during glucose stimulation (Henquin 2009). If arsenicals 
are inhibiting KATP closure, the membrane is spending less time at a depolarizing voltage, 
leading to less time Cav1.2 channels are open and lower calcium influx. Thus, although Bay 
K8644 maintains open Cav1.2 channels, there are fewer open Cav1.2 channels in MAs
III- and 






The restoration of GSIS by tolbutamide in MAsIII and DMAsIII- exposed islets appears to 
contradict the data showing their effects on Ca2+ influx and/or downstream mechanisms. 
However, tolbutamide has been shown to stimulate insulin secretion apart from its effects on the 
KATP channel (Barg et al. 1999). SURs have been also found in insulin granules and are thought 
to contribute to the acidification of insulin granules, a priming step needed for exocytosis 
(Eliasson et al. 2003). Thus, tolbutamide may be able to stimulate insulin secretion via this Ca2+-
independent pathway in MAsIII and DMAsIII-, but not iAsIII- exposed islets.  
Tolbutamide did not restore GSIS in iAsIII-exposed islets, suggesting that other actions of 
iAsIII in the β-cell may be more important in inhibiting insulin secretion. iAsIII may be interfering 
with remodeling of β-actin microfilaments that are needed for insulin granule transport and 
secretion, effects which tolbutamide stimulation would not be able to overcome (Izdebska et al. 
2013; Izdebska et al. 2014; Qian et al. 2005). Since actin reorganization is important for insulin 
granule transport, priming, and release (Wang and Thurmond 2009), iAsIII may be inhibiting the 




 We found that iAsIII and its methylated trivalent metabolites (MAsIII and DMAsIII) 
impaired glucose-stimulated Ca2+ influx in isolated pancreatic islets, at concentrations that also 
inhibit GSIS but do not affect islet viability. The methylated metabolites have been previously 
shown to be more potent inhibitors of GSIS than iAsIII. Here, we show that one of these 
metabolites, MAsIII, is also more potent than iAsIII as an inhibitor of glucose-stimulated Ca2+ 





other mechanisms that regulate GSIS in β-cells. Future studies should focus on identification of 
these targets to further characterize the role of iAs metabolism in the development of arsenic-
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6. CHAPTER 6- Synthesis 
 
Support for iAs-associated diabetes, even in populations with low levels of chronic 
exposure (<150 ppb), is increasing. Despite these epidemiological associations, our 
understanding of how iAs induces or predisposes individuals to diabetes is limited. Since 
methylation of iAs facilitates the clearance of iAs from the body, it has been proposed that 
increasing the rate of iAs methylation by increasing dietary nutrients used to generate SAM 
could reduce risk of iAs-associated disease. However, methylated trivalent metabolites of iAs 
also interfere with insulin signaling and insulin secretion more potently than iAs itself. A 
summary of our understanding of the relationship between arsenic and arsenic metabolism with 
diabetes in human, rodent, and in vitro studies is shown in Figure 6.1. A clearer understanding of 
how iAs metabolism contributes to the development of diabetes is essential for determining if 
increasing efficiency of iAs metabolism through nutritional means can be a protective 
intervention strategy. Furthermore, risk assessors would be able to better predict iAs toxicity 
based on an individual’s capacity to metabolize iAs and to identify and protect susceptible 
populations.  
This dissertation is a compilation of research that aimed to understand mechanisms of 
iAs-associated diabetes and the role of iAs metabolism through a diversity of approaches. 
Previous chapters have described projects involving metabolomics, in vivo exposure studies, and 
in vitro mechanistic studies. This chapter summarizes the results, suggests future directions, and 







Figure 6.1. Summary of the knowledge about the relationship of arsenic and arsenic metabolism 
with diabetes at the start of this dissertation work.  
 
6.1 Metabolomic assessment of iAs exposure and the As3mt-KO genotype 
Metabolomic studies have been conducted in iAs-exposed humans in efforts to 
understand mechanisms of iAs toxicity and identify biomarkers of exposure (Zhang et al. 2014; 
Martin et al. 2015; Wu et al. 2018). In Chapter 2, we investigated metabolite changes in C57BL6 
mice exposed to iAs in order to compare with iAs-associated metabolite changes in humans. By 
comparing these iAs-associated metabolites in mice and humans, we hoped to identify common 
metabolites that would indicate disrupted pathways that could be investigated further. We found 
that exposure to 1 ppm iAs for 4 weeks had little to no effect on urinary and plasma metabolites 
(Table 2.1), unlike in humans exposed to 20-152 ppb iAs where 132 metabolites were associated 





exposed to a higher dose of iAs for a relatively short period of time. These findings indicated that 
mice are more tolerant of iAs exposure than humans and are capable of metabolizing As faster. 
Since 1 ppm iAs exposure for four weeks did not change metabolite profiles, future metabolomic 
studies on iAs-associated biochemical changes in mice could modify the exposure dose either by 
concentration or length of exposure. 
We also evaluated metabolites in mice with an impaired capacity to methylate iAs (i.e. 
knockout of As3mt) in efforts to characterize this mouse model in the context of metabolic 
disease. Many metabolites were found to be different in As3mt-KO compared to C57BL6 (WT) 
mice. Urinary and plasma metabolites associated with KO were related to lipid metabolism, 
amino acid metabolism, and other methylation reactions. Interestingly, metabolite changes 
associated with As3mt-KO were different depending on the sex. Analysis of liver 
phosphatidylcholines showed similar findings to analyses of urinary and plasma metabolites: few 
metabolites associated with exposure and many metabolites associated with As3mt-KO in a sex-
dependent manner.  
    This metabolomics study was the first to suggest that there may be underlying 
metabolic differences in As3mt-KO mice. Subsequently, our lab assessed glucose metabolism in 
As3mt-KO mice compared to WT mice (Douillet et al. 2017). In that study, we found that the KO 
mice gained more weight, accumulated more fat, and were more insulin resistant than WT mice 
even without iAs exposure in drinking water. Interestingly, male KO mice were more insulin 
resistant than female KO mice, paralleling the sex-specific differences in their metabolic profiles 
described in Chapter 2. Additional investigation could determine if As3mt-KO mice are different 
from WT due to heightened susceptibility to iAs exposure in the diet or due to other 





components of genes related to lipid and/or/ glucose metabolism, leading to differential gene 
expression and this adverse metabolic phenotype. Another possible mechanism is through the gut 
microbiome, particularly since hippuric acid, a metabolite linked to the microbiome, was the 
metabolite with the highest fold change in As3mt-KO mice.  
Complete elimination of As3mt and iAs metabolism is not observed in humans; instead, 
human populations consist of individuals with different single nucleotide polymorphisms and 
haplotypes that are linked to modest changes in iAs methylation. Mice populations with high 
genetic diversity such as the Collaboratic Cross mice or the Jackson Lab’s Diversity Outbred 
mice emulate the genetic diversity in humans and would be useful populations in which to study 
the role of iAs metabolism and polymorphisms in As3mt in disease. 
 
6.2 In vivo studies of iAs-associated diabetes and B-vitamin nutritional interventions 
    Mice exposed to 3- 50 ppm levels of iAs develop impaired glucose tolerance and 
hyperglycemia (Maull et al. 2012; Paul et al. 2007). Given that humans are exposed to ppb levels 
of iAs, there is much interest in understanding the effects of more environmentally-relevant 
doses in animal models. Additionally, people are often exposed to iAs throughout the entire life, 
from preconception to adulthood. The effects of iAs exposure during early developmental 
periods and its potential to result in diabetes later in life has not been thoroughly examined in 
human or animal studies. One of the advantages of experimental studies is that we can separate 
these two windows of exposure and investigate mechanisms specific to each period of exposure. 
In Chapters 3 and 4, we discussed a prenatal exposure study and an adult exposure study in mice 
assessing the diabetogenic effects of low-level (100 ppb) iAs exposure on diabetes outcomes. B-





protect against iAs-associated toxicities. However, there are few human studies and experimental 
studies to support this theory. We aimed to address this knowledge gap as well in these studies. 
In Chapter 3, we studied the effects of prenatal iAs exposure in C57BL6 mice on glucose 
metabolism. Our results showed that prenatal exposure to 100 ppb iAs increased fasting blood 
glucose, insulin resistance, and %fat but only in male offspring. Interestingly, though maternal 
folate and B12 supplementation minimally stimulated iAs metabolism, it prevented the 
hyperglycemia, increased insulin resistance, and gains in fat mass in iAs-exposed male offspring, 
suggesting that maternal supplementation may protect against the diabetogenic effects of iAs.  
In Chapter 4, we assessed how folate intake modifies iAs metabolism and iAs-associated 
diabetes in adult male and female mice. We included the As3mt-KO mice with the hypothesis 
that altered folate intake in KO animals would not modify iAs-associated impairments in glucose 
metabolism because KO animals do not methylate iAs. To emulate how humans can be exposed 
to multiple environmental metabolic stressors at a time, we placed these animals on a high-fat 
diet after 24 weeks on a low-fat diet and continued iAs exposure.  
We found that high folate intake increased plasma folate by 3- to 4-fold but had minor 
effects on iAs metabolism, as measured by urinary As and liver As species. Neither exposure to 
100 ppb iAs or high folate intake for 24 weeks elicited significant effects on glucose metabolism 
measures in KO or WT mice. However, after eight weeks on a high-fat diet, mice exposed to iAs 
developed insulin resistance and gained more fat than non-exposed mice. These changes tended 
to occur in mice fed the low-folate diet. While on a purified diet containing ~40 ppb iAs, As3mt-
KO were more insulin resistant than WT, confirming our previous study of KO animals 
consuming a chow diet that contained 100 ppb iAs (Douillet et al. 2017). Males were more 





Results from these in vivo studies provide four main conclusions. First, mice exposed 
chronically to doses of iAs that are consistent with exposures in human populations do not 
demonstrate clear indications of diabetes. These studies and others show that mice appear to be 
more efficient methylators of iAs and more resistant to the effects of iAs at the levels to which 
humans are exposed. Additional studies need to be done to determine the appropriate iAs doses 
for mice in drinking water to generate tissue level exposures that are equivalent to those in 
exposed humans. Second, mice that do not metabolize iAs develop an adverse metabolic 
phenotype. While this could be due to changes in gene expression associated with knockout of 
As3mt, it is possible that dietary iAs exposure may be responsible for these effects. As3mt-KO 
mice accumulate more iAs in the tissue, suggesting that although there is no production of toxic 
methylated As metabolites, the increased concentration of iAs in the tissue is detrimental. Third, 
supplementation with the B-vitamins folate and B12 had very minimal effects on iAs metabolism 
at the doses used in these studies. Higher iAs exposure or higher supplementation may be needed 
to produce significant changes in iAs metabolism akin to changes observed in humans. Other 
vitamins or nutritional factors may also be important in modifying iAs metabolism and could be 
subjects of future studies. Lastly, male mice were more insulin resistant than female mice. 
Further investigation into mechanisms underlying the sex differences, such as the role of 
estrogen (Huang et al. 2015), and how they modify iAs toxicity would significantly advance risk 
assessment. 
Other avenues for future study include investigations into the interaction of high-fat diet, 
iAs exposure, and low folate that was observed in Chapter 4. The design of the presented study 
does not allow us to differentiate between effects of high-fat diet and age. The interactive effects 





high-fat diet groups. The role of nutrition in toxicology is less recognized than it deserves. While 
the addition of more variables complicates animal studies, understanding toxicity in these 
complex models is important and very relevant to human exposures.  
 
6.3 Mechanisms underlying the inhibition of glucose-stimulated insulin secretion by 
trivalent arsenicals 
Studies from our lab and others have shown the iAs and its methylated trivalent 
metabolites inhibit glucose-stimulated insulin secretion in pancreatic islets and β-cells (Douillet 
et al. 2013, Fu et al. 2010, Dover et al. 2018). Since the mechanism underlying this inhibition is 
largely unknown, we investigated if impairments in insulin secretion were due to effects on 
glucose-stimulated calcium influx. As described in Chapter 5, we found that iAsIII, MAsIII, and 
DMAsIII impaired glucose-stimulated calcium influx in pancreatic islets. This impairment could 
be due to interference with calcium channels or KATP channels. Notably, the methylated 
metabolites may target different steps in insulin secretion than iAs, increasing the complexity of 
iAs toxicity.  
Further studies could be done to determine how arsenicals affect these ion channels in the 
β-cell. Since trivalent arsenicals are highly reactive and can bind with thiol groups in proteins, 
broader assessments of impairments in β-cell function, such as transcriptomic, proteomic, or 
metabolomic assessments, would help clarify the mechanisms underlying the inhibition of 






Figure 6.2. Contribution of this work to the knowledge of the relationship of arsenic and arsenic 
metabolism with diabetes. 
 
6.4 Sex as an important biological variable 
  In all the animal studies, we repeatedly observed significant differences between male 
and female mice in response to iAs exposure. Male WT mice were more prone to developing 
insulin resistance after prenatal iAs exposure (Chapter 3) and male As3mt-KO mice, which have 
exposure to iAs through diet, were more insulin resistant than female KO mice (Chapter 4). 
Furthermore, metabolites associated with As3mt-KO were different in KO males compared to 
females (Chapter 2). There were even differences in insulin resistance among WT males and 
females, regardless of iAs exposure in drinking water.  
Differences in susceptibility to diabetes and metabolic disease have been reported in 
human populations. Women are more tolerant to weight gain and often have more adipose mass 





(Mauvais-Jarvis et al. 2015). Differences in estrogen and androgen levels is a major reason for 
sex differences in metabolic disease because both are heavily involved in the regulation of 
energy expenditure and tissue metabolism. Estrogen can influence neurological signaling in the 
brain to decrease food intake and regulate energy expenditure, has antilipogenic and 
antiadipogenic effects, is shown to protect β-cell survival and function (Tiano and Mauvais-
Jarvis 2012), may influence insulin sensitivity in muscle and liver, and mediates immunological 
responses (Mauvais-Jarvis et al. 2013). Androgen deficiency is linked to increased risk of 
cardiovascular disease, obesity, and T2D (Navarro et al. 2015). Since testosterone is converted 
into 17β-estradiol via aromatase, lower testosterone availability may lead to lower E2 production 
for influencing tissue metabolism. But testosterone can also influence metabolism through 
androgen receptors. Androgen receptors have been shown to regulate adiponectin production, 
stimulate differentiation away from adipocytes to myoctyes, improve insulin sensitivity, and also 
play a role in neural circuits regulating energy expenditure (Navarro et al. 2015). Additionally, 
sex differences in metabolic disease could be due to genetic and epigenetic differences: 
differences in fetal programming, in placental gene expression, and in expression of X-
chromosome-linked genes (Kautzky-Willer et al. 2016). 
The sex-specific effects of iAs exposure has been observed in other iAs-associated 
toxicities, such as in cancer and respiratory disease (Vahter et al. 2007; Ferrario et al. 2016), less 
so in diabetes (Huang et al. 2015; Palacios et al. 2012). These sex differences can be attributed to 
a variety of biological reasons. Women are more efficient methylators of iAs than men (Shen et 
al. 2016), possibly because women have higher levels of choline (Fischer et al. 2010) due to the 
induction of phosphatidylethanolamine-N-methyltransferase by estrogen (Resseguie et al. 2007). 





urine, as in humans (Chapter 2, 4), potentially explaining the increased susceptibility of males to 
iAs-associated insulin resistance. However, at the tissue level, females have more total As and 
lower %DMAs in the liver (Chapter 4; Douillet et al. 2017). This finding is perplexing and 
suggests that other actions of iAs could influence sex differences.   
As discussed above, estrogen and androgen steroid hormone receptors are integral in the 
regulation of energy use and metabolism. Disruption of these receptors by iAs could explain sex-
specific effects on metabolism. iAs has been shown to alter steroid hormone receptor-mediated 
gene regulation in all five steroid receptor types (estrogen, androgen, glucocorticoid, 
mineralcorticoid, and progesterone) (Bodwell et al. 2006; Davey et al 2007; Kaltreider et al. 
2001) and gene regulation via retinoic acid and thyroid hormone receptors (Davey et al. 2008). 
The mechanism underlying this disruption by iAs is unknown but appears to be unique from 
other endocrine disruptors which bind to the receptor as a hormone mimetic and/or compete as 
an antagonist. Since there is minimal sequence and structural similarity across these receptor 
types, it is thought that iAs affects common coregulatory proteins and/or pathways that regulate 
these receptors (Davey et al. 2007; Barr et al. 2009). Alternatively, iAs could be binding to 
sulfhydrl groups within these receptors, or related regulatory proteins, in a way that impairs 
function.  
Due to the prevalence of iAs in chow diets, all animals received from suppliers could 
potentially have had prenatal iAs exposure, which could result in differential programming of the 
fetus or the placenta by sex. Sex-specific differences in DNA methylation changes associated 
with iAs exposure have been reported (Broberg et al. 2014; Pilsner et al. 2012; Niedzwiecki et al. 
2015). Furthermore, iAs exposure has been linked to differential DNA methylation patterns in 





other studies suggest that differential placenta DNA methylation could drive sex differences due 
to differential regulation of transporters and signaling molecules in the placenta (Martin et al 
2017). Interestingly, folate acid supplementation modified placenta DNA methylation in a 
manner that was dependent on sex of the fetus (Penailillo et al. 2015), potentially explaining the 
differences in the protective effects of maternal supplementation in prenatal iAs exposures 
(Chapter 3). Further investigation of epigenetics as a mechanism underlying sex differences and 
iAs-associated diabetes is needed.  
 
6.5 Implications 
Our animal and in vitro studies show that the role of iAs metabolism in diabetes and 
metabolic disease is complex. We and others have found that methylated trivalent arsenicals are 
more toxic than iAsIII (Chapter 5) yet the inability to methylate iAs is associated with adverse 
metabolic health (Chapter 2, 4). There appears to be two forces involved in the effects of iAs on 
metabolic health: the production of methylated metabolites and the accumulation of iAs. Both 
processes lead to adverse effects on glucose metabolism. Since humans are never completely 
without iAs methylation, the toxicity of the methylated metabolites seems to be more relevant, 
but this theory needs further investigation. The effects of iAs metabolism on glucose metabolism 
may be better examined in models with a milder disruption of iAs metabolism. 
The research presented in this dissertation has, at least, three major implications. Firstly, 
our in vivo studies call for a reconsideration of the appropriate iAs doses used for assessment of 
iAs-associated toxicity, in the context of metabolic disease and others. Additionally, background 
dietary iAs may be a confounding factor that needs to be considered in future study designs. In 





only mild differences in metabolites and in glucose metabolism. The clear species difference 
between man and mouse in susceptibility to iAs toxicity, likely due to differences in iAs 
metabolism, needs to be addressed going forward by developing more accurate biological 
models of iAs exposure. 
Secondly, more research is needed to come to conclusions about proper strategies to 
protect against iAs-associated diabetes. Our data add insight on the mechanisms underlying the 
development of diabetes after iAs exposure, pointing to insulin resistance as an important 
characteristic, but more work needs to be done to detail the temporal progression of iAs-
associated diabetes. Based on our current understanding, iAs-associated diabetes appears to be 
distinct from both type 1 and type 2 diabetes. It is not associated with β-cell destruction, but 
rather β-cell dysfunction, leading to impaired insulin secretion. On the contrary, iAs-exposed 
animals develop high fasting plasma insulin and insulin resistance. With a better understanding 
of the development of iAs-associated diabetes, we will be able to accurately classify it into the 
proper diabetes typology, or delineate a novel category, and recommend treatment strategies in 
the clinic. 
Supplementation with B-vitamins is often discussed as a promising intervention to 
stimulate iAs metabolism, increase excretion of As, and, thus, diminish iAs toxicity. However, 
our findings indicate that more studies need to be done to determine if and how iAs metabolism 
can be modified via nutritional means and what changes in iAs metabolism mean in the context 
of iAs-associated diabetes and metabolic disease. The best strategy to suggest at this point is to 
reduce exposure to iAs through the dissemination of effective water purification technologies. 





reduce risk of obesity and diabetes in society. We can seek to encourage healthy eating and 
exercise lifestyles through education and through improving access to healthy food for all.  
Lastly, our data only strengthen the rationale for the NIH policy calling for the inclusion 
of both sexes in preclinical studies (Clayton and Collins 2014). Undoubtably, understanding how 
sex influences biology and the body’s response to toxicants will be important for the design, 
conduct, and interpretation of future toxicological studies in order to maximize protection of 
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A. Appendix A: Supplemental Material for Chapter 2 
 
 
Figure A.1. Arsenic species in urine of control and iAs-treated male (M) and female (F) wild-
type (WT) and As3mt-knockout (KO) mice: iAs, inorganic arsenic; MAs, methyl-arsenic; DMAs, 
dimethyl-arsenic. Mean and SE values are shown for N=15-21 per group. *Indicates statistically 









Figure A.2. Mouse body weights at start of the experiment (A), at sacrifice four weeks later (B), 
and change in body weight (weight at sacrifice – weight at start) (C) of male (M) and female (F) 
wild-type (WT) and As3mt-KO (KO) mice exposed to 1 ppm As (1) and the corresponding 








Figure A.3. Food and water consumption. Average food (A) and water (B) consumption over the 





Figure A.4. Number of significantly changed urinary and plasma metabolites (q<0.05) in 
As3mt-KO (KO) control and iAs-treated (1 ppm) mice as compared to wild-type (WT) 
counterparts. Venn diagrams show overlapping and iAs-associated plasma and urinary 
metabolites in female (left) and male (right) animals. Bolded numbers indicate the total number 
of changed metabolites in each comparison/overlap; arrows indicate direction of change of 














Figure A.5. Hierarchical clustering of hepatic phosphatidylcholines (PCs). Heat map generated 
by unsupervised two-way clustering analysis shows relative levels of PCs (columns) in untreated 
(0 ppm) and iAs-treated (1 ppm), male (M) and female (F), wild-type (WT) and As3mt-knockout 
(KO) mice (rows). The PC levels are mean centered with high relative levels indicated in red and 



















Table A.1. Metabolites identified by LC-MS and GC-MS in urine and plasma of mice in all 
experimental groups. 
Urine Plasma 
LC-MS GC-MS LC-MS GC-MS 
Alanine Dimethylglycine L-Alanine Dimethylglycine 
Arginine 2-Hydroxypyridine L-Arginine 2-Hydroxypyridine 
Asparagine Pyruvic acid L-Asparagine Pyruvic acid 
Aspartic acid L-Lactic acid L-Aspartic acid L-Lactic acid 
Citrulline Glycolic acid Citrulline Glycolic acid 
Glutamine Alpha-ketoisovaleric acid L-Glutamine Alpha-ketoisovaleric acid 
Glutamic acid 2-Hydroxybutyric acid L-Glutamic acid 2-Hydroxybutyric acid 





leucine/Isoleucine Ketoleucine L-Isoleucine L-Alpha-aminobutyric acid 
Methionine 3-Methyl-2-oxovaleric acid L-Lysine Ketoleucine 
Ornithine Malonic acid L-Methionine 3-Methyl-2-oxovaleric acid 
Phenylalanine Methylmalonic acid Ornithine Pyrophosphate 
Proline Glyceraldehyde L-Phenylalanine Benzoic acid 
Serine Urea L-Proline Glycerol 
Threonine Benzoic acid L-Serine L-Alloisoleucine 
Tryptophan Glycerol L-Threonine Succinic acid 
Tyrosine Succinic acid L-Tryptophan Glyceric acid 
Valine Glyceric acid L-Tyrosine Uracil 
Asymmetric 
dimethylarginine 
Uracil L-Valine Fumaric acid 
Symmetric 
dimethylarginine 
Fumaric acid N-Acetylornithine 3-Oxoalanine 
Carnosine Pelargonic acid Asymmetric 
dimethylarginine 
Glutaric acid 
Creatinine Acetylglycine Symmetric dimethylarginine Beta-Alanine 
DOPA Indoxyl sulfate Aminoadipic acid Erythrose 
Dopamine L-Pipecolic acid Carnosine Malic acid 
Histamine 3-Oxoalanine Creatinine 2-Phenylglycine 
Kynurenine Methylcysteine Dopa Pyroglutamic acid 
Methionine sulfoxide Beta-Alanine Dopamine L-Cysteine 
t4-Hydroxyproline L-Homoserine Histamine Creatine 
Putrescine Erythrose L-Kynurenine D-2-Hydroxyglutaric acid 
Serotonin 3-Aminoisobutanoic acid Methionine sulfoxide Oxoglutaric acid 
Spermidine Malic acid 4-Hydroxyproline 3-Hydroxybutyric acid 
Spermine Adipic acid 1-Phenylethylamine Dodecanoic acid 
Taurine D-Threitol Putrescine D-Xylose 





C10 Cytosine Serotonin Ribonolactone 
C10:1 Gamma-Aminobutyric acid Spermidine D-Ribose 
C10:2 L-Cysteine Spermine Rhamnose 
C12 Creatine Taurine L-Arabitol 
C12-DC Hydroxypropionic acid C10 Glycerol 3-phosphate 
C12:1 D-2-Hydroxyglutaric acid C10:1 O-Phosphoethanolamine 
C14 Oxoglutaric acid C10:2 Isocitric acid 
C14:1 Phenylpyruvic acid C12 Citric acid 
C14:1-OH 3-Hydroxybutyric acid C12:1 Myristic acid 
C14:2 Pimelic acid C12-DC 1,5-Anhydrosorbitol 
C14:2-OH 4-Hydroxybenzoic acid C14 L-Sorbose 
C16 N-Acetyl-L-aspartic acid C14:1 Gluconolactone 
C16-OH D-Xylose C14:1-OH D-Fructose 
C16:1 L-Arabinose C14:2 D-Mannose 
C16:1-OH Ribonolactone C14:2-OH D-Galactose 
C16:2 D-Ribose C16 D-Glucose 
C16:2-OH Suberic acid C16:1 Mannitol 
C18 Aminoadipic acid C16:1-OH D-Glucuronic acid 
C18:1 Rhamnose C16:2 Sorbitol 
C18:1-OH L-Arabitol C16:2-OH Pantothenic acid 
C18:2 Ribitol C16-OH Palmitoleic acid 
C2 Glycerol 3-phosphate C18 Galactonic acid 
C3 O-Phosphoethanolamine C18:1 Gluconic acid 
C5-OH (C3-DC-M) Hippuric acid C18:1-OH Palmitic acid 
C3-OH Isocitric acid C18:2 3-Indolepropionic acid 
C3:1 1-Octanoyl-rac-glycerol C2 Myoinositol 
C4 Citric acid C3 Heptadecanoic acid 
C3-DC (C4-OH) 1,5-Anhydrosorbitol C3:1 Linoleic acid 
C4:1 Adenine C3-DC (C4-OH) Petroselinic acid 
C5 Quinic acid C3-OH Oleic acid 
C5-DC (C6-OH) L-Sorbose C4 Elaidic acid 
C5-M-DC Allantoin C4:1 Stearic acid 
C5:1 Gluconolactone C5 Nonadecanoic acid 
C5:1-DC D-Fructose C5:1 Arachidonic acid 
C6 (C4:1-DC) Hydroxyphenyllactic acid C5:1-DC Arachidic acid 
C6:1 D-Mannose C5-DC (C6-OH) Docosahexaenoic acid 
C7-DC D-Galactose C5-M-DC MG(16:0/0:0/0:0) 
C8 D-Glucose C5-OH (C3-DC-M) Sucrose 
C9 4-Hydroxycinnamic acid C6 (C4:1-DC) MG(18:2(9Z,12Z)/0:0/0:0)[rac
] 





lysoPC a C16:0 D-Glucuronic acid C7-DC Cholesterol 
lysoPC a C16:1 Sorbitol C8 184 unidentified metabolites 
lysoPC a C17:0 Pantothenic acid C9 
 
lysoPC a C18:0 Galactonic acid PC aa C24:0 
 
lysoPC a C18:1 Gluconic acid PC aa C26:0 
 
lysoPC a C18:2 Guanidinosuccinic acid PC aa C28:1 
 
lysoPC a C20:3 Palmitic acid PC aa C30:0 
 
lysoPC a C20:4 Uric acid PC aa C32:0 
 
lysoPC a C24:0 Myoinositol PC aa C32:3 
 
lysoPC a C26:0 Normetanephrine PC aa C34:1 
 
lysoPC a C26:1 Heptadecanoic acid PC aa C34:2 
 
lysoPC a C28:0 Stearic acid PC aa C34:3 
 
lysoPC a C28:1 Nonadecanoic acid PC aa C34:4 
 
PC aa C24:0 Glucose 6-phosphate PC aa C36:0 
 
PC aa C26:0 Uridine PC aa C36:1 
 
PC aa C28:1 Inosine PC aa C36:2 
 
PC aa C30:0 Adenosine PC aa C36:3 
 
PC aa C32:0 Sucrose PC aa C36:4 
 
PC aa C32:1 Xanthosine PC aa C36:5 
 
PC aa C32:3 Cytidine PC aa C36:6 
 
PC aa C34:1 Alpha-Lactose PC aa C38:0 
 
PC aa C34:2 MG(18:2(9Z,12Z)/0:0/0:0)[rac
] 
PC aa C38:3 
 
PC aa C34:3 D-Maltose PC aa C38:4 
 
PC aa C34:4 320 unidentified metabolites PC aa C38:5 
 
PC aa C36:0 
 
PC aa C38:6 
 
PC aa C36:1 
 
PC aa C40:2 
 
PC aa C36:2 
 
PC aa C40:3 
 
PC aa C36:3 
 
PC aa C40:4 
 
PC aa C36:4 
 
PC aa C40:5 
 
PC aa C36:5 
 
PC aa C40:6 
 
PC aa C36:6 
 
PC aa C42:1 
 
PC aa C38:0 
 
PC aa C42:4 
 
PC aa C38:3 
 
PC aa C42:5 
 
PC aa C38:4 
 
PC aa C42:6 
 
PC aa C38:5 
 
PC ae C30:2 
 
PC aa C38:6 
 
PC ae C32:1 
 
PC aa C40:1 
 
PC ae C32:2 
 
PC aa C40:2 
 
PC ae C34:0 
 
PC aa C40:3 
 
PC ae C34:1 
 
PC aa C40:4 
 






PC aa C40:5 
 
PC ae C36:0 
 
PC aa C40:6 
 
PC ae C36:1 
 
PC aa C42:0 
 
PC ae C36:2 
 
PC aa C42:1 
 
PC ae C36:3 
 
PC aa C42:2 
 
PC ae C36:4 
 
PC aa C42:4 
 
PC ae C36:5 
 
PC aa C42:5 
 
PC ae C38:0 
 
PC aa C42:6 
 
PC ae C38:1 
 
PC ae C30:0 
 
PC ae C38:3 
 
PC ae C30:2 
 
PC ae C38:4 
 
PC ae C32:2 
 
PC ae C38:5 
 
PC ae C34:0 
 
PC ae C38:6 
 
PC ae C34:1 
 
PC ae C40:3 
 
PC ae C34:2 
 
PC ae C40:4 
 
PC ae C34:3 
 
PC ae C40:5 
 
PC ae C36:0 
 
PC ae C40:6 
 
PC ae C36:1 
 
PC ae C42:5 
 
PC ae C36:2 
 
SM (OH) C14:1 
 
PC ae C36:3 
 
SM (OH) C22:1 
 




PC ae C36:5 
   
PC ae C38:0 
   
PC ae C38:1 
   
PC ae C38:3 
   
PC ae C38:4 
   
PC ae C38:5 
   
PC ae C38:6 
   
PC ae C40:1 
   
PC ae C40:2 
   
PC ae C40:3 
   
PC ae C40:4 
   
PC ae C40:5 
   
PC ae C40:6 
   
PC ae C42:0 
   
PC ae C42:1 
   
PC ae C42:2 
   
PC ae C42:3 
   
PC ae C42:4 
   
PC ae C42:5 
   
PC ae C44:3 
   
PC ae C44:4 





PC ae C44:5 
   
PC ae C44:6 
   
SM (OH) C14:1 
   
SM (OH) C16:1 
   
SM (OH) C22:1 
   
SM (OH) C22:2 
   
SM (OH) C24:1 
   
SM C16:0 
   
SM C16:1 
   
SM C18:0 
   
SM C18:1 
   
SM C20:2 
   
SM C24:0 
   
SM C24:1 
   
SM C26:0 
   
SM C26:1 
   
CX:Y; acyl-carnitine, where X indicates number of carbons of the fatty acid tail and Y indicates 
number of double bonds. Phosphatidylcholine notation: PC; phosphatidylcholine, aa; two fatty 
acid ester linkages, ae; one ester and one ether linkage, CA:Z is a description of the fatty acid 
composition of two PC tails where A indicates total number of carbons in both fatty acid tails 
















Table A.2. Plasma and urinary metabolites significantly changed (p<0.05) by iAs treatment in 
male and female wild-type (WT) and As3mt-KO (KO) mice. Fold change indicates difference 












1 ppm vs 0 ppm (55)* 
Dopamine <0.01 -1.64 3-Indolepropionic 
acid 
0.05 -1.35 
D-Fructose 0.03 -2.59 PC ae C40:6 <0.01 -1.24 
Mannitol 0.02 -2.14 PC aa C38:6 <0.01 -1.23 
D-Galactose 0.02 -1.52 PC aa C40:6 <0.01 -1.22 
D-Glucose 0.02 -1.52 SM C18:0 0.01 -1.21 
C18:1 <0.01 -1.50 PC ae C30:2 0.02 -1.20 
Adenosine 0.04 -1.48 Citric acid <0.01 -1.20 
PEA 0.01 -1.47 PC aa C38:4 0.01 -1.19 
Ribitol 0.01 -1.44 SM C18:1 0.02 -1.19 
L-Arabitol 0.01 -1.41 PC ae C42:0 0.04 -1.18 
Myoinositol 0.02 -1.38 PC ae C38:4 0.01 -1.17 
Ribonolactone 0.03 -1.38 PC aa C40:5 0.03 -1.16 
C14 <0.01 -1.36 PC aa C36:4 0.01 -1.16 
C14:2 0.03 -1.32 Histidine 0.04 -1.14 
C18 0.01 -1.31 PC aa C40:4 0.01 -1.14 
C5-DC (C6-OH) 0.04 -1.23 PC aa C42:4 0.04 -1.13 
C18:1-OH 0.04 -1.22 PC aa C24:0 0.04 -1.13 
PC ae C34:1 <0.01 -1.21 PC ae C40:4 0.05 -1.13 
PC ae C36:3 0.02 -1.10 PC ae C40:2 0.01 -1.12 
Creatinine <0.01 1.03 PC ae C38:6 0.04 -1.12 
PC aa C36:1 0.03 1.19 PC aa C38:0 0.02 -1.12 
C10:1 0.04 1.28 PC aa C38:3 0.03 -1.12 
PC aa C34:2 0.01 1.35 PC ae C40:5 0.03 -1.11 
PC aa C42:6 0.04 1.37 PC aa C38:5 0.03 -1.11 
SM (OH) C22:1 0.02 1.44 PC aa C36:5 0.04 1.09 
SM C24:0 0.01 1.44   
 
  
PC ae C40:3 0.01 1.55   
 
  
SM (OH) C14:1 <0.01 1.79   
 
  
Normetanephrine <0.01 1.94   
 
  
Alanine 0.03 2.22       





1 ppm vs 0 ppm (18)* PC aa C36:0 0.02 -1.12 lysoPC a C17:0 0.03 -1.55 
Citric acid 0.02 -1.59 lysoPC a C16:1 0.03 -1.49 
PC ae C36:4 0.04 -1.17 lysoPC a C18:1 0.03 -1.45 
L-Arabitol 0.01 1.38 lysoPC a C20:3 0.03 -1.41 
O-
Phosphoethanolamine 
0.01 1.40 C16:1-OH 0.01 -1.38 
1,5-Anhydrosorbitol 0.02 1.44 Glycerol 0.01 -1.30 
Glycerol 3-phosphate 0.02 1.45 Nonadecanoic acid 0.01 -1.23 
L-Cysteine 0.02 1.53   
 
  
Adenine <0.01 1.56       
WT, female 
1 ppm vs 0 ppm (22)* 
Histidine 0.05 -1.85 Dopa 0.02 1.46 
C10 0.03 -1.29   
 
  
PC ae C36:3 0.04 1.13   
 
  
PC ae C36:5 0.04 1.16   
 
  
PC aa C38:6 0.02 1.16   
 
  
PC ae C34:1 <0.01 1.22   
 
  
Ketoleucine 0.04 1.24   
 
  
PC ae C40:6 <0.01 1.26   
 
  
PC aa C34:1 0.04 1.26   
 
  
C12:1 0.04 1.26   
 
  
PC aa C36:1 0.01 1.33   
 
  
PC aa C36:2 0.02 1.36   
 
  
C10:1 0.01 1.38   
 
  
PC ae C38:3 0.03 1.47   
 
  
PC ae C40:4 0.03 1.47   
 
  
PC ae C34:2 0.01 1.55   
 
  
D-Ribose 0.05 1.57   
 
  
PC ae C36:0 0.04 1.72   
 
  
PC ae C30:2 <0.01 2.11   
 
  
Glutamate <0.01 2.43   
 
  
Citric acid <0.01 3.19       
WT, male 
1 ppm vs 0 ppm (14)* 
Alpha-Lactose 0.05 -5.01 Glutamate 0.03 1.26 





  Spermidine 0.02 1.35 
  
 
  C8 0.04 1.40 
  
 








  C18:1 0.03 1.47 
  
 
  C18:2 0.02 1.49 
  
 
  Fumaric acid 0.02 1.49 
  
 







  Uracil 0.02 1.86 
      3-Oxoalanine 0.03 1.94 
*Number in parentheses indicates total number of metabolites significantly different in the 
comparison. CX:Y; acyl-carnitine, where X indicates number of carbons of the fatty acid tail and 
Y indicates number of double bonds. Phosphatidylcholine notation: PC; phosphatidylcholine, aa; 
two fatty acid ester linkages, ae; one ester and one ether linkage, CA:Z is a description of the 
fatty acid composition of two PC tails where A indicates total number of carbons in both fatty 

























Table A.3. Plasma and urinary metabolites significantly changed (p<0.05) in comparisons of 
male and female As3mt–KO (KO) and wild-type (WT) mice. Fold change indicates difference 











Control, female  
KO vs WT (102)* 
Serine 0.05 -2.64 Gluconic acid 0.01 -2.60 
Urea 0.01 -5.97 Carnosine 0.01 -1.45 
Acetylglycine 0.03 -3.68 Pyruvic acid 0.02 -1.29 
2-Hydroxybutyric acid <0.01 -2.48 PC aa C26:0 0.03 -1.10 
Ornithine 0.04 -2.38 PC aa C32:0 0.05 1.09 
Suberic acid 0.01 -1.81 PC aa C32:3 0.05 1.10 
Tryptophan 0.02 -1.69 PC aa C38:6 0.05 1.14 
Proline 0.01 -1.68 PC ae C42:3 0.04 1.14 
Adipic acid <0.01 -1.57 PC aa C36:5 0.01 1.14 
Pelargonic acid 0.01 -1.45 PC ae C36:2 0.04 1.15 
Glycolic acid 0.01 -1.39 PC aa C38:5 0.01 1.15 
Beta-Alanine 0.05 -1.34 PC ae C40:5 0.01 1.15 
C5-M-DC 0.01 -1.33 PC ae C42:4 0.01 1.16 
3-Methyl-2-oxovaleric 
acid 
0.01 -1.22 PC ae C38:5 0.01 1.16 
Creatinine 0.01 -1.04 SM C16:0 0.02 1.16 
PC ae C38:5 0.04 1.14 PC aa C42:5 0.02 1.17 
PC ae C36:5 <0.01 1.21 PC ae C44:6 0.01 1.17 
C14 0.03 1.22 PC ae C38:6 0.01 1.17 
PC aa C36:0 <0.01 1.25 PC aa C42:6 0.04 1.17 
PC ae C36:3 <0.01 1.26 PC aa C36:3 <0.01 1.17 
PC ae C36:4 <0.01 1.28 PC ae C38:4 0.01 1.18 
C3-OH 0.03 1.29 PC ae C44:5 0.03 1.18 
PC aa C36:2 0.04 1.30 PC ae C32:2 0.01 1.19 
PC aa C38:3 0.01 1.36 PC aa C40:5 0.02 1.19 
C18:1-OH <0.01 1.38 PC aa C36:4 0.01 1.19 
PC ae C38:3 0.05 1.40 PC aa C42:1 <0.01 1.19 
C18 <0.01 1.45 PC ae C38:3 <0.01 1.19 
D-Threitol 0.01 1.50 PC aa C34:2 0.03 1.19 
Ribonolactone 0.02 1.52 PC ae C36:4 <0.01 1.20 
Myoinositol <0.01 1.60 PC ae C40:2 <0.01 1.20 
C18:1 <0.01 1.62 PC aa C36:6 <0.01 1.20 
L-Arabitol <0.01 1.63 SM C16:1 0.01 1.20 
O-Phosphoethanolamine 0.04 1.67 PC aa C36:1 <0.01 1.20 
N-Acetylornithine 0.02 1.71 PC aa C40:3 <0.01 1.20 
1,5-Anhydrosorbitol 0.01 1.77 PC ae C42:2 <0.01 1.21 
Adenosine 0.01 1.78 PC aa C42:0 0.01 1.21 





Mannitol 0.04 1.95 PC ae C36:5 <0.01 1.22 
Cytosine 0.05 1.96 PC aa C42:2 <0.01 1.23 
Cytidine 0.02 2.21 PC aa C36:2 0.01 1.23 
Sarcosine <0.01 2.21 PC aa C40:1 <0.01 1.24 
Hydroxypropionic acid 0.03 2.22 PC ae C40:4 <0.01 1.25 
Galactonic acid <0.01 3.36 PC aa C40:4 <0.01 1.26 
Gluconic acid <0.01 3.36 PC aa C42:4 <0.01 1.26 
D-Fructose 0.03 3.40 SM C24:0 0.01 1.27 
Methionine sulfoxide 0.01 3.43 PC aa C40:6 <0.01 1.27 
L-Sorbose 0.02 4.00 PC ae C40:3 <0.01 1.27 
  
 
  PC aa C38:4 <0.01 1.28 
  
 
  Valine <0.01 1.28 
  
 
  SM (OH) C22:1 0.01 1.28 
  
 
  PC aa C38:0 <0.01 1.29 
      PC aa C38:3 <0.01 1.34 
    Ornithine 0.01 1.35 
    C14:2-OH 0.04 1.36 





KO vs WT (52)* 
Carnosine <0.01 -2.44 Carnosine <0.01 -1.49 
Acetylglycine <0.01 -16.82 SDMA <0.01 -1.41 
Alpha-Lactose 0.02 -6.77 Creatinine <0.01 -1.36 
Aminoadipic acid 0.02 -2.53 Putrescine 0.04 -1.32 
C14:2-OH <0.01 -2.31 t4-OH-Pro 0.01 -1.26 
Aspartate <0.01 -1.96 PC ae C40:6 0.01 -1.25 
C7-DC <0.01 -1.85 PC ae C30:2 0.01 -1.19 
Uracil <0.01 -1.64 PC ae C30:0 0.02 -1.16 
Uridine 0.02 -1.61 PC aa C26:0 <0.01 -1.16 
Beta-Alanine 0.04 -1.48 PC aa C40:2 0.03 1.16 
PC aa C36:0 <0.01 1.29 Glutamine 0.03 1.18 
Putrescine 0.03 1.35 PC ae C38:0 <0.01 1.19 
PC aa C40:4 <0.01 1.58 PC aa C36:6 0.01 1.19 
Malic acid 0.03 1.67 PC aa C36:5 <0.01 1.20 
O-Phosphoethanolamine 0.02 1.67 Histidine 0.01 1.21 
2-Hydroxy-3-
methylbutyric acid 
<0.01 1.69 PC aa C40:3 <0.01 1.24 
C6 (C4:1-DC) <0.01 1.69 PC aa C40:4 <0.01 1.25 
Oxoglutaric acid 0.01 1.73 PC aa C34:4 <0.01 1.25 
PC aa C40:5 <0.01 1.82 PC aa C36:3 0.01 1.26 
Sarcosine 0.04 2.36 Glutamate <0.01 1.32 





Hippuric acid <0.01 8.51 Alanine 0.02 1.36 
  
 
  PC aa C32:1 <0.01 1.47 
  
 
  Myristic acid 0.03 1.53 
  
 
  Petroselinic acid 0.01 1.53 
  
 
  Oleic acid 0.01 1.53 
  
 
  Palmitic acid <0.01 1.54 
  
 
  Oxoglutaric acid <0.01 1.59 
  
 
  lysoPC a C20:3 <0.01 1.76 
      Palmitoleic acid <0.01 1.88 
iAs-treated, female 
KO vs WT (59)* 
Citric acid <0.01 -3.58 Carnosine 0.01 -1.42 
PC aa C26:0 <0.01 -2.50 Beta-Alanine 0.01 -1.86 
Lysine 0.02 -2.47 Isocitric acid 0.01 -1.40 
DOPA 0.02 -2.44 Citric acid 0.01 -1.40 
Aminoadipic acid <0.01 -2.41 C12 0.01 -1.37 
Arginine 0.02 -2.35 C9 0.04 -1.35 
2-Hydroxybutyric acid <0.01 -2.32 PC ae C40:6 <0.01 -1.33 
PC ae C30:2 <0.01 -2.30 Myoinositol 0.05 -1.25 
Glutamate <0.01 -2.15 Glycolic acid 0.03 -1.22 
Phenylalanine 0.03 -1.72 PC aa C26:0 <0.01 -1.19 
Ketoleucine <0.01 -1.64 PC aa C28:1 0.02 -1.13 
Adipic acid 0.01 -1.55 PC ae C34:0 0.04 1.12 
PC ae C34:2 0.01 -1.51 PC aa C34:3 0.01 1.13 
C5-M-DC 0.01 -1.44 PC aa C40:3 0.03 1.16 
PC ae C34:1 <0.01 -1.39 PC aa C40:2 0.03 1.16 
PC aa C38:6 <0.01 -1.33 PC aa C36:2 0.03 1.17 
3-Methyl-2-oxovaleric 
acid 
<0.01 -1.31 PC ae C44:6 <0.01 1.18 
C5-DC (C6-OH) 0.02 -1.30 PC aa C38:0 <0.01 1.18 
PC ae C40:6 <0.01 -1.28 PC aa C36:6 <0.01 1.19 
PC aa C42:4 <0.01 -1.27 PC aa C42:2 <0.01 1.20 
PC ae C38:4 0.02 1.19 PC aa C36:1 <0.01 1.26 
PC aa C36:0 0.01 1.20 SM C24:0 0.01 1.26 
PC ae C36:4 <0.01 1.24 PC aa C36:5 <0.01 1.27 
C16:1 0.03 1.28 PC aa C38:3 <0.01 1.29 
PC ae C42:5 0.03 1.29 Histamine 0.01 1.71 
PC aa C40:3 0.04 1.34 Serotonin 0.02 2.16 
C3-OH 0.04 1.36   
 
  
SM (OH) C14:1 0.03 1.40   
 
  
Methylmalonic acid 0.01 1.47   
 
  
Histamine 0.01 1.85   
 
  
O-Phosphoethanolamine <0.01 1.92   
 
  







L-Homoserine 0.03 2.50       
iAs-treated, male 
KO vs WT (78)* 
C14:2-OH <0.01 -2.91 C18:1 <0.01 -1.89 
4-Hydroxybenzoic acid <0.01 -2.81 C18:2 <0.01 -1.88 
Aminoadipic acid 0.02 -2.25 C7-DC <0.01 -1.80 
Carnosine <0.01 -2.25 C18 <0.01 -1.77 
Gluconolactone <0.01 -2.01 Carnosine <0.01 -1.73 
C14:2 <0.01 -1.98 C16 <0.01 -1.67 
Uridine <0.01 -1.90 Spermidine <0.01 -1.62 
C16:1-OH 0.01 -1.82 Beta-Alanine 0.05 -1.56 
Pelargonic acid 0.01 -1.80 C16:2-OH <0.01 -1.54 
C5:1 0.03 -1.77 2-Hydroxy-
butyric acid 
<0.01 -1.53 
C14:1-OH 0.01 -1.70 C18:1-OH 0.01 -1.53 
C18 0.03 -1.68 PC ae C40:6 <0.01 -1.49 
C7-DC 0.02 -1.66 Kynurenine <0.01 -1.44 
C14:1 0.02 -1.60 L-Cysteine 0.03 -1.44 
3-Methyl-2-oxovaleric 
acid 
0.02 -1.47 C14:2 <0.01 -1.44 
PC ae C38:0 0.01 -1.41 C16:1-OH 0.01 -1.43 
PC ae C40:5 0.01 -1.37 Malic acid 0.02 -1.42 
Hydroxyphenyllactic 
acid 
0.02 -1.33 C14 0.03 -1.38 
PC aa C36:6 0.04 -1.33 t4-Hydroxy-
proline 
<0.01 -1.35 
PC aa C38:0 0.02 -1.32 PC ae C38:6 <0.01 -1.32 
D-Glucuronic acid 0.01 -1.31 Phenylalanine 0.01 -1.30 
PC ae C40:6 0.01 -1.29 Tryptophan 0.02 -1.26 
PC aa C40:6 0.02 -1.27 PC ae C36:4 0.04 -1.22 
PC aa C38:6 0.01 -1.26 PC ae C36:2 0.04 -1.18 
Oxalic acid 0.04 1.33 PC ae C34:1 0.01 -1.18 
L-Arabitol 0.02 1.34 PC ae C36:1 0.02 -1.17 
C6 (C4:1-DC) 0.02 1.35 PC aa C26:0 <0.01 -1.14 
PC aa C40:4 <0.01 1.39 PC aa C36:5 0.01 1.16 
1,5-Anhydrosorbitol 0.04 1.40 PC aa C40:4 <0.01 1.23 
Putrescine 0.01 1.44 PC aa C40:3 <0.01 1.28 
2-Hydroxy-3-
methylbutyric acid 
<0.01 1.45 PC aa C38:3 0.02 1.30 
Myoinositol 0.03 1.49 Alanine 0.02 1.38 
Adenine 0.00 1.52 PC aa C32:1 <0.01 1.51 
Palmitic acid 0.03 1.53 3-Indole-
propionic acid 
0.03 1.72 
D-Ribose 0.02 1.58 D-Xylose 0.02 1.94 
D-Galactose 0.01 1.58   
 
  
C4 0.02 1.65   
 
  







O-Phosphoethanolamine <0.01 1.86   
 
  
Glycerol 3-phosphate <0.01 1.94   
 
  
PC aa C40:5 <0.01 2.18   
 
  
Cytidine <0.01 2.49   
 
  
Hippuric acid <0.01 9.42       
*Number in parentheses indicates total number of metabolites significantly different in the 
comparison. CX:Y; acyl-carnitine, where X indicates number of carbons of the fatty acid tail and 
Y indicates number of double bonds. SM; sphingomyolipid. Phosphatidylcholine notation: PC; 
phosphatidylcholine, aa; two fatty acid ester linkages, ae; one ester and one ether linkage, CA:Z 
is a description of the fatty acid composition of two PC tails where A indicates total number of 












Table A.4. Pathways enriched for plasma (P) and urine (U) metabolites differentially changed in response to As3mt knockout or iAs 
treatment. Increase and decrease in metabolite levels are indicated with (+) and (-), respectively. 
    Knockout vs wild-type iAs-treated vs control 











KO vs WT 
iAs-treated, 
Male, 
KO vs WT  
KO, 
Female, 








1 ppm vs 0 
WT,  
Male, 
1 ppm vs 0 




    P=0.01 
Aspartate (-, U), 
glutamine (+, P), 
oxoglutaric acid 
(+, P) 
        P=0.009 
L-glutamic acid 
(+, P), fumaric 




    P=0.008 
Aspartate (-, U), 
glutamine (+, P), 
hydroxyl- 
proline (-, P), 
putresine (-, P) 
        P=0.002 
Spermidine  
(+, P), glutamic 
acid (+, P), 




    P= 0.004 
Aspartate (-, U), 
uracil (-, U),  
β-alanine (-, U) 
        P=0.004 
Spermidine 
(+, P),  





    P=6.03e-5 
Glutamine (+, P), 
glutamate (+, P), 
oxoglutaric acid 
(+, P) 
    P=0.02 
D-glutamic acid 
(+, U) 










pyruvate (-, P),  
serine (-, U) 
              
Histidine 
metabolism 
  P=0.03 
Carnosine  
(-, P), histamine 
(+, P/U) 
P=0.0024 
Histidine (+, P), 
aspartate (-, U), 
carnosine (-, U) 
    P=0.04 
histidine (-, U) 
    
Lysine 
biosynthesis 
  P=0.002 
Lysine (-, U), 
aminoadipic 
acid (-, U) 




Pyruvate (-, P), 
valine (+, P) 
        P=0.05 
ketoleucine  
(+, U) 











          P=0.03 
PC (+, U) 
    
Fatty acid 
biosynthesis 
    P=0.05 
oleic acid (+, P), 
myristic acid  
(+, P), palmitic 
acid (+, P) 
          
Glycerolipid 
metabolism 
            P=0.008 








    P=0.02 
PC (+/-, U/P),  
O-phospho-
ethanolamine  
(+, U),  
lysoPC (+, P) 
P=0.04 











phosphate (+, U), 
PC (-, U), 




          P=0.03 
PC (+, U) 
P=0.05 
PC (-, U) 
  
Carbohydrate  Ascorbate 
and aldarate 
metabolism 
      P=0.02 
Myoinositol  
(+, U),  
D-glucuronic 
acid (-, U) 
        
Citrate cycle 
(TCA cycle) 
  P=0.04 
citric acid (-, P), 
isocitric acid  
(-, P) 
            
Galactose 
metabolism 










  P=0.003 
Citric acid  
(-, P), isocitric 
acid (-, P), 
glycolic acid  
(-, P) 













      P=0.007 
L-arabitol (+, U), 
D-glucuronic 
acid (-, U),  
D-xylose (+, P) 








      
Other Glutathione 
metabolism 
      P=0.03 
L-cysteine (-, P), 
putrescine (+, U), 
spermidine  
(-, P) 
      P=0.01 
Spermidine  





    P=0.01 
Glutamine (+, P), 
histidine (+, P) 
    P=0.04 
histidine (-, U) 





Valine (+, P),  
β-alanine (-, U) 
  P=0.03 
β-alanine (-, U), 
uracil (-, U) 
P=0.05 
L-cysteine  
(-, P),  
β-alanine (-, P) 




β-alanine (-, U),  
2-hydroxy-
butyric acid  





β-alanine (-, P),  
2-hydroxy-
butyric acid  
(-, U) 
  P=0.01 
succinic acid (+, 
U),  
β-alanine (-, P), 
2-hydroxy-
butyric acid  
(-, P) 
        
Pyrimidine 
metabolism 
    P=8e-4 
Glutamine (+, P), 
cytidine (+, U), 
uridine (-, U), 
uracil (-, U),  
β-alanine (-, U) 
          
Significantly changed metabolites with a p-value<0.05 were used for pathway analysis using MetaboAnalyst. Significantly enriched 














Table A.5. Significantly changed (P<0.05) hepatic PCs in comparisons of untreated (0) and iAs-
treated (1) animals, separated by sex (M and F) and genotype (As3mt-knockout (KO) and wild-





WT 1 F vs WT 0 F (2) PC(34:1) 0.05 1.14 
PC(38:2) 0.04 1.48 
      
WT 1 M vs WT 0 M (1) PC(38:2) 0.02 1.33 
KO 1 F vs KO 0 F (3) PC(36:2) 0.01 1.11 
PC(34:1) 0.03 1.16 
PC(36:1) 0.04 1.27 
KO 1 M vs KO 0 M (3) PC(36:0) 0.02 -2.35 
PC(38:3) 0.04 1.15 
PC(32:1) 0.04 1.16 
aPhosphatidylcholine notation: PC(X:Y) indicates a phosphatidylcholine X total carbons and Y 
double bonds. PC(O-X:Y) indicates a phosphatidylcholine with one acyl and one ester linkage to 
the fatty acid tails with X total carbons and Y double bonds. 


























Table A.6. Significantly changed (P<0.05) hepatic PCs in comparisons of As3mt-knockout (KO) 
and wild-type (WT) mice, separated by sex (M and F) and iAs-treatment (0 and 1 ppm). 
 
Comparison Metabolite p-value Fold Change 
KO 0 F vs WT 0 F (4) PC(34:1) 0.020822 -1.18006 
PC(38:4) 0.036602 1.11768 
PC(38:3) 0.008267 1.22672 
PC(40:4) 0.026064 1.5 
KO 0 M vs WT 0 M (12) PC(O-40:4) 0.000659 -1.47126 
PC(34:2) 4.68E-10 -1.39544 
PC(O-40:6) 0.000436 -1.3037 
PC(40:6) 0.003391 -1.28049 
PC(38:6) 0.000135 -1.24784 
PC(O-36:2) 0.013842 -1.21739 
PC(32:0) 0.004818 -1.16583 
PC(36:2) 0.013628 -1.13956 
PC(36:4) 0.018577 -1.13131 
PC(32:1) 0.043028 1.21403 
PC(38:3) 0.01923 1.22603 
PC(38:2) 0.000518 1.45673 
KO 1 F vs WT 1 F (8) PC(O-36:1) 0.010833 -1.35333 
PC(34:1) 0.014616 -1.16294 
PC(O-34:1) 0.032848 -1.16098 
PC(32:0) 0.011641 -1.11679 
PC(36:2) 2.12E-05 1.21239 
PC(38:3) 0.029214 1.16103 
PC(38:4) 0.003345 1.17083 
SM(34:1) 0.02794 -1.11429 
KO 1 M vs WT 1 M (11) PC(32:2) 0.001262 1.53947 
PC(40:4) 0.035402 1.26563 
PC(34:2) 1.71E-08 -1.32809 
PC(32:1) 0.000558 1.35517 
PC(O-36:2) 0.000443 -1.35519 
PC(36:5) 0.042453 1.18617 
PC(38:6) 0.003432 -1.17678 
PC(O-40:6) 4.42E-05 -1.36364 
PC(32:0) 0.003397 -1.16586 
PC(O-38:4) 0.001113 -1.3037 
PC(38:3) 2.16E-05 1.42396 
aPhosphatidylcholine notation: PC(X:Y) indicates a phosphatidylcholine X total carbons and Y 
double bonds. PC(O-X:Y) indicates a phosphatidylcholine with one acyl and one ester linkage to 
the fatty acid tails with X total carbons and Y double bonds. 





B. Appendix B: Supplemental Material for Chapter 3 
 
 
Figure B.1. Study design. Dams were exposed to iAs in drinking (deionized) water (0, 100, and 
1000 ug As/L) and fed either the folate/B12-adequate or supplemented diet, based on a purified 
AIN-93G diet. The exposure and diet feeding started one week before mating and ended at the 
time dams gave birth to offspring. Offspring were maintained on deionized water and the 
folate/B12 adequate diet for 18 weeks. Phenotyping measurements were conducted on all 
offspring through the study period, measuring fasting blood glucose (FBG), intraperitoneal 





Figure B.2. Maternal body weight. Body weights of dams exposed to iAs and fed a folate/B12 
adequate or supplemented diet were measured (A) prior to exposure and (B) at the start of 






Figure B.3. Proportions of arsenic metabolites in urine of dams fed a folate/B12-adequate or 
supplemented diet and exposed to 0, 100, or 1000 ppb iAs. (A) %iAs, (B) %MAs, and (C) 
%DMAs in spot urine samples collected from dams exposed to iAs for 1 week, shortly before 







Figure B.4. Growth curves of offspring prenatally exposed to iAs, with and without maternal 
folate and B12 supplementation. Body weight was measured weekly after weaning in (A) female 
and (B) male offspring whose mothers were exposed to 0, 100, or 1000 ppb iAs in drinking water 
and fed either folate/B12-adequate (closed circles) or supplemented (open squares) diet before 
and during gestation. Mean for N=7-21 is shown. * p<0.05 significantly different from controls 
(0 ppb iAs) from the same diet; ǂ p<0.05 significantly different from 100 ppb iAs exposure; # 



















Figure C.1. Study design. Male and female C57BL6 (WT) and As3mt-knockout (KO) mice were 
given a folate-adequate (2 mg/kg) diet and drank deionized water for 4 weeks after weaning. 
Baseline metabolic measures were assessed. Animals were then exposed to 0 or 100 ppb iAs in 
drinking water and consumed either a low (0.2 mg/kg) or high (10 mg/kg) folate purified diet for 
24 weeks. After 24 weeks, all animals were fed a high-fat diet (HFD) with respective folate levels 
and continued iAs exposure until the end of the study. Metabolic phenotyping was conducted at 
week 5 and 24, and after 8 weeks on the HFD. Urine was collected for iAs speciation analysis at 
week 5 and at the end of the study. IPGTT, intraperitoneal glucose tolerance test; FBG, fasting 





Figure C.2. Food consumption of male and female WT and As3mt-KO mice on a low or high 
folate diet and exposed to 0 or 100 ppb iAs in drinking water. Mean ± SEM for N=3-4 cages. 
P<0.05 for the following comparisons: S, males vs females of the same diet, exposure, and 
genotype; F, low vs high folate intake animals of the same genotype, exposure, and sex; G, KO 
vs WT mice of the same sex, diet, and exposure; E, 0 vs 100 ppb iAs-exposed mice of the same 







Figure C.3. Water consumption of male and female WT and As3mt-KO mice on a low or high 
folate diet and exposed to 0 or 100 ppb iAs in drinking water. Mean ± SEM for N=3-4. P<0.05 
for the following comparisons: S, males vs females of the same diet, exposure, and genotype; F, 
low vs high folate intake animals of the same genotype, exposure, and sex; G, KO vs WT mice of 
the same sex, diet, and exposure; E, 0 vs 100 ppb iAs-exposed mice of the same sex, genotype, 





Figure C.4. Body weight over time of male and female WT and As3mt-KO mice on a low or high 
folate diet and exposed to 0 or 100 ppb iAs in drinking water, before and after high-fat diet. 











Figure C.5. Weight gain of male and female WT and As3mt-KO mice on a low or high folate diet 
and exposed to 0 or 100 ppb iAs in drinking water, before and after high-fat diet. Weight gain of 
animals during LFD and HFD is shown in grams (A, B) and as % of weight prior to exposure or 
prior to HFD as appropriate (C, D). Mean ± SEM for N=14-20. P<0.05 for the following 
comparisons: S, males vs females of the same diet, exposure, and genotype; F, low vs high folate 
intake animals of the same genotype, exposure, and sex; G, KO vs WT mice of the same sex, diet, 









Figure C.6. Glucose tolerance of male and female WT and As3mt-KO mice on a low or high 
folate diet and exposed to 0 or 100 ppb iAs in drinking water for 5 weeks. Mean ± SEM for 
N=14-20. P<0.05 for the following comparisons: S, males vs females of the same diet, exposure, 
and genotype; E, 0 vs 100 ppb iAs-exposed mice of the same sex, genotype, and folate level.    
 
 
 
 
 
 
